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 Abstract 
This thesis reports a number of experiments whose aim was to understand the role of 
placebo-type effects during withdrawal from a drug. The long-term goal of this 
research was that of developing interventions for treating addiction that have clinical 
utility. The review in Chapter 1 of previous research on this topic concluded that there 
was sufficient evidence to suggest that withdrawal symptoms can be manipulated 
independently of the pharmacological effects of abstinence via verbal instructions 
concerning either (i) the likelihood of experiencing withdrawal symptoms, or (ii) how 
much of a certain drug has been consumed. Chapters 2 and 3 report two experiments 
designed to test the relative ability of these two forms of verbal instruction to affect 
symptoms produced by caffeine withdrawal. Verbal instructions concerning the 
likelihood of experiencing withdrawal symptoms appeared to have no effect on such 
symptoms. In contrast, verbal instructions concerning whether or not caffeine had 
been ingested had a marked effect on caffeine withdrawal. This suggests that 
interventions that target beliefs about dose are more effective at reducing withdrawal 
symptoms than interventions that attempt to influence existing expectancies about the 
consequences of abstinence. Chapter 4 reports an experiment that tested whether 
placebo caffeine withdrawal relief could occur in the absence of conscious 
expectancies. A group who were given decaffeinated coffee and who were instructed 
it was decaffeinated reported a significantly greater reduction in withdrawal 
symptoms than a group who were given water and told it was water, despite endorsing 
beliefs that decaffeinated coffee would not reduce symptoms produced by withdrawal 
from caffeine. This suggests that exposure to contextual cues surrounding caffeine use 
could elicit a withdrawal reduction effect even when this effect was not consciously 
expected. Chapters 5 and 6 investigated whether knowing about the timing and 
 magnitude of dose reductions during a dose taper procedure leads to increased 
withdrawal symptoms. Caffeine was reduced at an identical rate over five days across 
three different sets of dosing instructions. One group was given accurate information, 
another was misinformed that their dose was remaining stable on three days and 
dropping to zero on the final day, and a third was given no information about dose. 
Knowing the caffeine dose was being reduced was associated with: (i) greater 
withdrawal symptoms than misinformation on the two final days, and (ii) a greater 
rate of increase in withdrawal across the test days than both misinformation and no 
information. These results support the hypothesis that being aware of the timing and 
magnitude of dose reductions during a dose taper can lead participants to expect an 
increase in withdrawal symptoms and that such expectancies can exacerbate 
withdrawal symptoms. Overall, the results reported in this thesis indicate that beliefs 
concerning how much of a drug is in the body can influence withdrawal symptoms 
independently of pharmacological factors. Treatments of drug addiction that reduce 
the negative impact of such placebo-type processes may improve clinical outcomes.  
  
 
 
“The literature on methadone maintenance suggests…that we have not developed 
clinical methods for controlling the effect of expectation – an effect almost universally 
acknowledged to be important but not as yet established by rigorous observation.” 
Senay, Dorus, Goldberg, & Thornton, 1977  
 
 
 
 
“To sum up, I am suggesting that many of the reinforcing consequences and 
antecedents of drug addiction have no direct pharmacological basis. For a given 
individual the temporal pattern of drug use may be maintained almost entirely by 
secondary reinforcers.“   
Vaillant, 1988  
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Chapter 1: The placebo effect and placebo withdrawal 
Drug addiction exacts a heavy toll—on the individuals who suffer from it, their 
families and the society in which they live. One of the chief impediments to quitting 
addictive drugs is the host of debilitating psychological and physiological withdrawal 
symptoms that accompany abstinence. There is evidence that beliefs held by 
individuals about the amount of a drug in their body can influence their withdrawal 
symptoms independently of the actual pharmacological effects of the absence or 
presence of that drug. The experiments that make up this thesis will test whether there 
are ways to reduce the negative impact these beliefs have on withdrawal symptoms, 
and thus, potentially, improve the chance of successful quit attempts. This chapter 
involves a general discussion of the theories used to explain placebo effects, followed 
by a more specific discussion of the placebo effect as it pertains to drug withdrawal.  
 
1.1 Theories of the Placebo Effect 
1.1.1. Definition of Expectancies 
Expectancies are important moderators of how we perceive and interact with the 
world. They occupy a central role in influential theories of learning as well as in 
clinical, social, educational, and developmental psychology. Expectancies can be 
defined as schemas that are activated based on appraisals of the likelihood of a 
stimulus or response signaling the arrival of another stimulus (Bolles, 1972). Schemas 
are organised patterns of stored information acquired by observing the relations 
between stimuli. We derive schemas by organising stimuli into classes based on 
salient features that individuals within each class share (DiMaggio, 1997). This means 
that completely novel stimuli can be fit into an existing schema, and thus elicit 
expectancies, if they are judged to belong to a class with which the organism has prior 
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experience, a process known as stimulus generalisation. In psychology a stimulus is 
any object or event that can be perceived by the organism (Eikelboom & Stewart, 
1982). If an observed stimulus belongs to a class of stimuli that has been observed in 
the past to reliably precede the occurrence of another class of stimuli, it will activate 
the schema pertaining to the first class, thus eliciting an expectancy that a stimulus 
from the antecedent class will also occur.  
Expectancies are useful because they provide organisms with a heuristic that 
allows them to efficiently assimilate novel information into their existing worldview, 
making it possible for them to respond quickly and appropriately to stimuli they have 
not encountered before, based on their past experience with similar stimuli. 
Expectancies alter the way organisms perceive and respond to any stimuli that occur 
after the schema that generates the expectancies has been activated. The ability to 
change the way organisms respond to stimuli is thought to be the means by which 
expectancies evoke placebo effects (Kirsch, 1985). Some believe that expectancies 
must be held consciously (Kirsch, 2004) but others have suggested that they can be 
held unconsciously (Colagiuri et al., 2015; Hahn, 1997). A less elaborate definition of 
expectancies is that they are beliefs, held consciously or unconsciously, about what 
will happen when a particular class of stimuli occurs.  
1.1.2  What is the Placebo Effect? 
Placebos are used widely in clinical trials to isolate the active effects of a treatment 
from the effect of expectancy. As a result, in medical circles the placebo effect has 
been considered a nuisance variable, a factor to be ‘controlled out’ in order to gauge 
the precise effects of the treatment alone. However new advances in placebo research 
suggest that patients’ expectancies of treatment effects, far from being a nuisance, can 
in fact be harnessed in order to enhance treatment outcomes. Placebo researchers have 
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developed some promising methods for achieving these aims. However, before 
discussing these, it is important to define the placebo effect.  
A placebo effect is “a genuine psychological or physiological effect, in a human or 
other animal that is attributable to receiving a substance or undergoing a procedure, 
but is not due to the inherent powers of that substance or procedure” (Stewart-
Williams & Podd, 2004, p. 326). The archetypal example of a placebo effect is when 
an individual experiencing pain is given an inert sugar pill under the guise of an 
analgesic and subsequently reports a reduction in pain. However the scope of placebo 
effects goes far beyond this canonical example. In fact modern conceptions of placebo 
effects extend beyond the mere effects of a sham pharmacological vehicle to include 
the whole psychosocial context in which the treatment is given, including the patient’s 
conscious expectancies of their likely response to the treatment, unconscious 
expectancies evoked by the environmental setting in which the treatment takes place, 
the instructions surrounding possible effects or side-effects of the treatment, the 
patient’s feelings surrounding the practitioner who administers the treatment, and 
even their reverence for the intellectual tradition from which the treatment originates 
(Linde et al., 2007; Price, Finniss, & Benedetti, 2008). These factors can all 
potentially contribute to the expectancies we hold about the likely consequences of 
whatever treatment we receive, and it is these expectancies lead to the placebo effect. 
Placebo effects have been observed across a wide range of psychophysiological 
phenomena, including analgesia (see Price, Finniss, & Benedetti, 2008, for a review) 
hyperalgesia (see Colloca & Miller, 2011b, for a review), improved motor function 
(Pollo et al., 2002), reduced insomnia/improved sleep (Neukirch & Colagiuri, 2015; 
Suetsugi et al., 2007), bronchioconstriction (Butler & Steptoe, 1986) and 
immunosuppression (Longo et al., 1999). Placebo effects can be positive or negative, 
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depending on what the individual is expecting from the treatment. Positively-valenced 
placebo effects occur when expectancies of a desirable outcome (e.g. pain relief) lead 
to that desired outcome. Negatively-valenced placebo (or ‘nocebo’) effects occur 
when the individual expects that the treatment they receive will have negative 
consequences. Nocebo effects can be induced in much the same way as positive 
placebo effects. However, it is thought that different neurological mechanisms may be 
behind each (Benedetti et al., 1997; Benedetti, Amanzio, Vighetti, & Asteggiano, 
2006). Examples of nocebo effects are an increased incidence of a side-effect 
following warnings about the unpleasant side-effects of a drug (Colagiuri, 
McGuinness, Boakes, & Butow, 2012; Shapiro, Chassan, Morris, & Frick, 1974) or 
the nausea experienced by cancer patients when confronted with stimuli that were 
present during chemotherapy, such as the needles used for the injections or the room 
in which the chemotherapy drugs were administered (Montgomery & Bovbjerg, 2001, 
2004; Roscoe, Hickok, & Morrow, 2000). For the rest of this thesis I will attempt to 
refer to ‘negative placebo effects’ rather than ‘nocebo effects’ however there may be 
times when I use the latter term. For the purposes of this thesis they are equivalent.  
The form (e.g. pain, nausea) and valency (i.e. positive or negative) of the placebo 
effects elicited by a given treatment depend on the particular expectancies held by an 
individual concerning the likely outcomes of that treatment. These expectancies can 
be acquired directly or indirectly. Direct acquisition of expectancies involves having 
personally experienced the contingency between the treatment and its effects, either in 
the laboratory or in a real world setting.  We can also acquire expectancies about the 
likely effects of a treatment indirectly, either through: (i) verbal instruction by a 
person or some other source or information (e.g. books, websites, television), (ii) by 
observing the effects that the treatment has on others (i.e. social learning), and (iii) via 
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stimulus generalisation (i.e. by judging the treatment to belong to the same class as a 
treatment with which one does have expectancies) (Colloca & Miller, 2011a).  
Expectancies of the effects of a treatment can be acquired from many sources. 
However, regardless of how we acquire the expectancies, most modern theories agree 
that the effects of placebos occur because we expect them to. 
1.1.3 Theories of the Placebo Effect 
1.1.3.1 Expectancy, Conditioning, and Hybrid Models   
Over most of the last seventy years there has been an ideological battle between 
advocates of expectancy theories and advocates of conditioning theories of placebo 
effects. However, in recent years more holistic models have been developed, which 
view the placebo effect not as a result of either expectancy or conditioning, but rather 
as a combination of several possible factors, including conscious expectancies, 
unconscious conditioning, and many other psychosocial factors. In these newer 
models the factors need not be mutually exclusive and which precise factors cause 
specific placebo effects depends on the particular situation and condition in question. 
The placebo effect is most often explained as a learning phenomenon, specifically 
an example of classical conditioning. In classical or Pavlovian conditioning, when a 
neutral stimulus (conditioned stimulus or CS) is repeatedly paired with a non-neutral 
stimulus (unconditioned stimulus or US) that reliably elicits a response 
(unconditioned response; UR), the neutral stimulus eventually acquires the ability to 
elicit the same or a similar response on its own in the absence of the US. This latter 
response to the solitary CS is known as the conditioned response (or CR). The 
archetypal example of classical conditioning is Pavlov’s (1927) famous experiment 
using a dog, its food, and a bell. Pavlov observed that the sight and smell of food (US) 
caused the dog to salivate (UR). He rang a bell (CS) each time the food was presented 
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to the animal and did this over repeated feedings. Eventually ringing the bell on its 
own came to induce salivation (CR). Theorists such as Wickramasekera (1980) 
believed that the placebo effect could be explained within this framework; with the 
treatment itself the US, the cues surrounding the treatment’s administration such as 
the vehicle of administration (e.g. pill, injection) or more general environmental cues 
(e.g. the room the treatment is administered in and/or the doctor who administers the 
treatment) the CS, and the acute effects of the treatment on the central nervous system 
the UR. Repeated contiguous pairings of the effects of the treatment (US) and the 
context surrounding its administration (CS) eventually lead to a conditioned response 
(CR) that is similar to the UR, which can be elicited following the presentation of the 
CS alone. 
Like the early models of classical conditioning on which they were based, early 
models of placebo effects explained classical conditioning via stimulus substitution: 
where the CS comes to stand in for or substitute for the US in its ability to elicit the 
response in question. In this model the essential process that allows the substitution—
and hence the conditioned response—to take place is the contiguous pairing of the CS 
with the US. Through stimulus substitution, inert treatments such as saline injections 
or sugar pills are able to evoke conditioned responses that mimic the responses to the 
active treatment.  
The stimulus substitution model, of both classical conditioning and placebo effects, 
has largely fallen out of favour, mainly because it frames classical conditioning as a 
form of low-level mechanical process, something akin to a reflex; with the 
implication being that it occurs unconsciously. This contradicts evidence that learning 
is often influenced by conscious processes (for a review see Mitchell, De Houwer, & 
Lovibond, 2009). In modern theories of classical conditioning, learning is not merely 
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a reflexive response to the repeated co-occurrence of stimuli, but is an active process 
that involves the organism making inferences about the relations between events. In 
modern theories of classical conditioning, learning is dependent not purely on 
contiguity but on the formation of expectancies, which are beliefs concerning the 
likelihood of one set of stimuli being followed or accompanied by another (Bolles, 
1972). The extent to which a CS is able to produce a conditioned response depends on 
the information the CS provides about the likelihood of the arrival of the US and 
subsequent UR (Rescorla, 1988). 
The expectancy model of placebo effects states that acquiring information about an 
association between stimuli leads to the formation of conscious expectancies that one 
stimuli will lead to another. When activated, these expectancies lead to nonvolitional 
responses that are in line with the expectancies (Kirsch, 1985). For example, when a 
person expects pain relief from a pill, they experience pain relief; when a person 
expects anxiety reduction, they experience anxiety reduction.  
 Even today these two models are often discussed as if they are mutually exclusive 
and diametrically opposed (e.g. Draganich & Erdal, 2014), which is baffling when 
one considers that the foremost theorists in each opposing camp stated explicitly that 
both conscious and unconscious learning could be involved in placebo effects. For 
example, Wickramasekera (1980) states that social learning and verbal instruction – 
which must be mediated consciously – can provide the means by which associations 
between stimuli are initially formed, with the association becoming more reflexive 
over time. Similarly Kirsch (1997) states that unconscious conditioning can be 
involved in placebo effects, as a source of conscious expectancies – because we 
consciously take note of the effects that result from certain stimuli and therefore come 
to consciously expect those effects. Much of the reason for the dichotomising of the 
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role of unconscious and conscious processes lies in the conflating of experimental 
procedures with the cognitive phenomenon that they are thought to give rise to – 
verbal instruction with conscious expectancy, and conditioning procedures with 
unconscious conditioning. This conflation of procedures with their underlying causes 
may be due to findings that would seem to indicate that expectancies and conditioning 
are separate processes that are overseen by separate systems. For example objectively 
measurable, physiological placebo effects have been brought about by conditioning 
procedures that were undetectable by participants and that therefore could not have 
been due to conscious expectancies (e.g. respiratory depression following opiate 
administration, Benedetti et al., 1998; or secretion of human growth hormone, 
Benedetti et al., 2003). The existence of certain types of placebo effects that can be 
conditioned without conscious awareness does not necessarily imply that conditioning 
procedures always lead to unconscious conditioning only. In fact, if the effects of the 
treatment used in a conditioning procedure are able to be detected by participants, 
they will usually generate conscious expectancies about the consequences of the 
treatment (e.g. Schafer, Colloca, & Wager, 2015), making it very difficult to separate 
the relative contribution of conscious expectancies from those of unconscious 
conditioning in any resultant placebo effects. 
The debates over the relative merits of expectancy vs conditioning models of 
placebo effects are largely a thing of the past, giving way to hybrid models that 
integrate the two approaches. Stewart-Williams and Podd (2004) state that there is no 
reason why the two traditional explanations of the placebo effect need be mutually 
exclusive. According to their model, presented in Figure 1.1, both subjectively- and 
objectively-measurable placebo effects can be caused by instruction, conditioning 
procedures, or a combination of both. The difference between the two is that placebo 
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Other sources of 
learning (verbal, 
information, 
vicarious) 
Classical 
conditioning 
procedures 
Nonconscious 
learning 
Conscious 
Expectancy 
Learning 
Physiological 
Placebo Effects 
Subjective 
Placebo Effects 
Input: 
The source of learning 
Output: 
The outcome of learning 
Mediation: 
The form of learning 
effects brought about by a conditioning procedure can be mediated either consciously 
or unconsciously whereas placebo effects induced by instruction only must be 
mediated consciously. A similar integrated model has been proposed by Benedetti and 
colleagues (2003), who suggest that unconscious physiological functions (e.g. 
hormone secretion) are affected more by conditioning, whereas expectancies play a  
greater role in conscious physiological processes (e.g. pain). 
Fig 1.1 The role of classical conditioning procedures and expectancy in the 
production of the placebo effect (reproduced from Stewart-Williams and Podd, 2004). 
 
 
 
 
 
 
 
 
 
 
Another integrated theory of placebo effects developed by Colloca and Miller 
(2011a), proposes that while verbal cues, conditioning, and social cues are different, 
all are sources of information that can be decoded by organisms in order to generate 
expectancies. This framework does not marry the source of information to the type of 
learning involved, instead suggesting that all cues can provide information that 
generates expectancies. Colagiuri and colleagues (2015) used this framework and 
took it a step further, suggesting that, rather than being thought of as a purely 
conscious process, expectancy should be defined more broadly as a 
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predictive/anticipatory state that may or may not be consciously accessible. Removing 
the need for expectancies to be conscious sidesteps the chief problems faced by both 
sides of the expectancy vs conditioning debate. Collapsing conscious and unconscious 
learning into a single broad expectancy construct: (i) recognises that species who do 
not possess formal language can still anticipate events, which creates continuity in the 
learning literature across species, (ii) provides a unified, flexible framework for 
understanding placebo effects, regardless of the source of the information provided to 
subjects. In this thesis when I refer to expectancies, it will be in this broader sense.   
1.1.3.2 Alternative Theories of Placebo Responding 
There are other theories about how changes in observed symptoms following an 
inert treatment occur. Three of these of these could be considered theories of placebo 
responding rather than placebo effects, whereas the fourth is a theory concerning a 
legitimate – though non-traditional – form of placebo effect. The difference between 
placebo responses and placebo effects is a subtle but important one. Placebo 
responding involves any change that occurs following the administration of a placebo 
treatment, whereas the placebo effect consists of only those changes that are caused 
by patients’ expectancies (Chung et al., 2017). Thus placebo responding can be 
divided into non-expectancy-driven placebo responding (i.e. response bias) and 
placebo responding that is a legitimate placebo effect. 
Three of the most commonly acknowledged sources of response bias are: (i) 
demand characteristics (where participants consciously misrepresent the way they feel 
following placebo treatment in line with what they believe are the aims of the 
experiment), (ii) response shift (where placebo treatment prompts a retroactive 
recalibration of a response scale rather than an actual change), and (iii) the Hawthorne 
effect (where a change in a variable is brought about by the simple act of being 
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observed rather than due to any experimental manipulation of expectancies). 
Determining what portion of observed placebo responses are due to genuine placebo 
effects and what portion are due to response bias can be extremely difficult, especially 
when the variables measured are subjective – e.g. pain – and can only be measured by 
self-report. Research into variables that cannot be measured objectively must assume: 
(1) that participants are able to access and accurately report their attitudes and 
perceptions; and (2) that, if they are able to appraise these variables accurately, that 
they will then decide to truthfully report this to researchers. Whether these 
assumptions are justified is a matter of considerable debate. It is hard to accurately 
estimate the extent to which response bias affects behaviour and reports of subjective 
phenomena. In fact a meta-analysis of placebo-controlled clinical trials that compared 
size of change following placebo to change in a no-treatment control group found 
evidence suggesting that placebo effects may be weak or non-existent (i.e. mostly 
response bias (Hróbjartsson & Gøtzsche, 2001). This review has been called into 
question however for including multiple medical conditions in a single analysis rather 
than examining placebo effects on a condition-by-condition basis (Stewart-Williams 
& Podd, 2004).  
A fourth theory suggests that the placebo effect is a form of perceptual shift. 
Perceptual shift can be defined as an unconscious change in the attitude to or 
perception of a sensation. This is in contrast to the most popular current model of the 
placebo effect, which suggests that the placebo effect is due to the organism learning 
to endogenously simulate a previously exogenous process (e.g. a cued endogenous 
secretion of endogenous opiates following cues formerly paired with ingestion of 
exogenous opiates). Stewart-Williams and Podd’s (2004) definition of a placebo 
effect states that the placebo effect is a genuine psychological or physiological effect 
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brought about by a treatment that is not due to the inherent powers of the treatment 
itself. Most traditional theories of placebo effects would not consider perceptual shift 
a “genuine” placebo effect. Yet, if it comes about unconsciously, perceptual shift 
could certainly be considered a genuine change in a psychological outcome (i.e. the 
perception of pain). While there are theories that present intriguing, plausible, and 
coherent accounts of the placebo effect as a form of perceptual shift (e.g. Buchel, 
Geuter, Sprenger, & Eippert, 2014; Wall, 1993) these are yet to be confirmed via 
direct evidence. 
1.1.3.3 Summary 
The debates of the past concerning whether conscious expectancy or unconscious 
conditioning are the chief source of placebo effects have been largely abandoned in 
recent years in favour of theories that take a more lateral ??approach, focusing on 
examining the information provided by cues rather than what category those cues fall 
into. It is not the goal of this thesis to test any of the theories discussed in section 1.1 
formally. Therefore I will confine my discussion of the placebo effect in the 
experimental chapters within the framework of the modern hybrid theories, such as 
Stewart-Williams and Podd’s (2014) outlined in section 1.1.3.1 above. I will also use 
the broader definition of expectancy proposed by Colagiuri and colleagues (2015).  
1.2  Drug Withdrawal and Expectancy 
The total economic, social, political, medical, and personal costs of drug addiction 
are indisputably high. The 2011 UN report on Drugs and Crime estimated that 3.1-
6.1% of the world’s population (149-271 million) used cannabis, cocaine, opiates, or 
methamphetamine the previous year and of these 15-39 million were problem users 
(UNODC, 2011). The National institute on Drug Abuse estimates that in North 
America alone the costs related to crime, lost work productivity, and health care from 
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abuse of tobacco, alcohol, and illicit drugs totals $712 billion (NIH, 2016). The total 
societal cost of abusing prescription opiates in the US was estimated at $55.7 billion 
in 2007 alone (Birnbaum et al., 2011). The scale of the problem is even more striking 
when one considers that the estimates above do not include readily available and 
widely-used prescription drugs such benzodiazepines, barbiturates, and 
nonbenzodiazepam hypnotics. The cost of problem drug use and the difficulty in 
treating it makes the continued investigation of the factors that contribute to addiction 
of vital importance. 
Theories concerning drug addiction naturally inform addiction treatments. 
Evidence is conclusive that receiving treatment for drug addiction is generally more 
effective for maintaining abstinence than not being in treatment (for a review see 
Prendergrast, Podus, Chang, & Urada, 2002). However relapse rates following 
treatment have remained high (Allsop & Saunders, 1989; Dimeff & Marlatt, 1998; 
Gossop, 1989; Mulé, 1984; Prochaska et al., 1991), despite a wide array of treatment 
approaches. The main impediment to developing more successful treatments of 
addiction is the sheer complexity and variability of reasons why different individuals 
start using and continue to use drugs (DiClemente, Schlundt, & Gemmell, 2004; 
Polivy & Herman, 2002). Treatments for addiction can be grouped into two broad 
categories: cognitive-behavioural therapies and pharmacological therapies.  
Cognitive-behavioural therapies are based on psychosocial theories of problem 
drug use which hold that drug use satisfies a psychological need for certain people. 
For example, it is thought that drug use; (i) helps people reduce negative affect (Baker 
et al., 2004) or increases positive affect (Stewart, De Wit, & Eikelboom, 1984), (ii) 
helps people feel social acceptance in situations when drug use is encouraged by peers 
(Brown, Goldman, & Christiansen, 1985), or (iii) simply satisfies an innate 
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compulsion caused by certain fixed personality characteristics, such as a greater-than-
normal need for stimulation and arousal (Barnes, 1979).  
Pharmacological treatments on the other hand are not designed to address the 
underlying psychosocial motivations behind drug addiction, but instead attempt to 
manage the physiological responses to either drug use or drug withdrawal. The most 
common forms of pharmacotherapy take one of two approaches: (i) reducing 
withdrawal symptoms via replacement of the drug in question with an agonist (e.g. 
methadone for heroin addiction or nicotine patches for smoking), or (ii) maintaining 
the addicted individual on a drug that is antagonistic to the drug to which they are 
addicted (e.g. naltrexone for opiates or alcohol) and which will induce aversive 
physiological symptoms if they break abstinence and use the drug. Psychosocial 
therapies are generally less effective than pharmacotherapies at delivering longer-term 
abstinence from addictive drugs (Barnett, 1999; Higgins et al., 1995; Latt, Jurd, 
Houseman, & Wutzke, 2002; Lee & Rawson, 2008; Magill & Ray, 2009; Sees et al., 
2000; Silverman et al., 1998; Stead et al., 2012), but the best results are obtained 
when the two are used concurrently (Ball & Ross, 2012; O’Brien, 1997).  
Addiction research tends to take either a cognitive-behavioural or a 
pharmacological approach; however there is a smaller branch of the addiction 
literature that is based on the idea that placebo effects, and the expectancies that 
generate them, can play a role in maintaining addiction. This approach is based on the 
theories of conditioning and expectancy discussed in section 1.1. Its central premise is 
that addicted individuals’ expectancies of what will happen when they ingest or 
abstain from drugs can affect the real-time experience of drug use or abstinence and 
maintain addiction. Like cognitive-behavioural and pharmacological theories of 
withdrawal and relapse, theories of placebo withdrawal can also inform treatment of 
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addiction. This thesis will explore the potential of two methods for integrating drug 
withdrawal expectancies into clinical interventions: manipulating information about 
the likely effects of abstinence and manipulating information about dose. Each of 
these methods will be discussed in more detail in subsequent sections. Before doing 
so, however, it is important to review the theory and evidence as to how expectancies 
affect addiction and withdrawal. 
1.2.1 Expectancies and Addiction 
A drug outcome expectancy is a belief held by an individual about what will 
happen if they choose to use or abstain from a drug (Bandura, 1977). These 
expectancies are derived mostly from direct experience with drug use and the strength 
of the expectancies correlated with the individual’s experience with both drug use 
(e.g. linked with duration and regularity of use) and abstinence (e.g. linked with 
number of quit attempts). However expectancies can also be influenced by other 
factors such as: (i) the attitude of the individual’s peer group, parents, or society at 
large to drug-use and abstinence, (ii) differences across individuals in personality, and 
(iii) cognitive and attentional biases (Leventhal & Schmitz, 2006). Bandura (1977) 
states that the objective outcomes of each individual’s use (and abstinence) over the 
years are not as important in determining that individual’s future use (or abstinence) 
as their memory of those outcomes, in that the memory of these outcomes and the way 
those outcomes made them feel that inform outcome expectancies.  
 The study of expectancies in addiction falls into two broad areas: study of the role 
of expectancies in volitional behavior (why a person chooses to continue to use a drug 
despite net negative outcomes) and the role of expectancies in non-volitional 
behaviour. The study of expectancies in volitional behavior is the study of value: if 
the expected effects are valued by the individual, they will be motivated to take the 
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drug, irrespective of whether those expected effects are warranted based on what 
actually happens when they take the drug (Cox & Klinger, 1988). The primary arbiter 
of motivation is affect, in that the individual will be motivated to use the drug if they 
believe the drug will enhance positive affect (positive reinforcement) and/or reduce 
negative affect (negative reinforcement) (Cooper, 1994). Negative reinforcement is 
thought to be one of the primary motivators of continued drug use for individuals with 
addiction (Baker et al., 2004). For these people continued use of the drug is mainly 
driven by expectancies that it will help them avoid the host of unpleasant 
physiological and psychological symptoms that accompany abstinence. The 
expectancies then guide their instrumental behavior: to use the drug.  
The study of how expectancies motivate drug use is the study of instrumental 
responding – the study of why people choose to use drugs. But expectancies 
concerning: (i) the likelihood of experiencing certain withdrawal symptoms, (ii) the 
presence or absence of a drug in the body, can also influence drug users’ involuntary 
physiological and psychological responses. Involuntary responses to drug 
expectancies are thought to be the principal source of placebo effects (Kirsch, 1999).  
As referred to in previous sections, most of the study of drug placebo effects has 
been in the area of pain and analgesia. However as long as there is information 
available about a drug – such as the name of the drug, what family of drugs it belongs 
to, and what its effects will be – most drugs, analgesics or otherwise, will have 
expectancies attached to their use, and therefore will also be subject to placebo 
effects. Drugs of abuse are no exception. For example studies have shown that the 
expectancy of having ingested alcohol (Briddell & Wilson, 1976; De Boer, Schippers, 
& van der Staak, 1993; Fillmore & Vogel-Sprott, 1992; Lyvers & Maltzman, 1991), 
THC (Camí et al., 1991; Kirk, Doty, & De Wit, 1998; Metrik et al., 2009), caffeine 
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(Flaten & Blumenthal, 1999; Irving. Kirsch & Weixel, 1988; Lotshaw, Bradley, & 
Brooks, 1996), opiates (Benedetti et al., 1998; Bingel et al., 2011), nicotine (Juliano 
& Brandon, 2002), and d-Amphetamine (S. H. Mitchell et al., 1996) can elicit 
subjective and objective effects that mimic or augment the active pharmacological 
effects of ingesting the drug. For example, informing people they have consumed 
caffeine can increase alertness and systolic blood pressure irrespective of whether it 
has actually been consumed (Kirsch & Rosadino, 1993) and telling abstinent smokers 
they have consumed nicotine can reduce cravings even if no nicotine has been 
consumed (Gottlieb et al., 1987).  
Drug users hold expectancies concerning both the effects of drug use and the 
effects of abstinence (Huntley & Juliano, 2012). And just as expectancies that one has 
consumed a drug can lead to placebo effects consistent with drug use, expectancies 
that one does not have a drug in one’s system can lead to placebo withdrawal. It has 
been suggested that these placebo withdrawal symptoms may play a role in 
maintaining addiction by exacerbating pharmacological withdrawal symptoms and 
therefore increasing likelihood of relapse (Hendricks & Leventhal, 2013; Kleber, 
1981; Phillips, Gossop, & Bradley, 1986). Before discussing the evidence for this 
however, it is important to define and describe drug withdrawal and the part it plays 
in maintaining addiction.    
1.2.2 Drug Withdrawal and its Role in Addiction 
Withdrawal is the name given to a cluster of mostly unpleasant symptoms that 
occur following discontinuation or reduction of dose of a substance that has come to 
be relied upon for maintaining affective, cognitive and physiological equilibrium. 
Withdrawal symptoms can be divided into two categories: physical and 
psychological. Physical withdrawal symptoms are more likely to be specific to 
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particular drugs, begin rapidly upon cessation of drug-taking, generally peak within 
the first 1-3 days of abstinence, and dissipate within 7-21 days (Hughes, Higgins, & 
Bickel, 1994)1. These symptoms include tremors, goose-bumps, runny nose, diarrhea, 
constipation, headache, vomiting, sneezing, sweating, muscle-cramps, and 
hallucinations. Psychological symptoms on the other hand tend to be common among 
all drugs of abuse (West & Gossop, 1994) and persist considerably longer (Gawin & 
Kleber, 1986; Hughes et al., 1994; Hughes, Higgins, & Hatsukami, 1990; Loimer, 
Linzmayer, & Grünberger, 1991; Maurer & Vogel, 1967). These symptoms include 
restlessness, irritability, depression, anxiety, boredom, fatigue, and difficulty 
concentrating. Addicts generally rate psychological withdrawal symptoms as more 
distressing and difficult to endure than physical withdrawal symptoms (Cohen, Klett, 
& Ling, 1983).  
Whether psychological or physical, withdrawal symptoms are a major obstacle for 
the abstinent addict to overcome. They are a source of great fear (Eiser & Gossop, 
1979) and are among the primary predictors of both maintenance of and relapse to 
addiction (Allsop et al., 2012; Baker et al., 2004; Capell & Le Blanc, 1981; Killen et 
al., 1992; McCarthy, Piasecki, Fiore, & Baker, 2006; Piasecki, 2006; Piasecki, Fiore, 
& Baker, 1998; Piper et al., 2011; Strong et al., 2011; West, Hajek, & Belcher, 1989). 
There are, of course, many factors other than withdrawal that contribute to addiction, 
abstinence, and relapse (e.g. abstinence goals, expectation of success, expected 
difficulty of quitting, perceived self-efficacy, negative affect, and stress); however, 
treating these other factors usually involves some form of psychotherapy. As 
mentioned in Section 1.2, psychotherapy tends to be less effective than at promoting 
                                                 
1 Although there is evidence that certain symptoms – such as reduced blood pressure, heart rate, body 
temperature, pupillary dilation and sensitivity of the respiratory centre to CO2 – can persist for 3 to 6 
months following abstinence, albeit at a level that is unobservable to the naked eye and unnoticeable to 
the addict themselves.(Martin & Jasinski, 1969) 
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long-term abstinence than pharmacotherapeutic interventions targeted at managing 
withdrawal symptoms during abstinence. Hence an intervention that can increase the 
efficacy of these pharmacotherapeutic interventions may also further reduce chances 
of relapse and help individuals recovering from addiction to remain abstinent. The 
interventions discussed and examined in this thesis – that are designed to reduce 
overall withdrawal by reducing the negative impact of expectancies of withdrawal – 
have great potential: They are cheap and easy to implement, involve no 
psychotherapy, and can be easily integrated into existing pharmacotherapeutic 
interventions.  
1.2.3 Evidence for Placebo Withdrawal  
Most research on drug placebo effects has concentrated on investigating placebo 
effects that occur in the context of drug taking. Far less effort has been spent 
investigating placebo effects that occur when an addicted individual believes they 
have a reduced level of a drug in their system – i.e. placebo withdrawal. The placebo 
withdrawal literature can be grouped into studies that use experimental conditioning 
procedures and those that manipulate the information provided to participants. Both 
conditioning procedures and instructional manipulations can be sources of 
expectancies, using the broader definition discussed in section 1.1.3.1. Many of the 
studies discussed pre-date more modern theories of expectancy and placebo effects 
and are thus framed in the language of the earlier theories of classical conditioning 
discussed in Section 1.1., which treat conditioning as unconscious and expectancy as 
conscious. For the sake of fidelity to the original theories I will also use this language, 
despite the theories themselves being superseded. 
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1.2.3.1 Placebo Withdrawal Brought About By Cue Exposure 
The idea of a placebo drug withdrawal response is not new. The first incarnation of 
the idea came from research in drug-related learning and, though it was not described 
as such, the phenomena and mechanisms described bare all the hallmarks of a placebo 
effect. There are three models of drug conditioning: conditioned tolerance, 
conditioned mimicry, and conditioned withdrawal. Largely because the symptoms are 
the same, conditioned tolerance and conditioned withdrawal are terms that have been 
used interchangeably by some theorists (e.g. O’Brien and colleagues, 1975, 1977). 
The discussion below attempts to separate the two concepts conceptually. 
Conditioned Tolerance: Tolerance is a neuroadaptive, conditioned compensatory 
response of the organism to overexposure to a stimulus that results in decreases in 
sensitivity to that stimulus’s incentive properties (Craft & Lustyk, 2013) among other 
psychophysiological changes. The process that leads to the development of tolerance 
to a drug is called allostasis, which is a long-term shift in homeostatic balance-point 
due to overexposure to a stimulus (in this case a drug). Tolerance is the reason why, in 
addicted organisms, the dose of a drug required to achieve the same 
psychophysiological effects increases with repeated exposures. According to 
conditioned tolerance theory (Siegel, 1979), repeated pairings of environmental 
stimuli with the effects of a drug causes these stimuli to become a signal that the drug 
effects are imminent, triggering these compensatory drug-opposite effects prior to the 
ingestion of the drug (Siegel, 1975, 1983). Conditioned tolerance has been 
demonstrated by showing that morphine-induced analgesia in rats is reduced if rats 
receive a painful stimulus in the same environment that they received morphine 
injections (see Siegel et al., 2000, for a review). An important point to note is that, 
according to this theory, the objective symptoms of the pre-emptive preparatory 
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tolerance response are identical to the symptoms of the acute phase of withdrawal; 
both responses are opposite in direction to the direct effects of the drug and will 
appear so both to the addict and outside observers. This is because, the theory goes, 
tolerance and withdrawal are intimately entwined phenomena: withdrawal is a result 
of tolerance and is its outward manifestation (Craft & Lustyk, 2013; Poulos & 
Cappell, 1991). The difference between withdrawal and a conditioned tolerance 
response is that withdrawal occurs due to medium- to long-term lack of the drug that 
has come to be relied upon for homeostasis, whereas conditioned tolerance is a 
preparatory response that readies the addicted organism for a dose of a drug that, 
without the response, may otherwise cause overdose. However the symptoms of 
conditioned tolerance and acute withdrawal are identical. 
Importantly, Siegel (1979) suggests that the conditioning of withdrawal symptoms 
to otherwise unrelated stimuli could contribute to relapse even after long periods of 
abstinence, when physical withdrawal symptoms have subsided. This process unfolds 
in several stages. The first is that during phases of an addicted individual’s life when 
they are using drugs regularly there are times when they must temporarily go without 
drugs. On these occasions they experience aversive withdrawal symptoms, which are 
rapidly abolished by using the drug. Thus, over the course of a drug-user’s ‘career’, 
drug use is repeatedly negatively reinforced via its reduction of withdrawal 
symptoms. Over time repeated negative reinforcement of drug use causes the drug-
seeking behaviour to become more reflexive and habitual, involving less conscious, 
goal-directed processing in initiating and carrying out the actions required to obtain 
drugs, and with less consideration of long-term consequences (Baker et al., 2004). 
However, when the drug-user finally does manage to quit, due to the conditioning 
processes described above, and even after long periods of abstinence, exposure to 
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drug-related cues can elicit a dormant Pavlovian conditioned-tolerance response, 
evoking symptoms similar to the withdrawal symptoms experienced during addiction. 
The re-appearance of withdrawal signs then triggers the dormant, habitual 
instrumental response to withdrawal acquired during periods of regular use – drug 
seeking – and the user relapses. This model is important because it explains how drug 
users may relapse even after long periods of abstinence when they are no longer 
experiencing any physical withdrawal symptoms.  
Experimental evidence from the addiction literature provides support for Siegel’s 
theory of ‘drug-opposite’ conditioned tolerance responses occurring after long 
abstinence. For example, when shown drug-related stimuli such as injecting 
apparatus, either in-person or via videotape, addicts who have been abstinent for 
months can experience subjective symptoms such as acute craving and tension, as 
well as objectively observable symptoms such as goose-bumps, lachrymation (tears), 
runny nose, and decrease in skin temperature and skin resistance (Childress, 
McLellan, & O'Brien, 1986; O'Brien et al., 1977; Sideroff & Jarvik, 1980; Teasdale, 
1973; Ternes et al., 1979; Vaillant, 1988). In contrast non-addicted control groups 
show no such responses after exposure to the same stimuli (Ternes et al., 1979). In 
these studies visual cues associated with drug use were able to induce withdrawal-
like, drug-opposite reactions in individuals who should not have had any 
physiological or pharmacological reason for experiencing them because they had been 
abstinent for months and were no longer physically addicted. The literature on cue-
induced withdrawal tends to refer to these drug-opposite reactions caused by exposure 
to drug-taking stimuli as ‘conditioned withdrawal’. However, as I will argue below, 
they are better described as conditioned tolerance, since the drug-opposite response is 
evoked by stimuli associated with drug-taking rather than with abstinence.  
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Conditioned Withdrawal: Like Siegel (1979), Wikler (1948, 1973) also believed 
that drug-opposite responses could be conditioned and re-appear long after the 
addicted individual had ceased regular use. However, unlike Siegel’s conditioned 
tolerance theory, he proposed that the conditioned drug-opposite response was due to 
conditioning to cues present during abstinence and withdrawal rather than to cues 
present during drug use. He called this syndrome ‘conditioned withdrawal’ (Wikler & 
Pescor, 1967).  Like Siegel’s conditioned tolerance theory of relapse, Wikler believed 
that conditioned withdrawal led to relapse by evoking a Pavlovian conditioned 
response that was opposite to the direct effects of the drug and which acted as a 
conditioned stimulus to reinstate a dormant, reflexive, instrumental drug-use 
response. Conditioned withdrawal differs from conditioned tolerance not in its 
relationship to the direct effects of the addictive drug – both theories hold that 
aversive conditioned drug-opposite responses reinstate negatively-reinforced drug-
seeking behaviour – but in its relationship to the stimuli that evoked the response. 
Siegel believed the aversive conditioned symptoms were evoked by associations with 
drug use, whereas Wikler believed they were associated with drug withdrawal.  
The difference between conditioned tolerance and what might be called 
conditioned withdrawal responses is best captured in opponent-process theory 
(Solomon & Corbit, 1974). Opponent-process theory has much in common with 
theories of tolerance to addictive drugs, but is much broader in scope as it applies to 
all hedonic and affective states, positive or negative. Opponent-process theory states 
that repeated exposure to a stimuli that causes a particular hedonic or affective state 
evokes compensatory mechanisms in the central nervous system that lead to reduction 
in the intensity of those affective states (i.e. allostasis and tolerance). These 
compensatory mechanisms they call ‘opponent processes’, and cite drug use 
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specifically as an example. Drug tolerance and withdrawals, like any homeostatic 
response, are a slave process, that can only be evoked indirectly via the absence of the 
primary process, which in this case is the drug. According to the theory, both the 
primary process and its opponent process can be classically conditioned to stimuli 
paired with either state. However, and importantly for this discussion, whereas the 
response to stimuli associated with the primary process should be biphasic, the 
response to stimuli associated with the opponent process should be monophasic. Thus 
exposure to stimuli related to drug use should produce both conditioned appetitive 
responses and conditioned compensatory responses. This may explain why presenting 
cues that have been paired with drug administration has led to such seemingly 
contradictory results, with conditioned responses that both mimic and oppose the 
unconditioned stimulus in different studies (see evidence for ‘conditioned tolerance’ 
and ‘conditioned mimicry’ above). Stimuli paired with hedonic and affective states 
related to the absence of the drug on the other hand (i.e. withdrawal symptoms) 
should only produce conditioned responses in the same direction as the opponent 
process (Solomon & Corbit, 1974).  
If Solomon and Corbit’s (1974) theory is correct, a properly-named conditioned 
withdrawal effect should occur in response to presentation of cues associated with 
drug abstinence and drug withdrawal, not with the direct euphoric effects of using the 
drug, and it should be monophasic – in the same direction as the withdrawal 
syndrome. To test this, experimental paradigms are needed that pair environmental 
cues with withdrawal symptoms rather than with drug use. Two designs have been 
used to achieve this. The first method of testing conditioned withdrawal was 
employed by Wikler and Pescor (1967), who attempted a naturalistic simulation of a 
conditioned withdrawal scenario. Rats were given morphine injections every day over 
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several days. Following injections rats were housed in their home cage but sixteen 
hours later were moved to a separate distinctive environment for the 7.5 hours 
preceding the next injection, when presumably they were in a state of withdrawal. 
After several days of this procedure morphine administration was then terminated and 
the rats observed in both their home environment and the ‘withdrawal’ environment 
for the presence of ‘wet-dog shakes’, a distinctive and well-proven withdrawal 
response in rodents. The rats exhibited this behavior more in the withdrawal 
environment than the home environment, indicating that a symptom experienced 
during abstinence could be conditioned to cues presented during abstinence, but then 
evoked long after recovery. Supporting Wikler and Pescor’s (1967) finding, Trost 
(1973) found that morphine-addicted rats exposed to locked running wheels during 
the acute stages of withdrawal engaged in significantly more running behavior – a 
behavioural symptom of withdrawal in rodents – in the same (unlocked) wheels long 
after recovery than non-addicted rats who had undergone identical exposure without 
the presence of addiction. Thus it appears that cues present during acute withdrawal 
can elicit withdrawal-like symptoms long after recovery, providing support for the 
theory that exposure to these cues after recovery could evoke withdrawal symptoms 
and prompt relapse.  
The second method for testing conditioned withdrawal involves inducing 
withdrawal artificially via the administration of an antagonist drug to addicted 
organisms. Antagonist drugs allow the rapid inducement of withdrawal without 
having to wait, and thus allow for pairing of external cues with the opponent process 
in a more controlled manner. During the trial phase the antagonist (e.g. naloxone, an 
opiate antagonist) is injected repeatedly in the presence of neutral cues so that cues 
and the injection apparatus are paired with the effects of the antagonist (i.e. 
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withdrawal symptoms). Another group is given the same schedule of antagonist 
injections but without the presence of the cue. During the test phase a saline injection 
is administered alongside presentation of the cues and withdrawal symptoms are 
monitored. Studies using this design have found conditioned withdrawal effects. For 
example, former heroin addicts on a methadone program, who had a compound 
stimulus of an odour plus music paired with naloxone injections during a conditioning 
phase, exhibited both physiological and psychological symptoms of withdrawal when 
given saline injections under the guise of naloxone alongside the paired cues (O’Brien 
et al., 1977). Because the individuals in question were given the saline injection + 
cues when they had methadone in their system they had no pharmacological reason 
for experiencing withdrawal, yet the cues paired with the antagonist during training 
were able to evoke withdrawal symptoms such as yawning, tearing/lachrymation, 
runny nose, and subjective feelings of withdrawal sickness. Furthermore, participants 
were aware that the saline injection they were given during test was actually saline 
not naloxone, thus should not have had a conscious expectancy of experiencing 
withdrawal. Animal studies have found similar effects. Rats presented with compound 
‘tone + light’ cues paired with naloxone injections during a trial phase showed higher 
rates of heroin self-administration and inter-cranial self-stimulation when they were 
presented alongside a saline injection on test than rats given the same cues but in an 
unpaired fashion (Kenny et al., 2006; Kenny & Markou, 2005).  
The findings in the studies above clearly demonstrate that, in both humans and 
animals, the experience of withdrawal is influenced by more than just the level of a 
drug in the body and time spent abstaining from a drug. In these studies presentation 
of contextual cues paired with drug withdrawal elicited withdrawal symptoms. 
Consistent with Colagiuri and colleagues’ (2015) definition of expectancies as a 
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general preparatory/anticipatory state, such contextual cues could be considered a 
source of expectancies of the unpleasant symptoms associated with abstinence, and 
hence the placebo withdrawal effects that were observed.. 
There are weaknesses in the human studies discussed above, particularly with 
regard to inadequate sample size (e.g. none of the studies conducted by O’Brien and 
colleagues listed above had a total sample size greater than N = 10) and lack of 
replication. However, overall they indicate a potential for cues paired to both 
administration of a drug and abstinence from a drug to evoke placebo withdrawal-like 
symptoms in individuals who had no reason pharmacological reason for experiencing 
them, either because they were long abstinent and their withdrawal symptoms had 
disappeared, or because they were on a high dose of methadone. If experienced during 
acute or chronic abstinence these placebo withdrawal effects could potentially 
augment pharmacological withdrawal symptoms and increase chances of relapse. 
1.2.3.2 Verbal Instruction and Placebo Withdrawal 
Addicted individuals’ expectancies about what will happen when they use or 
abstain from a drug generally reflect their own direct experience with use and 
abstinence, their observation of others’ experiences, the value their peer group places 
on use or abstinence, personality factors, and the way they remember their 
experiences of use or abstinence (for a review, see Leventhal & Schmitz, 2006). Like 
research using conditioning procedures, the majority of research into the effect of 
verbal instruction on drug states is directed at manipulating expectancies concerning 
drug use and symptoms of drug use rather than on abstinence and withdrawal.  
However there is some evidence that individuals’ expectancies about what will 
happen when they abstain from a drug can influence not only the likelihood that they 
will use drugs in the future, but also, via the placebo effect, their actual experience of 
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withdrawal symptoms (Hendricks & Leventhal, 2013). There are several research 
designs that have been used to measure the influence of expectancy on withdrawal. 
Correlational studies: In correlational designs participants’ expectancies 
surrounding withdrawal and abstinence are measured prior to testing. Other factors 
such as level of dependence (e.g. number of drinks or cigarettes per day) and 
demographic factors are also measured. Participants then abstain from their drug of 
choice and report on their withdrawal symptoms. If participants’ expectancies predict 
incremental variance in withdrawal during abstinence over and above level of 
dependence and other factors, this is taken as evidence that expectancies have a direct 
influence on the experience of withdrawal.  
Hendricks and Leventhal (2013) found that smokers’ expectancies of withdrawal 
were the strongest predictors of withdrawal symptoms such as negative affect, urge to 
smoke, headaches, hunger, and anhedonia, following 16 hours of abstinence, than age, 
gender, ethnicity or level of dependence. Optimistic expectancies of abstinence 
predicted weaker reported withdrawal effects than did pessimistic expectancies. 
Phillips, Gossop, and Bradley (1986) measured maximum withdrawal distress 
experienced by 34 abstinent heroin addicts during a 21-day methadone dose-taper 
procedure. Dose tapering is a commonly-used procedure for transitioning off an 
addictive drug, where dose of the drug is progressively reduced over a certain period, 
instead of abruptly terminated. They found that, of a list of predictors including 
personality factors, length of opiate use, age, expected withdrawal symptoms, and 
starting dose of methadone, only expectancy of withdrawal and neuroticism (a proxy 
measure of anxiety) significantly predicted level of withdrawal distress. That factors 
relating to expectancy and anxiety would be better predictors of subjective withdrawal 
distress than more objective indices such as starting dose of methadone (a proxy for 
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level of dependence at admission) or duration of dependence, is compelling, and an 
indicator that expectancies can mediate the experience of withdrawal.  
The limitation with purely correlational studies is that they do not establish 
causation. Therefore, in order to determine whether they influence the experience of 
withdrawal directly, expectancies must be manipulated directly by researchers.  
Experimental Studies: There are two methods of manipulating the expectancies 
surrounding drug effects verbally: either by attempting to manipulate users’ existing 
expectancies about the effects of use (or abstinence), or by manipulating their beliefs 
as to whether or not they have ingested the drug in question. The first method rarely 
succeeds, since users of drugs generally have well-established beliefs about any well-
known drug’s effects and these are unlikely to be altered by the assertions of an 
unfamiliar researcher (for an interesting discussion of this and other procedural issues 
surrounding placebo drug testing see Rohsenow & Marlatt, 1981). Most of the 
occasions when pre-existing expectancies of a drug’s effects have been manipulated 
successfully to produce placebo effects are when those effects are little known or 
invented by the researcher, such as the effect of caffeine on performance of a motor 
task (Fillmore, Mulvihill, & Vogel-Sprott, 1994; Fillmore & Vogel-Sprott, 1992). An 
exception to this is found in Tate and Colleagues (1994) who gave smokers 
instructions about what type of withdrawal symptoms to expect during 48 hours of 
abstinence. Those participants who were instructed that abstinence would lead to 
mainly physical (i.e. no psychological) complaints reported less mood disturbance but 
more physical withdrawal symptoms than those who were instructed to expect mainly 
psychological but no physical complaints. Those told to expect no symptoms reported 
less symptoms of both kinds. This is the sole study where placebo withdrawal effects 
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have been obtained by manipulating participants’ beliefs about the likely effect of 
abstinence on withdrawal symptoms.  
The second method of manipulating withdrawal with instructions has been much 
more widely used and has been much more successful in producing placebo 
withdrawal effects. In this method what is manipulated by researchers is not 
information about the likely effects of the drug, but information about either whether 
or not the drug has been ingested or how much of the drug has been ingested. Using a 
balanced placebo design – a factorial design where information about whether or not a 
drug has been administered is crossed with actual administration of the drug or its 
absence – one study found that when smokers who were quitting were told that they 
were receiving nicotine gum they reported fewer withdrawal symptoms than smokers 
who were told their gum contained no nicotine, irrespective of whether the gum 
actually contained nicotine or not (Gottlieb et al., 1987). Another balanced placebo 
study found that being told a nicotine inhaler contained nicotine significantly reduced 
intention to smoke in overnight abstinent smokers compared to being told the inhaler 
was placebo, once again regardless of whether the inhaler contained nicotine or not 
(Darredeau & Barrett, 2010). One might think from these results that expectancy has 
more of an influence on withdrawal than actual nicotine content. However Juliano and 
Brandon (2002), found that both instruction and nicotine administration had an effect 
on withdrawal symptoms.  
Nicotine is not the only drug whose withdrawal syndrome is affected by verbal 
instructions about dose. Tyrer, Owen & Dawling (1983) told 36 participants addicted 
to diazepam that their dose would be reduced over the course of 14 weeks, but varied 
the timing of these dose reductions surreptitiously, so that there were periods when 
they were actively misinformed about their dose. These misinformation periods were 
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different for each group. One group, the late withdrawal group, was allowed to 
believe their dose was being reduced when it was actually maintained on a steady 
dose. Another group, the early withdrawal group, had their dose reduced immediately 
to zero, but were allowed to believe they were staying on a low dose of diazepam 
when in fact they were being administered only placebo tablets. Eight of the 36 
addicted individuals reported experiencing withdrawal symptoms during times when 
there was no pharmacological reason for doing so (i.e. placebo withdrawal): in the 
late withdrawal group because they were on a maintenance dose and not being 
reduced, and in the early withdrawal group because they were had reached a zero-mg 
dose many weeks before and should not have been experiencing the acute effects of 
drug withdrawal any longer. Unfortunately however the authors do not report from 
which group(s) the 8 individuals came, information that seems important given that 
the two groups would have had slightly different expectancies during their 
‘misinformation period’.  
Alcohol withdrawal also seems to be affected by verbal instruction. Patients in an 
alcohol detoxification unit made more requests for diazepam and hydroxyzine tablets 
(two drugs that relieve the symptoms of withdrawal) when the drugs were given to 
them in a commercially recognisable form than when the same drugs were presented 
in an unrecognisable form. This finding implies that being able to recognise a drug 
one has ingested leads to expectancies about its effects and that these expectancies 
can increase the drug’s withdrawal-reduction effects (Francis & Nelson, 1984).  
1.2.4  Summary  
The idea of placebo withdrawal has been in existence in some form for a long time. 
According to Senay and Colleagues (1977) it is “an effect almost universally 
acknowledged to be important but not as yet established by rigorous observation.” (p. 
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361). Sadly our knowledge of the role of expectancy, or conditioning, in drug 
withdrawal has not improved a great deal in the forty years since this was written. 
This may be due to the many difficulties in conducting studies of sufficient power on 
individuals with addiction, who often have high rates of attrition and are (rightly) 
protected by rigorous experimental codes of conduct. Other than the literature 
examining craving and urge-to-use in nicotine addiction, few experimental studies 
have been conducted into the effect of expectancies, whether induced by conditioning 
or verbal instruction, on withdrawal symptoms in humans. The studies that have 
looked at placebo withdrawal in humans often suffer from inadequate sample sizes 
and omission of important inferential statistical analyses.  
Despite these issues, the results of the studies reviewed in the previous sections do 
seem to indicate at the very least that a placebo withdrawal syndrome exists and that it 
is driven by expectancies, using the broad definition of expectancy advocated by 
Colagiuri and colleagues (2015). It appears as though withdrawal symptoms can be 
paired with neutral environmental cues and then evoked by those cues alone, even 
long after recovery. It also appears as if verbal instructions concerning: (i) the 
likelihood of experiencing certain withdrawal symptoms and (ii) the presence or 
absence of drugs in the body, can elicit withdrawal symptoms even when there is no 
pharmacological reason for experiencing these symptoms. This thesis will examine 
whether expectancies can be manipulated via these two methods and which, if any, 
produces stronger placebo withdrawal effects. 
1.3 Aims and Hypotheses 
The goals of the series of experiments contained in this thesis are as follows. 
Experiments 1-3: To test the effectiveness of two types of verbal 
instruction to affect withdrawal symptoms in addicted individuals: (i) 
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instructions concerning the likely withdrawal symptoms they will 
experience during abstinence, and (ii) instructions concerning whether or 
not they have ingested caffeine.    
Experiments 4-5: To test whether being aware of the timing and 
magnitude of dose reductions in a dose taper procedure leads to more 
pronounced withdrawal symptoms than either (i) misinformation 
indicating no reductions or (ii) no information.  
1.3.1. Using Caffeine to Model Addiction 
The drug used to test these research questions will be caffeine. Caffeine is an ideal 
drug to model placebo withdrawal effects because: 
(i) it is an addictive drug with a well-proven withdrawal syndrome (for a 
review see Juliano and Griffiths, 2004) 
(ii) it is consumed on a daily basis by 80-90% of the adult population (Hughes 
& Oliveto, 1997), thus facilitating recruitment and ensuring sufficient 
statistical power to detect placebo effects.  
(iii)  its regular use is free from the social repercussions of addiction to class-A 
drugs, making it possible to use deceptive information techniques to model 
placebo effects that (a) are more analogous to expectancy in real-world 
situations and (b) would not be ethical if applied to individuals addicted to 
more serious and debilitating drugs. 
All drugs of addiction have withdrawal symptoms that are unique to that drug, and 
yet all drugs of addiction have symptoms in common (Hughes et al., 1994). In 
addition the principles of tolerance and withdrawal are universal across all addictive 
drugs (Craft & Lustyk, 2013; Shaffer et al., 2004). Thus, a central assumption of this 
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thesis is that findings related to placebo caffeine withdrawal can plausibly be 
generalised to the withdrawal syndrome of other addictive drugs.   
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Chapter 2: The Role of Withdrawal Information and Expectancies of 
Consumption in Caffeine Withdrawal2 (Study 1) 
 
2.1 Introduction 
Though placebo effects have been demonstrated for the positive effects of caffeine, 
such as increased alertness and improvements in mood (Flaten & Blumenthal, 1999; 
Kirsch & Rosadino, 1993; Kirsch & Weixel, 1988), no studies have examined 
whether nocebo caffeine withdrawal symptoms can be either induced or reduced by 
information alone. 
Study 1 attempted to test the extent to which caffeine withdrawal symptoms are 
affected by different types of information. As discussed in Section 1.2, expectancies 
of withdrawal have been manipulated by verbal instruction in two principal ways: (i) 
by manipulating information concerning the likelihood of experiencing symptoms, 
and (ii) by manipulating information concerning how much of the drug has been 
ingested. This study attempted to do both, thus allowing comparison of the two types 
of expectancy manipulation.  
Verbal instructions concerning the likely consequences of a treatment can 
influence the way people experience that treatment. For example warnings about side-
effects of a medication on a consent form can increase reporting of those side effects 
in the patients who are given the warning. Such warnings have produced cognitive 
deficits in chemotherapy patients (Schagen, Das, & van Dam, 2009), increased reports 
of gastrointestinal complaints in treatment of unstable angina with aspirin (Myers, 
                                                 
2 Published in a similar format as Mills, Boakes, and Colagiuri (2016). Placebo caffeine 
reduces withdrawal in abstinent coffee drinkers, Journal of Psychopharmacology, 30(4) 388-
394, doi: 10.1177/0269881116632374.  
 59 
Cairns, & Singer, 1987), and appetite change in participants receiving a placebo 
treatment for insomnia (Colagiuri, McGuinness, Boakes, & Butow, 2012).  
When it comes to withdrawal, verbal instructions about how much of a drug has 
been ingested have generally been more effective at inducing placebo withdrawal 
symptoms than studies that attempt to provide instructions about which symptoms to 
expect (Darredeau & Barrett, 2010; Francis & Nelson, 1984; Gottlieb, Killen, Marlatt, 
& Taylor, 1987; Juliano & Brandon, 2002). Only one study has successfully used the 
latter method to induce placebo withdrawal, eliciting greater reports of somatic 
withdrawal symptoms and less mood disturbance in abstinent smokers who were 
warned about somatic symptoms than those who were warned about psychological 
withdrawal symptoms (Tate et al., 1994). It has been suggested that this lack of 
success using the latter method is because drug users are sufficiently experienced with 
the withdrawal symptoms that they will experience during abstinence that any 
warnings about withdrawal have no incremental effect (Rohsenow & Marlatt, 1981). 
Caffeine withdrawal however may be an exception. Generally instructions about the 
likely outcomes of a drug or procedure only produce placebo effects successfully 
when the instructions relate to little-known or fictional effects, such as the effect of 
caffeine on motor performance (Fillmore & Vogel-Sprott, 1992). The fifth edition of 
the Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric 
Association & American Psychiatric, 2013) suggests that many regular caffeine users 
may never go without caffeine for long enough to be made fully aware of the 
relationship between non-consumption of caffeine and abstinence symptoms. Thus it 
is possible that a warning about symptoms of caffeine withdrawal may elicit a placebo 
caffeine withdrawal effect. 
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The central questions in this study were: (i) whether providing a group of abstinent 
caffeine consumers with a written statement alluding to caffeine withdrawal would 
lead to reports of more intense withdrawal symptoms than in a control group who did 
not receive this written statement, and (ii) whether a group of abstinent caffeine users 
led to believe they have received caffeine will report a greater reduction in withdrawal 
symptoms than a control group who are told they have received no caffeine. 
 
2.2 Method 
Design 
The flow diagram for Study 1 is presented in Figure 2.1. The study used a 2 x 2 x 
(2) mixed design. The first factor was Withdrawal Information, where participants 
were either given information suggesting that abstaining from caffeine could lead to 
substantial withdrawal symptoms (Told Withdrawal group) or were not given this 
information (Not Told Withdrawal group). The second factor was Caffeine 
Information, where participants were given decaffeinated coffee and were either told 
that it was caffeinated (Told Caffeine group) or decaffeinated (Told Decaf group). The 
third factor was Time, either pre-coffee ingestion (Pre-Beverage) or post-coffee 
ingestion (Post-Beverage). The primary outcome of interest was total self-reported 
caffeine withdrawal symptoms. However, blood-pressure readings and a test of 
concentration were also performed and recorded at both time points. 
Participants 
Participants were 89 (60 female) adult (mean age: 21.3; range 18-45) moderate to 
heavy coffee drinkers (≥ 3 ~200-ml cups per weekday) studying at the University of 
Sydney and participating in exchange for either course credit (n=84) or for $30 
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payment. All participants gave informed consent to participate in a study on the effect 
of caffeine on cognitive performance and were fully debriefed at the conclusion of the 
study that the true purpose of the study was to understand the effect of expectancy on 
withdrawal symptoms. 
A desired sample size of 20 per group (40 per main-effect group) was determined 
by consulting published studies examining caffeine placebo effects that had observed 
moderate to high effects sizes for outcomes equivalent to caffeine withdrawal (e.g. the 
Alertness and Tension variables in Kirsch and Weixel, 1988). 
Fig 2.1. Flow Diagram for Study 1. The Told Withdrawal group has a passage 
included in their Participant Information Statement (PIS) suggesting that they were 
likely to experience withdrawal symptoms. The Not Told Withdrawal group received 
an identical PIS except that this passage was omitted. The Told Caffeine group was 
told they were receiving caffeinated coffee. The Told Decaf group was told truthfully 
that they were receiving decaffeinated coffee. Pre- and Post-Beverage tests were, in 
order: 1) Blood Pressure; 2) CWSQ; 3) RVIP task.  
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Materials and Measures 
Demographic and Caffeine Use Questionnaire: Participants’ demographic 
information and daily caffeine use across all beverages was ascertained via a 
computerised questionnaire (see Appendix 3a). Estimates of caffeine content of 
beverages were obtained from Barone and Roberts (1996) or from content listed by 
the manufacturer. 
Drinks: Coffee was prepared in a DeLonghi Magnifica Automatic Coffee Machine 
using Peet’s Major Dickason’s Blend Decaffeinated coffee beans (see Appendix 1). 
These beans contain approximately 4% of the caffeine content of regular caffeinated 
coffee beans, amounting to 4 mg or less of caffeine per cup. The estimate for caffeine 
content per 10-gm shot of coffee was obtained directly from email correspondence 
between myself and the U.S. manufacturers of Peet’s Major Dickason’s Decaf blend. 
 Caffeine Withdrawal Symptom Questionnaire: A computerised version of the 
Caffeine Withdrawal Symptom Questionnaire (CWSQ; Juliano, Huntley, Harrell, & 
Westerman, 2012) was used to assess withdrawal symptoms The 32-items comprising 
this version of the CWSQ are arranged in nine separate factors: Drowsiness/Fatigue; 
Decreased Alertness/Difficulty Concentrating; Mood Disturbances; Decreased 
Sociability/Motivation to Work; Nausea/Upset Stomach; Flu-like Feelings; Headache, 
Acute Caffeine Effects, and Craving. Participants were asked to rate to what extent 
they were experiencing each symptom on a 5-item response scale from 0 (‘not at all’) 
to 4 (‘extremely’). Questions 2, 4, 6, 12, 15, 18, 19, and 20 of the CWSQ are reverse-
worded. These items were reverse-scored prior to analysis. The maximum possible 
score was 128. For a full list of items see Appendix 3b. 
RVIP task: In order to disguise the true purpose of the study participants were 
given a version of the Rapid Visual Information Processing (RVIP) task, a test of 
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sustained attention used in previous research measuring caffeine-related placebo 
effects (Colagiuri & Boakes, 2010; Yeomans et al., 2002). In this 5-min task 
participants were required to monitor single digits appearing on a screen in semi-
random order and to detect strings of three consecutive odd or three consecutive even 
digits amongst the random digits. Performance on the test was measured via four 
metrics: hit rate (Hit), false-alarm (FA) rate, reaction time of correct responses, and a 
composite accuracy score, calculated as (pHit – pFA)/(1-pFA) following the method 
used in Colagiuri and Boakes (2010).  
Blood Pressure: Systolic and diastolic blood pressure was measured via an Omron 
HEM-7221 electronic sphygmomanometer. 
Exit Questionnaire/Manipulation Check: This computer-based questionnaire 
contained five questions designed to probe for awareness of deception and estimated 
likelihood that caffeine was consumed. Questions appeared in isolation on screen in 
the following order: 1) ‘Did you think the experimental procedures differed in any 
way from what you had been told?’ (Y/N response); 2) ‘Tell us what you think the 
purpose of the study was.’ (open response); 3) ‘Do you have any other comments on 
the testing or procedure?’ (open response); 4) Do you think that there was caffeine in 
your coffee? (Y/N response); 5) Estimate how likely it is that the coffee you drank 
was caffeinated (Responses: 0 –“Certainly Decaffeinated”; 1 – “Probably 
Decaffeinated”; 2 – “Possibly Decaffeinated”; 3 – “Do not know”; 4 – “Possibly 
Caffeinated”; 5 – “Probably Caffeinated”; 6 – “Certainly Caffeinated”) (see 
Appendix 3e.).  
Procedure 
To reduce the possibility of demand characteristics, participants were recruited 
under the guise of a study testing the effects of caffeine on cognitive performance. 
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Participants signed up for the study by booking a test session on the University of 
Sydney’s research participation website. Upon signing up participants were randomly 
allocated to either the Told Withdrawal or Not Told Withdrawal condition. The 
Withdrawal Information manipulation was administered via a Participant Information 
Statement (PIS) sent to participants by email. In the email participants were instructed 
to read the PIS carefully prior to the test session.  The PISs sent to the Prime and No 
Prime group were identical, except that those given the prime contained the additional 
text:  
“IMPORTANT: Because caffeine withdrawal symptoms become 
stronger over time it is likely that you will experience some withdrawal 
symptoms due to abstaining from coffee. These withdrawal symptoms 
can include headache, fatigue, difficulty concentrating, irritability, 
depression, flu-like feelings, nausea, upset stomach, and cravings. If 
any of these withdrawal symptoms become too severe please contact the 
researchers.”  
See Appendices 3c and 3d for both versions of the PIS. The email itself also 
contained this passage or did not depending on group allocation. 
Participants were told in advertisements for the study, in the initial contact email, 
and on the PIS sent out with the contact email, that they must drink more than three 
cups of coffee on a standard weekday and be 24-h caffeine abstinent in order to be 
included in the study. Using a ‘bogus pipeline’ procedure to enhance compliance with 
the 24-h abstinence requirement (Murray, O'Connell, Schmid, & Perry, 1987), 
participants were told in the email and PIS that abstinence would be verified upon 
arrival via a saliva test.  
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Participants were tested individually in a single 90-min test session. Prior to this 
session they were allocated to either Told Caffeine or Told Decaf conditions. In order 
to screen out participants who did not meet inclusion criteria, participants were asked 
upon arrival at the test session how many cups of coffee a day they drank and when 
they last consumed caffeine. If participants answered less than three cups per day or 
less than 24 h since last caffeine consumed they were not tested. 
Participants meeting eligibility criteria had saliva samples collected and were given 
the allocation-appropriate PIS to read once again in the presence of experimenters (in 
case they had not read it in the email). The demographic and caffeine use 
questionnaire were then administered. All questionnaires were completed on 
computers in the test lab during the 90-min test session. Following the demographic 
and caffeine use questionnaire participants had their blood pressure measured, and 
completed the RVIP and CWSQ tests for the first time. Next, participants were given 
their cup of coffee, which was prepared in front of them in the test room. All 
participants received decaffeinated coffee. The coffee beans used to make participants’ 
beverages were placed in the test room prior to participants’ arrival according to group 
allocation; either in original packaging or in decoy packaging of a popular 
(caffeinated) blend sold by Gloria Jean’s coffee chain. During preparation of the 
coffee, participants in the Told Decaf group were instructed that they had been 
allocated to a control condition of the study and would therefore receive decaffeinated 
coffee. The Told Caffeine group on the other hand were not given any further 
instructions, since all participants had been led to believe that they would be receiving 
caffeinated coffee as part of the general study description. Participants then consumed 
their coffee, after which they were given a 45-min ‘caffeine absorption period’. During 
this time, participants remained in the lab but were free to study, browse the internet, 
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or use their smartphones. Following the ‘absorption period’ participants had their 
blood pressure read and completed the RVIP and CWSQ tests a second time. Finally, 
participants were given the exit questionnaire and debriefed as to the true nature of the 
study (for debrief form see Appendix 3f).  
All the procedures in this study were approved by the University of Sydney 
Human Research Ethics Committee (Protocol # 2014/1034) and were conducted in 
accordance with the 1964 declaration of Helsinki. 
Data Analysis  
To determine the effect of Withdrawal Information and Caffeine Information on 
withdrawal symptoms, 2 x 2 x (2) ANCOVAs, with Withdrawal Information and 
Caffeine Information as the between-subjects factors, Time (Pre- vs Post-Beverage) 
as the within-subject factor, and pre-existing daily caffeine consumption as the 
covariate, were conducted on CWSQ scores, blood-pressure, and RVIP scores.  
In order to gauge whether individuals’ strength of belief that their beverage 
contained caffeine predicted size of the placebo withdrawal effect, a difference score 
was calculated (pre-beverage CWSQ – post-beverage CWSQ; with higher scores 
indicating a greater reduction in reported withdrawal symptoms). This difference 
score was then regressed on participants’ response to Question 5 of the Exit 
Questionnaire (see section 2.2/Materials and Methods/Exit Questionnaire). 
 
2.3 Results 
Exclusions 
Eight participants from the Told Caffeine group and seven Participants from the 
Told Decaf group whose belief in the caffeine content of their beverage was 
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incongruent with their instructions were excluded from analysis, leaving 74 
participants in total: 42 in the Told Withdrawal Condition, 32 in the Not Told 
Withdrawal condition, and 37 participants in each of the Caffeine Information 
conditions (for individual cell numbers see Table 1). Excluding participants who 
failed the manipulation check was an a priori decision based on the idea that, in most 
real-world settings, people tend not to doubt that the drugs they purchase or are given 
contain active ingredients. Since this study’s main aim was to model real-world 
placebo withdrawal effects, admitting participants who doubted what they were told 
about their beverage caffeine content would be contrary to this aim. The exclusion of 
these participants did not affect the overall pattern of results.  
Caffeine Use 
Mean caffeine consumption per weekday from all sources (e.g. coffee, tea, cola) 
was 554.1 mg (SD = 295.8). Coffee was the most commonly consumed caffeinated 
product. A two-way ANOVA revealed no significant between-group differences in 
daily caffeine consumption (Withdrawal Information: F(1,85) = 0.30, p = 0.585, 𝜂𝑝2 = 
0.004; Caffeine Information: F(1,85) = 0.91, p = 0.343, 𝜂𝑝2 = 0.011).  
Effect of Withdrawal Information and Caffeine Information on Withdrawal 
Symptoms 
Descriptive Statistics for the three outcome measures are presented in Table 2.1. 
Mean Pre- and Post-Beverage CWSQ scores across groups are presented in Figure 2.2 
and the main effects of Withdrawal Information and Information about Caffeine 
Content in Figure 2.3. The results are summarized as follows: 
Effect of Time 
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There were significant main effects of Time, with CWSQ scores (F(1,69) = 15.73, p 
<0.001, 𝜂𝑝2 = 0.186), systolic blood pressure (F(1,69) = 15.78, p < 0.001, 𝜂𝑝2 = 0.186), 
and RVIP False Alarm Rate (F(1,69) = 21.40, p < 0.001, 𝜂𝑝2 = 0.237) decreasing, and 
RVIP Hit Rate (F(1,69) = 4.91, p = 0.016, 𝜂𝑝2 = 0.066), and RVIP Accuracy scores 
(F(1,69) = 12.72, p = 0.001, 𝜂𝑝2 = 0.156) increasing significantly across all groups from 
Pre- to Post-Beverage. 
Effect of Withdrawal Information  
As it was hypothesised that the two different PISs would induce a difference in 
perceived caffeine withdrawal after 24-h abstinence, the key test was differences in 
Pre-Beverage CWSQ scores according to Withdrawal Information. Mean Pre-
Beverage CWSQ score was 43.5 in the Told Withdrawal group and 42.1 in the Not 
Told Withdrawal group (see black bars in Figure 3-left), a non-significant difference 
of 1.4 points (𝐹(1,69) = 0.230; p = 0.633, 𝜂𝑝2 = 0.003). Given the extremely low F and 
𝜂𝑝2 statistics, a post-hoc Bayes Factor test was performed. Bayes factors are an 
alternative form of hypothesis testing that allow direct comparisons of null hypotheses 
to alternative hypotheses, thus allowing researchers to quantify evidence for the 
absence of an effect (an inference that cannot be made with tradition null hypothesis 
significance testing). Bayes Factors > 3.2 in favour of one hypothesis over another 
constitute ‘substantial’ evidence for that hypothesis (Kass & Raftery, 1995). I used 
the BayesFactor package (Morey & Rouder, 2015) in R (R Core Team, 2016) to test 
the null hypothesis of no difference in Pre-Beverage CWSQ scores between the Told 
Withdrawal and Not Told Withdrawal groups against the directional alternative 
hypothesis of the Told Withdrawal group having a higher withdrawal level at the Pre-
Beverage test. The prior distribution for the alternative hypothesis was a folded 
Cauchy distribution with scale parameter = √2/2 (see BayesFactor package manual: 
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Morey and Rouder, 2015) which places more prior credibility on smaller effect sizes. 
This yielded a Bayes Factor of 3.78. Thus it is 3.78 times more likely, given the data, 
that there was no difference in Pre-Beverage CWSQ scores due to the Withdrawal 
Information manipulation (null hypothesis) than that the Told Withdrawal group had a 
slightly higher level of withdrawal (alternative hypothesis).  
     There was no significant main effect of Withdrawal Information at Pre-Beverage 
for any of the other dependent variables (F range: 0.06 – 3.07). The interaction 
between Withdrawal Information and Time was not significant for any of the other 
dependent variables (F range: 0.002 – 2.08). 
Effect of Caffeine Information  
There was a significant interaction between Caffeine Information and Time in total 
CWSQ scores (F(1,69) = 8.36, p = 0.005, 𝜂𝑝2 = 0.108), with the Told Caffeine group 
reporting a reduction from Pre- to Post-Beverage that was 8.1 points greater than the 
reduction in the Told Decaf group. Figure 3-right is a graph of mean Total CWSQ 
scores Pre- and Post-beverage according to Caffeine Information group allocation. 
There was no significant interaction between Caffeine Information and Time for 
blood pressure or any of the RVIP measures (F range: 0.30 – 3.10).  
Other Interactions 
The interaction between Withdrawal Information and Caffeine Information (i.e. 
ignoring Time) was not significant for any of the dependent variables (F range: .059 – 
1.41). There were no significant three-way interactions between Withdrawal 
Information, Caffeine Information, and Time for any of the dependent variables (F 
range: 0.18 – 2.92).  
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Table 2.1 Descriptive Statistics for CWSQ Scores, Blood Pressure, and RVIP Score Across Time Points and Groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CWSQ Score 
Blood Pressure RVIP 
  Systolic Diastolic Hit FA rt Accuracy 
 n M (SD) M (SD) M (SD)       M (SD) M (SD) M (SD) M (SD) 
Time 
Pre-Beverage 
Post-Beverage 
 
74 
74 
 
42.86 (13.0) 
32.85 (11.1) 
 
112.88 (12.8) 
106.64 (13.4) 
 
71.43 (9.8) 
68.75 (9.6) 
 
17.52 (5.5) 
19.96 (6.8) 
 
13.16 (12.5) 
9.03 (14.7) 
 
362.39 (58.0) 
377.12 (51.8) 
 
0.39 (0.19) 
0.48 (0.21) 
Withdrawal Information 
 Told Withdrawal 
 Not Told Withdrawal 
 
42 
32 
 
39.10 (14.2) 
36.23 (11.2) 
 
107.50 (11.7) 
112.72 (15.1) 
 
68.81 (8.8) 
71.77 (10.8) 
 
19.14 (5.4) 
18.22 (7.3) 
 
9.31 (13.2) 
13.44 (14.2) 
 
372.35 (49.2) 
366.34 (62.6) 
 
0.45 (0.18) 
0.40 (0.24) 
Caffeine Information 
Told Caffeine 
Told Decaf 
 
37 
37 
 
35.42 (13.5) 
40.30 (12.2) 
 
110.35 (13.0) 
109.18 (13.9) 
 
68.90 (10.2) 
71.28 (9.3) 
 
19.59 (6.4) 
17.89 (6.1) 
 
13.09 (14.3) 
9.09 (12.3) 
 
372.95 (56.8) 
366.56 (54.0) 
 
0.44 (0.23) 
0.42 (0.19) 
Withdrawal Information x Time 
 Told Withdrawal/Pre 
 Not Told Withdrawal/Pre 
 Told Withdrawal/Post 
 Not Told Withdrawal/Post 
 
42 
32 
42 
32 
 
43.45 (14.2) 
42.10 (11.5) 
34.74 (13.0) 
30.37 (7.3) 
 
111.20 (11.1) 
115.08 (14.6) 
103.81 (11.2) 
110.36 (15.3) 
 
69.72 (9.1) 
73.67 (10.4) 
67.90 (8.5) 
69.87 (11.0) 
 
17.76 (4.6) 
17.22 (6.6) 
20.52 (5.8) 
19.22 (8.0) 
 
11.12 (11.2) 
15.84 (13.8) 
7.50 (14.9) 
11.03 (14.3) 
 
368.84 (45.5) 
353.93 (71.1) 
375.87 (53.0) 
378.76 (51.0) 
 
0.41 (0.16) 
0.36 (0.23) 
0.50 (0.18) 
0.44 (0.25) 
Caffeine Information x Time 
Told Caffeine/Pre 
Told Decaf/Pre 
Told Caffeine/Post 
Told Decaf/Post 
 
37 
37 
37 
37 
 
42.70 (13.4) 
43.03 (12.8) 
28.14 (8.9) 
37.57 (11.1) 
 
113.23 (12.6) 
112.52 (13.2) 
107.46 (13.0) 
105.82 (14.0) 
 
70.10 (10.6) 
72.76 (9.0) 
67.70 (9.7) 
69.80 (9.6) 
 
18.08 (5.3) 
16.97 (5.7) 
21.11 (7.2) 
18.81 (6.3) 
 
16.11 (14.0) 
10.22 (10.2) 
10.08 (14.2) 
7.97 (15.3) 
 
358.39 (64.8) 
366.39 (50.9) 
387.51 (43.7) 
366.74 (57.6) 
 
0.38 (0.21) 
0.18 (0.18) 
0.50 (0.23) 
0.45 (0.20) 
Withdrawal Information x 
Caffeine Information x Time 
 TW/Told Caffeine/Pre 
 TW/Told Decaf/Pre 
NTW/Told Caffeine/Pre 
NTW/Told Decaf/Pre 
TW/Told Caffeine/Post 
 TW/Told Decaf/Post 
NTW/Told Caffeine/Post 
NTW/Told Decaf/Post 
 
 
21 
21 
16 
16 
21 
21 
16 
16 
 
 
45.76 (14.5) 
41.14 (13.8) 
38.69 (10.9) 
45.50 (11.4) 
29.95 (10.2) 
39.52 (15.6) 
25.75 (6.5) 
35.00 (4.6) 
 
 
111.06 (8.1) 
111.33 (13.7) 
116.07 (16.6) 
114.08 (12.8) 
103.64 (8.7) 
104.00 (13.4) 
112.48 (16.1) 
108.25 (14.7) 
 
 
67.84 (8.7) 
71.60 (9.4) 
73.06 (12.4) 
74.27 (8.4) 
65.85 (7.7) 
69.95 (9.0) 
70.13 (11.7) 
69.60 (10.6) 
 
 
18.67 (4.8) 
16.86 (4.3) 
17.31 (6.0) 
17.13 (7.3) 
21.05 (6.5) 
20.00 (5.1) 
21.19 (8.2) 
17.25 (7.5) 
 
 
12.33 (11.9) 
9.90 (10.6) 
21.06 (15.3) 
10.63 (10.1) 
6.48 (10.9) 
8.52 (18.2) 
14.81 (16.7) 
7.25 (10.7) 
 
 
372.66 (39.5) 
365.00 (51.5) 
339.65 (85.7) 
368.2 (51.7) 
384.68 (35.7) 
367.07 (65.8) 
391.22 (53.4) 
366.30 (46.8) 
 
 
0.43 (0.16) 
0.39 (0.15) 
0.33 (0.25) 
0.40 (0.22) 
0.53 (0.19) 
0.47 (0.19) 
0.48 (0.28) 
0.42 (0.21) 
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Fig 2.2 Effect of Time, Withdrawal Information, and Caffeine Information on Caffeine 
Withdrawal Symptoms 
 
Fig 2.3 Effect of Withdrawal Information (left) and Caffeine Information (right) before and 
after decaffeinated coffee, on total reported caffeine withdrawal symptoms. Higher scores 
indicate more severe withdrawal. All participants received decaffeinated coffee.  
 
Belief About Beverage Caffeine Content 
Since all participants, regardless of instruction, indicated some estimate of the 
likelihood that their beverage was caffeinated, the regression gauging the extent to 
which strength of belief in caffeine content predicted Pre-Post difference in CWSQ  
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scores was conducted using all 89 participants.  The strength of belief that the 
beverage was caffeinated significantly predicted the magnitude of the reduction in 
total CWSQ score (R2 = 0.047, F(1,87) = 4.282, b = 8.175, SEb = 3.95,  p = 0.041). 
This meant that for every 1-point increase in participants’ estimates of likelihood 
that there was caffeine in their beverage, there was a predicted 1.39-point decrease 
in their post-beverage total withdrawal score. 
 
2.4 Discussion 
The results of this study demonstrate that caffeine withdrawal symptoms can be 
reduced by the simple belief that caffeine has been ingested, even when it has not. 
Participants who were led to believe that they were receiving caffeinated coffee 
showed a significantly greater reduction in total CWSQ scores following 
consumption of their beverage than those who were told that they had consumed 
decaf.  Supporting this, participants’ ratings of the likelihood that their beverage 
contained caffeine were positively correlated with the magnitude of the reduction in 
CWSQ scores.  
Interestingly, however, the withdrawal information included in the Participant 
Information Statement did not have any effect on reported pre-beverage withdrawal 
symptoms. High p-values (e.g. p = 0.940) are often taken as evidence of 
equivalence, however technically they cannot support this inference. The Bayes 
Factor of 3.78 in favour of the null hypothesis of no effect of Withdrawal 
Information on the other hand is substantial proof that Withdrawal Information had 
no effect on caffeine withdrawal. It is possible that this was due to the experienced 
caffeine consumers in the study being sufficiently well aware of the negative 
consequences of abstinence, so that a simple passage stating common caffeine 
 73 
withdrawal symptoms had no differential effect on the expectancies of withdrawal 
in the Told Withdrawal vs Not Told Withdrawal condition (Rohsenow & Marlatt, 
1981). However, given that a number of participants booked and attended the test 
session without having fully read even the prerequisites for admission to the study, 
it cannot be ruled out that the reason for the absence of an effect of Withdrawal 
Information was due simply to the fact that participants failed to read the passage 
contained in the participant information statement. 
Overall, the current study indicates that caffeine withdrawal symptoms can be 
reduced by the belief that one has ingested caffeine. These findings add to the 
growing body of research indicating that, in addition to known pharmacological 
factors, expectancies concerning current levels of a drug in the body also play a 
significant role in the way individuals addicted to that drug perceive their 
withdrawal symptoms.  
There were two principal limitations in Study 1 that needed to be addressed in 
Study 2. Firstly it was unclear whether the failure of the Withdrawal Information 
manipulation to induce a nocebo withdrawal effect was due to a general non-
susceptibility of withdrawal symptoms to verbal instruction or to a methodological 
flaw in the Study – that participants either did not read the passage pertaining to 
caffeine withdrawal symptoms contained in their PIS. To control for this Study 2 
replicated the design of Study 1 but used a method of delivering information about 
withdrawal that attempted to capture participants’ attention more effectively, and 
one where researchers could verify that the information had been absorbed by 
participants. Secondly, even given the fact that we deliberately selected moderate to 
high coffee consumers, the average daily consumption of caffeine reported by 
participants in Study 1 (554 mg) seemed high compared with the average US 
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population (280 mg; Barone & Roberts, 1996). Discussions with participants 
obtained during the verbal debrief and probe at the end of the study revealed 
possible discrepancies between the number of cups consumed per day reported in 
the Demographic and Caffeine use questionnaire and the number of cups 
participants verbally reported consuming to researchers during the debrief. I 
reasoned that providing participants with a separate question for each of a number 
of different ‘types’ of coffee (e.g. instant, café-bought brewed, home-made brewed, 
capsule) may have led many participants to ‘play it safe’ and answer in the 
affirmative with each question, thus inflating their estimates of total daily caffeine 
consumption. Study 2 would attempt to address this limitation by making the 
questions concerning daily caffeine use simpler and easier to understand. 
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Chapter 3: The Effect of Genetic Information and Information About Caffeine 
Content on Caffeine Withdrawal Symptoms3 (Study 2) 
 
3.1 Introduction 
Study 1 attempted to prime a nocebo caffeine withdrawal effect via a passage 
describing caffeine withdrawal symptoms contained in a participant information statement. 
This failed to produce a placebo withdrawal effect. However, there was a possibility that 
the method of delivering the information was not effective and that some or many 
participants simply failed to read or absorb it. To explore this possibility Study 2 used a 
very similar design, but attempted to manipulate expectancies of withdrawal in a way that 
was more salient to participants. This took the form of the result of a bogus genetic test for 
presence or absence of a gene related to caffeine withdrawal. This method of influencing 
expectancies had two advantages over the prime used in Study 1. Firstly, it was framed in 
a ‘medical’ context and pertained directly to participants’ own future health, and thus was 
arguably a stronger manipulation than in Study 1, which was merely a description of a 
phenomenon that has been observed in the general population. Secondly, the information 
was delivered verbally in a way that allowed me to verify that the information had been 
absorbed by participants. 
The choice to manipulate expectancies via the results of a genetic test was made 
because of the special nature of genetic information and its proven ability to elicit negative 
treatment placebo effects in other areas. According to the genetic-essentialism framework 
(Dar-Nimrod & Heine, 2011), genetic explanations of health outcomes can induce 
attributional biases that alter perceptions of those outcomes, so that they are seen as more 
                                                 
3 Published in a similar format as Mills, Dar-Nimrod, and Colagiuri (2017). Effect of Genetic 
Information and Information About Caffeine Content on Caffeine Withdrawal Symptoms, 
Scientific Reports, 7. 
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enduring, unchangeable, and innate. These biases mean that when individuals are told they 
possess a gene known to be associated with a condition it changes the way they assess the 
risk of developing that condition in the future. The change in perceived risk prompts an 
increase in disease-specific negative affect, such as worry about the future risk and 
consequences of developing the condition (Aktan-Collan et al., 2001; Bloss, Schork, & 
Topol, 2011; Meiser et al., 2004; van Roosmalen et al., 2004), which in turn increases 
voluntary behaviours that might reduce the risk of developing the condition in the future, 
such as screening for the relevant condition or enrolling in educational workshops (Botkin 
et al., 2003; Chao et al., 2008; Dar-Nimrod, Zuckerman, & Duberstein, 2012; Johnson et 
al., 2002; Lynch et al., 2006) or changing insurance arrangements to minimize the impact 
of the adverse condition should it occur (Roberts et al., 2005). These voluntary 
behavioural changes are consistent with an increase in regularity of thought concerning the 
relevant condition brought about by discovering one has the gene. 
 Most studies examining the consequences of receiving ‘gene-positive’ information 
have focused on volitional outcomes, such as those mentioned above. However, the 
increase in thought and worry about the condition demonstrated in these studies may 
also affect non-volitional outcomes via changing expectancies and inducing a negative 
placebo effect. To date, two studies have reported what could be interpreted as negative 
placebo effects following the delivery of gene-positive information. One study found 
that healthy participants who were informed, following a bogus genetic test, that they 
possessed a gene associated with alcoholism, reported a significantly greater increase in 
negative affect and significantly greater reduction in positive affect than those told they 
did not possess the gene (Dar-Nimrod et al., 2012). Whether this result could be termed 
a negative placebo effect depends on the nature of the negative affect. If information 
indicating a genetic predisposition for alcoholism makes the receiver of that information 
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worry about their future risk of contracting alcoholism this would not meet the definition 
of a negative placebo effect. If it did then worrying about crashing a car after being told 
your brakes had failed would also be negative placebo effect. However, if it could be 
demonstrated that the information caused an increase in negative affect that was 
unrelated to concern over contracting alcoholism, then this could be considered a 
placebo effect. Because the scale used to measure negative and positive affect in Dar-
Nimrod and colleagues (2012) was of a general nature (i.e. it was not designed to 
distinguish worry that was isolated to concern over future of alcoholism from other 
forms of negative affect) it is difficult to determine whether their result indicates a 
negative placebo effect or merely an increase in disease-specific distress. The second 
study found that participants who genuinely tested positive for a gene related to 
Alzhemier’s disease and were informed of the result scored lower on a memory test than 
participants who also tested positive for the gene but were not informed (Lineweaver, 
Bondi, Galasko, & Salmon, 2014). As memory impairment is widely known as the 
hallmark symptom of Alzheimer’s disease, this result suggests that receiving the gene-
positive information served as a type of ‘memory-loss prime’ that elicited an objective, 
non-volitional response that was congruent with the prime. Thus Lineweaver and 
colleagues’ (2014) finding could be interpreted as gene-positive information inducing a 
negative placebo effect. If viewed this way, their finding is consistent with studies in 
areas unrelated to genetic testing, where verbal instructions have brought about nocebo 
effects. (Colagiuri, McGuinness, Boakes, & Butow, 2012; Myers, Cairns, & Singer, 
1987; Schagen, Das, & van Dam, 2009). 
 Study 2 aimed to improve on the shortcomings of Study 1 in testing the extent to 
which caffeine withdrawal symptoms are affected by different forms of information. It 
sought to test whether genetic information can prompt a placebo caffeine withdrawal 
 80 
effect.  Specifically it aimed to determine whether information indicating genetic 
susceptibility to caffeine withdrawal symptoms produces an increase in self-reported 
caffeine withdrawal. To my knowledge this study is the first to use genetic information 
to induce a negative placebo effect in a healthy population. Study 2 also sought to 
replicate the finding in Study 1 that caffeine withdrawal symptoms can be reduced by 
the belief that one has ingested caffeine.  
 
3.2 Methods 
Design 
The flow diagram for Study 2 is presented in Figure 3.1. Study 2 used a 2 x 2 x (2) 
mixed design similar to Study 1. There were two two-level, between-subjects factors: 
Genetic Information (Gene + vs Gene – conditions) and Caffeine Information (Told 
Caffeine vs Told Decaf condition). The two-level within-subjects factor was Time, with 
one measurement being taken after 24 h abstinence from caffeine (Pre-Beverage) and 
the other being taken 40 min after a cup of decaffeinated coffee (Post-Beverage). Once 
again the primary outcome of interest was self-reported caffeine withdrawal symptoms, 
and once again the two secondary outcomes, blood-pressure and the RVIP test, were 
also measured at both time points. Unlike Study 1, the current study added an additional 
pre-test baseline session. The addition of this session was necessary to perform the 
saliva sample that would form the basis of the ruse of the genetic test, however it also 
afforded an opportunity to collect a baseline ad-libitum CWSQ score to use as a 
covariate in analysis. An additional difference between Study 1 and and Study 2 was the 
inclusion of two questions in the exit questionnaire. In Study 1 participants were asked 
in the Demographics and Caffeine Use questionnaire to estimate their daily caffeine 
consumption. This estimate was included as a covariate in statistical analyses. Following 
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a search of the addiction literature two additional bio-historical factors were identified 
that that could potentially create differences in withdrawal levels across groups and 
individuals. These were (i) number of past attempts to quit or cut back caffeine 
consumption, (ii) number of years of regular (i.e. daily) caffeine use. Questions 
pertaining to these bio-historical factors were added to the Exit Questionnaire given to 
participants (see ‘Materials and Measures’ section below) and included as covariates in 
statistical analyses. 
  
Fig 3.1 Flow Diagram for Study 2. The Gene + group were told they had tested positive 
for a gene associated with heightened caffeine withdrawal symptoms. The Gene – group 
were told they had tested negative for this gene. The Told Caffeine group were told they 
were receiving caffeinated coffee. The Told Decaf group were told truthfully that they 
were receiving decaffeinated coffee. Baseline, Pre-Beverage and Post-Beverage tests 
were, in order: 1) Blood Pressure; 2) Score on the Caffeine Withdrawal Symptom 
Questionnaire (CWSQ; Juliano et al., 2012); 3) Score on the RVIP task, a test of 
concentration. 
Participants 
 Ninety-three regular coffee drinkers (38 male; average age = 29.9; range = 18 – 64) 
were paid $50 in exchange for their participation. Participants were included in the study 
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if they consumed at least 270 mg (≥3 ~200-ml cups of coffee) per day, were 18 years of 
age or over, had sufficient written and verbal English skills, and had not participated in 
any of the author’s previous studies. Participants gave informed consent to take part in a 
study investigating the effect of genes on mood during caffeine abstinence, but were fully 
debriefed as to the study’s true purpose upon completion. 
Materials and Measures 
Demographic and Caffeine Use Questionnaire: This questionnaire was identical to that 
used in Study 1 except for the questions pertaining to the type of coffee they consumed. 
For reasons explained in the limitations of Study 1 (Section 2.4), instead of several 
separate questions asking participants to indicate how many cups of different types of 
coffee they consumed (e.g. instant vs capsule vs home-brewed vs store brewed) it only 
asked a single question about how many “standard cups (approximately 200 ml) or shots” 
of coffee they would consume on an average weekday (see Appendix 4a). 
Outcome Measures: The outcome measures used in Study 2 – CWSQ questionnaire, 
RVIP task, and blood pressure – were all identical to those used in Study 1 (see Section 
2.2, and Appendix 3b). 
Exit Questionnaire/Manipulation Check: A computerised exit questionnaire was used. 
This exit questionnaire was identical to the exit questionnaire used in Study 1 (Appendix 
3e) except for (i) a question asking how long the participant had been a regular caffeine 
user, (ii) a question asking how many times, if at all, the participant had attempted to quit 
or cut back on their caffeine consumption (iii) several additional questions concerning 
whether or not the participant believed the genetic test was real or not (see Appendix 4b 
for this version of the Exit Questionnaire). 
Bogus DNA-Test: Each participant provided a saliva sample via Isohelix SK-2S buccal 
mouth swabs. Swabs were stored in a GVA 42-L bar refrigerator housed in the test room. 
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Procedure 
Recruitment: Participants were recruited via an online classifieds website or on the 
University of Sydney Careers website. Advertisements requested participants for a study 
testing the effect of genes on mood during caffeine abstinence (Appendix 4c). As a way 
of ensuring participants were honest about their caffeine use, no mention was made in the 
ad of the minimum daily consumption required for inclusion in the study. Advertisements 
asked interested participants to email the researchers telling them how many cups of 
coffee they drank on an average weekday. If participants met the minimum daily coffee 
consumption criteria (equivalent of ≥ 3 ~200-ml cups per day), they were sent a return 
email saying they qualified for the study and detailing the general study procedures.  
Ad-Libitum Baseline Session: Prior to attendance participants were instructed that on 
the day of the Baseline session they should consume caffeine as they normally would. 
When a participant first arrived a researcher verbally told them the cover story, which 
was: (i) that studies had found a link between presence of the A1 allele of the Dopamine 
D2 receptor gene (DRD2) and addiction to various drugs; (ii) that this was thought to 
occur because people who possess this gene experience more severe withdrawal 
symptoms during abstinence than people who do not possess the gene; and (iii) that this 
had been found to be true for several addictive drugs, including caffeine. Participants 
were then informed of the most common caffeine withdrawal symptoms. The specific 
gene used in the cover story was chosen because it has been shown to be a possible risk 
factor in the development of addiction, and hence would withstand scrutiny if participants 
chose to research it independently. In addition participants were asked to read a 
Participant Information Statement (PIS) containing a written version of the cover story 
(Appendix 4d). Participants were asked to take this sheet with them at the completion of 
the baseline session.  After reading the PIS participants completed the Demographic and 
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Caffeine Use questionnaire. Following this participants completed the primary test 
battery: CWSQ, RVIP, and blood pressure. When baseline tests were completed 
participants provided a tissue sample via buccal mouth swab, which they were told would 
be analysed and the results delivered directly to them by phone in a few days. Swabs were 
not analysed in any way.   
Delivery of ‘Results’ of Genetic Test: Prior to delivery of the bogus test results 
participants were randomly assigned to either the Gene + or Gene – groups. Results were 
predominately delivered 24-36 hours prior to participants’ test session. However, 
occasionally participants had to reschedule this session in which case the duration 
between receiving results and testing was longer. To account for these differences, 
duration between 'results' and test was recorded, to be used as a covariate in analyses. 
Researchers delivered the bogus results by reading a pre-written script directly to 
participants over the phone (Appendices 4e and 4f). In this script participants were told 
either that they had tested positive or negative for presence of the A1 allele. The link 
between the allele and addiction/withdrawal was re-iterated and participants were told 
that, due to their testing positive or negative, they may or may not be at a heightened risk 
of suffering caffeine withdrawal symptoms. Once again these caffeine withdrawal 
symptoms were read out to participants. Participants were then asked if they understood 
the results and if they had any questions. If participants had questions these were 
answered as briefly as possible and in line with the cover story. Participants were then 
reminded of their test session appointment and that they were required to remain abstinent 
from all sources of caffeine (these sources were listed) for 24-h prior to the test session. 
Once again using the ‘bogus pipeline’ procedure, to enhance compliance with this 
requirement (Murray, O'Connell, Schmid, & Perry, 1987) participants were told that 
caffeine abstinence would be verified upon arrival via a saliva test.  
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Test Session: Participants were tested individually in a single 90-min test session. Prior 
to this session they were randomly allocated to either the Told Caffeine or Told Decaf 
conditions. Upon arrival participants had saliva samples collected (these samples were not 
analysed). Following saliva collection participants were administered the primary test 
battery (RVIP, CWSQ, and blood-pressure). Next, participants were given their cup of 
coffee, which was prepared in front of them in the test room. All participants received 
decaffeinated coffee. Beans used to make participants’ coffee were placed in the test room 
prior to participants’ arrival according to group allocation, i.e. either in original packaging 
or in decoy packaging of an inexpensive popular (caffeinated) blend. During preparation 
of the coffee, participants in the Told Decaf group were instructed that they had been 
allocated to a control condition of the study and would therefore receive decaffeinated 
coffee. The Told Caffeine group on the other hand were not given any further 
instructions, since all participants had been led to believe that they would be receiving 
caffeinated coffee as part of the general study description. Participants then consumed 
their coffee, after which they were allowed a 45-min ‘caffeine absorption period’ in which 
they remained in the lab but were free to study, browse the internet, or use their 
smartphones. Following the ‘absorption period’ participants had their blood pressure read 
and took the RVIP and CWSQ tests a second time. Finally, participants were given the 
exit questionnaire and debriefed as to the true nature of the study (see Appendix 4g). 
During the debrief participants were probed for: (i) whether they had abstained from 
caffeine for 24 hrs; (ii) what withdrawal symptom, if any, they had experience; and (iii) 
whether they had suspected at any time that the caffeine content of their beverage was 
anything other than instructed. If they answered in the affirmative to question (iii), they 
were asked whether they suspected before or after they read the same question in the 
online exit questionnaire. 
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     All the procedures in this study were approved by the University of Sydney Human 
Research Ethics Committee (Protocol # 2014/974) and were conducted in accordance 
with the 1964 declaration of Helsinki. 
Data Analysis  
Data analysis in Study 2 was identical to Study 1 except the first between-subjects 
factor was Genetic Information instead of Withdrawal Information. 2 x 2 x (2) mixed-
model ANCOVAs were performed on CWSQ scores, blood pressure, and RVIP scores, 
with Genetic Information (Gene – vs Gene +), Caffeine Information (Told Caffeine vs 
Told Decaf), and Time (Pre-Beverage vs Post-Beverage) as the primary predictors and 
covariates: (i) daily caffeine consumption (covariate in Study 1); (ii) number of past 
attempts to quit or cut back caffeine consumption; (iii) number of years of regular (i.e. 
daily) caffeine use; (iv) baseline ad-libitum CWSQ score; and (v) duration in days 
between delivery of ‘results’ and test.  
Once again, Pre-Post difference in participants’ CWSQ scores was regressed on their 
strength of belief that their beverage contained caffeine. 
 
 
3.3 Results 
Exclusions 
    Thirteen participants were excluded from analyses. A different decision rule for 
exclusions was used in Study 2 compared to Study 1. In Study 1 participants were 
excluded if they indicated in the Exit Questionnaire that they believed the caffeine content 
of their beverage to be different to what they were instructed. However, during the debrief 
sessions in Study 1 it became clear that participants were answering this question based 
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on their opinion after reading the question rather than what they believed before reading 
the question; however, this question was not asked consistently of all participants. This 
was addressed in some of the instructions included in the Exit Questionnaire (e.g. “If 
possible, when answering please refer to what you thought DURING the test BEFORE 
reading this question”). In addition all participants were asked the same question in 
person. If participants indicated in this in-person debrief that they came to believe that the 
true caffeine content of their beverage differed from what they were instructed because of 
the way they felt (e.g. because they felt more alert or because they felt no change), they 
were not excluded. My reasoning for this decisions was that the experiment was 
attempting to gauge whether expectancies concerning dose influenced withdrawal 
symptoms. If participants had expectancies of beverage caffeine content that were 
consistent with their instructed caffeine content, but then those expectancies changed (or 
were not changed) by the information coming from their senses, to exclude them would 
be illegitimate, as that would be excluding the people for sensitivity to the signals from 
their body rather than because they doubted the trustworthiness of the information they 
were given for any ‘global reasons’. To exclude people simply because there was no 
placebo effect would be to exclude people on incorrect grounds. Participants were 
excluded: (1) if they gave any indication, either in the post-test in-person debrief or in the 
computer-based exit questionnaire, that they had suspicions about the genetic test prior to 
or during testing; or (2) if they were suspicious about the instruction given to them about 
the caffeine content of their beverage for any reasons other than their withdrawal 
symptoms (e.g. a general distrust of psychology experiments). This left 80 participants 
upon whose data analyses were performed (n = 20 participants in each of the four groups).  
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Participant Characteristics  
Group mean and standard deviation of relevant participant characteristics are 
provided in Table 3.1. Mean daily caffeine consumption was 296.9 mg per day. All 
participants indicated that their primary source of caffeine was from coffee. The modal 
number of attempts at quitting caffeine prior to enrolling in the study was 1 (average = 
2.0). The mean number of years of daily caffeine use was 11.9.  
Table 3.1 Relevant Participant Baseline Characteristics By Group 
Group 
Years of 
Caffeine Use 
No. of Quit 
Attempts 
Per Diem 
Caffeine 
Baseline 
CWSQ Score 
Gene –/Told Caffeine  7.40 (5.6)  1.70 (3.4) 274.73 (140.9) 24.46 (14.4) 
Gene –/Told Decaf  10.30 (9.4) 1.30 (2.1) 308.92 (115.8) 23.15 (13.5) 
Gene +/Told Caffeine  13.04 (12.0) 1.65 (2.0) 293.90 (105.1) 23.50 (8.9) 
Gene +/Told Decaf  16.74 (13.0) 3.15 (5.6)  310.15 (123.3) 19.40 (8.8) 
Note: Numbers indicate means and standard deviations. Standard deviations in parentheses 
Effect of Genetic Information and Caffeine Information on Withdrawal Symptoms       Descriptive statistics for the three outcome measures are presented in Table 3.2. Mean 
Pre- and Post-Beverage CWSQ scores across groups are presented in Figure 3.2 and the 
main effects of Genetic Information and Information about Caffeine Content in Figure 
3.3. The results are summarised as follows:  
Effect of Time 
The main effect of Time on CWSQ scores was significant (𝐹(1,71) = 6.241; p = 0.015, 𝜂𝑝2 
= 0.081) with CWSQ scores tending to decrease from Pre- to Post-Beverage. There were 
no other significant main effects of time for any of the other dependent variables (F range: 
.051 – 2.57). 
 
 
 89 
Effect of Genetic Information  
 As it was hypothesised that the two different test results (Gene + vs Gene –) would 
induce a difference in perceived caffeine withdrawal after 24-h abstinence, once again the 
key test for the Genetic Information variable was the difference in mean Pre-Beverage 
CWSQ scores according to type of genetic information. Mean Pre-Beverage CWSQ score 
was 44.8 in the Gene + group and 45.45 in the Gene – group (see black bars in Figure 3.3-
left), a non-significant difference of 0.65 points (𝐹(1,71) = .004; p = 0.950, 𝜂𝑝2 < 0.001). 
Given the extremely low F and 𝜂𝑝2 statistics, a post-hoc Bayes Factor test was performed, 
yielding a Bayes Factor of 4.87. Thus it is 4.87 times. more likely, given the data, that 
there was no difference in Pre-Beverage CWSQ scores due to the Genetic Information 
manipulation (null hypothesis) than that the Gene + group had a slightly higher level of 
withdrawal (alternative hypothesis).  
There was no significant main effect of Withdrawal Information at Pre-Beverage for 
any of the other dependent variables (F range: .015 – 2.22). The interaction between Time 
and Genetic Information was not significant for CWSQ scores (𝐹(1,71) = 3.21; p = 0.078, 
𝜂𝑝2 = 0.043) nor for any of the other dependent variables (F range: .001 – 2.99). 
Effect of Caffeine Information 
The interaction between Caffeine Information and Time was significant (𝐹(1,71) = 22.86; p 
< .001, 𝜂𝑝2 = 0.244; see Figure 3.3-right) with participants in the Told Caffeine group 
experiencing an average reduction in CWSQ score from Pre- to Post-Beverage that was 
14.6 points greater than in the Told Decaf group. There was no significant interaction 
between Caffeine Information and Time for blood pressure or any of the RVIP measures 
(F range: .009 – 2.22).   
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Other Interactions 
The interaction between Withdrawal Information and Caffeine Information (i.e. 
ignoring Time) was not significant for any of the dependent variables (F range: .056 – 
3.68). There were no significant three-way interactions between Withdrawal Information, 
Caffeine Information, and Time for any of the dependent variables (F range: .059 – 2.79). 
Post-Hoc Tests of Simple Effects 
There appeared to be differences in Pre-Beverage CWSQ scores across the four 
groups, particularly between the Gene +/Told Caffeine (Pre-Beverage mean = 51.4) and 
the Gene +/Told Decaf group (Pre-Beverage mean = 38.2). Since the Caffeine 
Information manipulation had not occurred at the time of the Pre-Beverage measurement 
it is likely these differences were random; however, to ensure the significant interaction 
between Time and Caffeine Information was not an artifact of these pre-manipulation 
differences post-hoc tests of simple effects were performed at each level of Time. At Pre-
Beverage neither Genetic Information (𝐹(1,71) = 0.004; p = 0.950, 𝜂𝑝2 < 0.001) nor 
Caffeine Information (𝐹(1,71) = 2.987; p = 0.088, 𝜂𝑝2 = 0.040) were significant predictors 
of caffeine withdrawal. At Post-Beverage Genetic Information did not have a significant 
effect on caffeine withdrawal (𝐹(1,71) = 2.41; p = 0.125, 𝜂𝑝2 = 0.033) but Caffeine 
Information did (𝐹(1,71) = 5.76; p = 0.019, 𝜂𝑝2 = 0.075), indicating that the greater 
reduction in withdrawal in the Told Decaf condition was not driven by pre-existing 
differences in withdrawal symptoms.  
Effects of Belief in Caffeine Content of Beverage on CWSQ Difference Scores 
As in Study 1, the analysis regressing Pre-Post CWSQ difference scores on strength of 
belief on beverage caffeine content was performed on all 93 participants regardless of 
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Table 3.2 Descriptive Statistics for CWSQ Scores, Blood Pressure, and RVIP Score Across Time Points and Groups 
  
CWSQ Score 
Blood Pressure RVIP 
  Systolic Diastolic Hit FA rt Accuracy 
 n M (SD) M (SD) M (SD)       M (SD) M (SD) M (SD) M (SD) 
Time 
Pre-Beverage 
Post-Beverage 
 
80 
80 
 
45.13 (16.6) 
31.38 (15.4) 
 
111.24 (13.1) 
109.78 (12.9) 
 
70.89 (10.4) 
70.87 (12.6) 
 
18.98 (6.6) 
20.11 (7.3) 
 
9.73 (18.0) 
7.85 (18.5) 
 
386.35 (46.8) 
396.06 (46.3) 
 
0.43 (0.28) 
0.46 (0.30) 
Genetic Information 
 Gene + 
 Gene – 
 
40 
40 
 
39.15 (18.2) 
37.35 (16.5) 
 
111.50 (13.4) 
109.52 (12.5) 
 
72.64 (12.7) 
69.12 (10.0) 
 
19.59 (6.1) 
19.50 (7.8) 
 
11.2 (22.0) 
6.38 (13.1) 
 
381.16 (48.8) 
401.26 (42.4) 
 
0.42 (0.30) 
0.47 (0.27) 
Caffeine Information 
Told Caffeine 
Told Decaf 
 
40 
40 
 
38.20 (16.8) 
38.30 (18.1) 
 
108.85 (12.9) 
112.17 (12.9) 
 
70.35 (12.7) 
71.41 (10.3) 
 
19.48 (6.7) 
19.61 (7.2) 
 
10.26 (21.5) 
7.31 (14.1) 
 
391.60 (50.8) 
390.83 (42.4) 
 
0.42 (0.30) 
0.47 (0.27) 
Withdrawal Information x Time 
 Gene +/Pre 
 Gene –/Pre 
  Gene +/Post 
  Gene –/Post 
 
40 
40 
40 
40 
 
44.80 (18.4) 
45.45 (14.7) 
33.50 (16.4) 
29.25 (14.2) 
 
112.29 (13.5) 
110.20 (12.8) 
110.71 (13.4) 
108.85 (12.4) 
 
72.32 (11.5) 
69.46 (9.2) 
72.95 (13.9) 
68.78 (10.9) 
 
19.33 (6.0) 
18.63 (7.1) 
19.85 (6.2) 
20.38 (8.3) 
 
12.43 (21.5) 
7.01 (13.2) 
9.98 (22.6) 
5.73 (13.1) 
 
381.04 (49.7) 
391.67 (43.7) 
381.28 (48.5) 
410.86 (39.3) 
 
0.41 (0.31) 
0.45 (0.25) 
0.44 (0.30) 
0.49 (0.29) 
Caffeine Information x Time 
Told Caffeine/Pre 
Told Decaf/Pre 
Told Caffeine/Post 
Told Decaf/Post 
 
40 
40 
40 
40 
 
48.28 (15.5) 
41.98 (17.2) 
28.13 (11.1) 
34.63 (18.4) 
 
108.78 (12.3) 
113.71 (13.6) 
108.92 (13.7) 
110.63 (12.1) 
 
69.76 (10.6) 
72.03 (10.3) 
70.94 (14.5) 
70.80 (10.5) 
 
18.83 (6.3) 
19.13 (6.8) 
20.13 (7.0) 
20.10 (7.7) 
 
10.9 (20.6) 
8.55 (15.1) 
9.63 (22.6) 
6.08 (13.2) 
 
387.80 (52.3) 
384.91 (41.2) 
395.39 (49.7) 
396.75 (43.2) 
 
0.41 (0.31) 
0.45 (0.25) 
0.44 (0.31) 
0.48 (0.28) 
Withdrawal Information x 
Caffeine Information x Time 
 Gene +/Told Caffeine/Pre 
 Gene +/Told Decaf/Pre 
Gene –/Told Caffeine/Pre 
Gene –/Told Decaf/Pre 
Gene +/Told Caffeine/Post 
 Gene +/Told Decaf/Post 
Gene –/Told Caffeine/Post 
Gene –/Told Decaf/Post 
 
 
20 
20 
20 
20 
20 
20 
20 
20 
 
 
51.40 (16.4) 
38.20 (18.4) 
45.15 (14.2) 
45.75 (15.6) 
31.10 (11.2) 
35.90 (20.4) 
25.15 (10.3) 
33.35 (16.6) 
 
 
110.29 (12.4) 
114.28 (14.6) 
107.27 (12.4) 
113.13 (12.9) 
111.07 (15.4) 
110.35 (11.6) 
106.78 (11.8) 
110.92 (12.9) 
 
 
71.33 (12.4) 
73.32 (10.7) 
68.19 (8.4) 
70.73 (9.9) 
74.50 (17.4) 
71.43 (9.6) 
67.38 (10.3) 
70.17 (11.5) 
 
 
18.60 (5.0) 
20.05 (6.9) 
19.05 (7.5) 
18.20 (6.9) 
18.90 (5.3) 
20.80 (7.1) 
21.35 (8.4) 
19.4 (8.3) 
 
 
17.00 (27.4) 
7.85 (12.5) 
4.8 (6.3) 
9.25 (17.6) 
16.05 (30.8) 
3.90 (4.7) 
3.20 (3.6) 
8.25 (18.0) 
 
 
375.06 (61.7) 
387.02 (34.4) 
400.55 (38.2) 
382.79 (47.9) 
372.55 (56.0) 
390.01 (39.1) 
418.23 (29.0) 
403.48 (47.0) 
 
 
0.33 (0.37) 
0.48 (0.23) 
0.33 (0.25) 
0.41 (0.28) 
0.34 (0.35) 
0.53 (0.20) 
0.55 (0.23) 
0.44 (0.34) 
Note: ‘Hit’ refers to the number of correct responses to the target sequences in the RVIP task, ‘FA’ to the number of incorrect responses; ‘rt’ to the 
reaction time for correct responses. ‘Accuracy’ = (pHit – pFA)/(1-pFA). TW = Told Withdrawal; NTW = Not Told Withdrawal.  
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Fig 3.2 Effect of Time, Genetic Information, and Caffeine Information on Caffeine 
Withdrawal Symptoms 
 
Fig 3.3 Effect of interaction between Time and Genetic Information (left) and Time 
and Caffeine Information (right) on Caffeine Withdrawal. 
 
whether they were excluded from the group analysis or not. When the five other 
covariates were controlled for the strength of belief that the beverage was caffeinated 
significantly predicted the magnitude of reduction in CWSQ scores (t = 5.209; b = 
3.77; SEb = 0.723; p < 0.001) such that every 1-point increase in likelihood that 
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beverage was caffeinated predicted a 3.77-point decrease in reported withdrawal 
symptoms.  
3.4 Discussion 
Despite the changes to the design to make the prime more salient and the inclusion 
of several additional covariates in the analysis the results of Study 2 replicate those of 
Study 1.  
Beliefs concerning the presence or absence of a drug in the body once again 
influenced the way people perceived their withdrawal symptoms. In Study 2 
participants given decaffeinated coffee who were allowed to believe they had 
consumed caffeinated coffee showed a significantly greater reduction in reported 
caffeine withdrawal symptoms than participants who knew they had been given 
decaffeinated coffee.  Perhaps due to the fact that more efforts were made in Study 2 
to make the Study appear more ‘medical’ in nature, the effect of information about 
beverage caffeine content on change in caffeine withdrawal was greater in Study 2 
(𝜂𝑝2 = 0.244) than in Study 1 (𝜂𝑝2 = 0.108). Further, as in Study 1, the degree of belief 
in consumption caffeine predicted level of self-reported withdrawal symptoms in 
Study 2. Once again this effect was stronger in Study 2, with a one-point increase 
predicting a 3.77-point decrease in CWSQ score, compared to a 1.39-point decrease 
in Study 1. These two results once again demonstrate that caffeine withdrawal, like 
withdrawal from other forms of addictive agents, is a syndrome whose interoceptive 
indices are sensitive to the influence of cognition.  
The most interesting result, however, was that once again withdrawal-relevant 
verbal instructions had no detectable effect on withdrawal symptoms. Participants 
who were told over the phone that they had tested positive for the DRD2 allele 
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reported levels of caffeine withdrawal after 24 hours of caffeine abstinence that were 
almost identical to those who were told they did not have the gene. The Bayes Factor 
of 4.78 in support of the null hypothesis of no effect was greater than the same 
statistic in Study 1 (BF = 3.78), indicating perhaps that the genetic information 
manipulation had even less effect in this study. When considered in combination these 
results suggest that, at least in the domain of caffeine withdrawal, genetic information 
may not be sufficient to produce a negative placebo effect in the same way as 
warnings of side-effects have been able to induce other negative placebo effects such 
as change in appetite  (Neukirch & Colagiuri, 2015), gastrointestinal complaints 
(Myers et al., 1987) and cognitive deficits in chemotherapy patients (Schagen et al., 
2009). 
Only two prior studies have shown that being told one has tested positive for a 
gene related to a negative medical condition can induce negative-placebo-like effects. 
Dar-Nimrod et al. (2012) found that ‘gene positive’ information can increase 
subjective distress, however it is unclear whether the distress was disease-specific or a 
non-volitional nocebo effect. Lineweaver et al. (2014) found that being made aware of 
testing positive for a gene related to Alzheimer’s caused a significant decrease in 
performance on a memory test compared to not being made aware. This is much 
closer to a true negative placebo effect than Dar-Nimrod et al.’s (2012) finding, as the 
effect was observed in a disease-relevant domain. Why Lineweaver et al. (2014) 
observed a negative genetic information effect when we did not is unknown. It may 
be because of the different nature of our outcome variable. Lineweaver et al. (2014) 
used a performance-based test rather than a self-report test concerning perception of 
internal bodily signals. Performance-based tests are very sensitive to testee’s 
motivational state; thus the receipt of information that one has a high likelihood of 
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contracting a debilitating, irreversible condition may simply have caused a drop in 
motivation and a corresponding drop in performance. Whatever the source of the 
difference in results, in light of our findings the ability of genetic information to elicit 
a condition-relevant placebo response is questionable. 
The Bayes Factor of 4.78 in favour of the null hypothesis, rather than simply the 
failure to find an effect, constitutes substantial evidence that genetic information, 
similarly to withdrawal information in Study 1, does not affect caffeine withdrawal. 
Some results in the placebo field have yielded remarkable results, such as lowering 
body-mass index and blood pressure (Crum & Langer, 2007) and producing 
differences in ghrelin secretion (Crum, Corbin, Brownell, & Salovey, 2011). Not 
surprisingly, such findings have drawn substantial attention. However, the current 
results suggest that, far from being ubiquitous, placebo effects may be restricted to 
specific contexts and conditions. To this end, it is important to encourage researchers 
to publish the results of any adequately-designed studies on verbal instruction 
manipulations, irrespective of their outcomes. 
Studies 1 and 2 tested the ability of two different types of verbal instructions to 
influence caffeine withdrawal: instructions concerning the likelihood of experiencing 
withdrawal, and instructions concerning whether or not participants beverage 
contained caffeine. The results indicate that the former had no effect on caffeine 
withdrawal. This results is broadly consistent with observations made by Rohsenow 
and Marlatt (1981), who suggested that it is difficult to influence expectancies of the 
effects of a drug (or in this case abstinence from a drug) if participants are already 
familiar with those effects. Though in the modern world caffeine users rarely are 
forced, or even encouraged, to go without caffeine for very long, it is possible that 
most regular caffeine users are sufficiently well aware of their individual likelihood of 
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suffering from caffeine withdrawal that our attempt to change those expectancies and 
elicit a placebo withdrawal effect, was not likely to succeed. On the other hand it 
appears that, when the verbal instructions concern whether or not caffeine has been 
ingested, these instructions have a much greater effect. Any clinical interventions into 
addiction that sought to manipulate withdrawal symptoms via information should 
focus on information concerning the amount of drug ingested rather than the 
likelihood of experiencing withdrawal. 
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Chapter 4: Conscious and Unconscious Expectancies in Caffeine Withdrawal  
(Study 3) 
 
4.1 Introduction 
It appeared from the results of Studies 1 and 2 that instructions concerning whether 
or not a drug has been consumed are more effective at producing changes in 
withdrawal symptoms than instructions concerning the likelihood of experiencing 
withdrawal during abstinence. As a result the remaining studies in this thesis made no 
further attempt to manipulate participants’ expectancies concerning the likely effects 
of abstinence. Instead the focus of the remaining three studies was to explore how 
participants’ beliefs concerning the current level of a drug in their system affect their 
withdrawal symptoms.  
The current study, in particular, sought to clarify a somewhat curious pattern that 
emerged in the preceding studies whereby participants truthfully told they were being 
given decaffeinated coffee still reported decreases in their withdrawal symptoms 
(albeit less than those deceptively told that they were receiving caffeinated coffee). 
Post-hoc tests of simple effects performed at each level of Caffeine Information in 
studies 1 and 2 confirmed this intriguing finding. These tests showed that although the 
reduction from Pre- to Post-Beverage was greater in the Told Caffeine condition 
(Study 1: mean difference = 14.29, F(1,71) = 51.12, p < 0.001, 𝜂𝑝2 = 0.430; Study 2: 
mean difference = 21.05, F(1,71) = 97.44, p < 0.001, 𝜂𝑝2 = 0.578), the reduction in the 
Told Decaf group was still significant (Study 1: mean difference = 6.16; F(1,71) = 9.65, 
p = 0.003, 𝜂𝑝2 = 0.123; Study 2: mean difference = 6.45, F(1,71) = 9.15, p = 0.003, 𝜂𝑝2 = 
0.114). This is interesting because: (i) the Told Decaf group knew their abstinence 
would continue because they were drinking decaf and so should not have had any 
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expectancy of their withdrawal symptoms being reduced over time and (ii) the dose of 
caffeine they were given (~ 4 mg) was so small that they had no pharmacological 
reason for experiencing caffeine withdrawal either.  
There are several possible explanations for this curious finding. It may be that 
contextual cues surrounding coffee consumption, such as the smell and taste of the 
coffee and the warmth of the cup and the liquid, unconsciously evoked a withdrawal-
reduction effect that occurred despite participants knowing they were receiving no 
caffeine. There are precedents for such an interpretation. For example, one study 
found that the placebo analgesia observed following a sham conditioning procedure – 
where application of a cream was accompanied by surreptitious reduction of a painful 
stimulus – persisted even after participants were informed that the analgesia they 
experienced during conditioning was faked and that the cream had no active analgesic 
properties (Schafer, Colloca, & Wager, 2015). Expectancies of pain relief were 
measured before and after the revelation of the sham procedure and, despite still 
exhibiting placebo analgesia, participants’ expectancies of pain relief post-reveal had 
dropped to near zero. This finding suggests that experience with the effects of a 
treatment can produce placebo effects even when those effects are not expected 
consciously. It should be noted, however, that earlier studies with similar designs 
have found the opposite – that revealing the sham procedure abolished the placebo 
effects caused by the conditioning procedure (Montgomery & Kirsch, 1997). More 
study is needed to determine whether placebo effects can occur in the absence of 
conscious expectancies. However, if placebo effects brought about by exposure to 
cues paired with a drug’s effects truly can persist even when individuals are aware 
those cues no longer predict an active treatment, there may be potential for integrating 
conditioning procedures into treatment of addiction in some way in order to reduce 
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withdrawal. It is important to establish first that such effects can occur in the context 
of withdrawal symptoms as well as pain. To my knowledge there are no studies 
demonstrating a withdrawal-reduction effect (i.e. a placebo effect rather than a 
negative placebo effect) following presentation of contextual cues associated with 
withdrawal reduction, but in the absence of a conscious expectancy of withdrawal 
reduction.  
Another possible explanation of the reduction of withdrawal symptoms observed in 
the Told Decaf group is that participants receiving decaf consciously expected their 
withdrawal symptoms to decrease. However, participants’ expectancies of withdrawal 
relief were not measured in Studies 1 and 2. While this was an intentional decision 
aimed at reducing the likelihood that participants might guess the true nature of these 
studies, it means that it could be possible that participants in the Decaf group believed 
that consuming decaf might reduce their withdrawal symptoms. If this were the case, 
then the improvement in the Decaf group would be consistent with a conscious 
expectancy account of the placebo and negative placebo effect.  
A further possible explanation for the reduction in the Told Decaf groups in 
Studies 1 and 2 is that there was no true placebo effect, but merely one or more non-
specific effects that led to improvement in self-reports of withdrawal symptoms 
following the administration of the decaf. There are several specific mechanisms that 
could be responsible for these changes. One possibility is that having their blood 
pressure measured, performing the RVIP tasks, and generally taking part in an 
experiment caused an increase in alertness or concentration, and that this manifested 
as lower scores on the items of CWSQ measuring fatigue, lack of concentration etc. 
Another possibility is that simply receiving a cup of any liquid made participants feel 
better, by being hydrated for example. Definitively ruling out such possibilities 
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requires the inclusion of a no-treatment control group, who receive the same 
experimental procedure as the placebo groups except for the administration of the 
active drug or placebo. By comparing this group to the placebo group it is possible to 
separate the portion of the observed effect that is due to non-specific experimental 
factors from that caused by the placebo effect (Ernst & Resch, 1995). 
To address these questions, Study 3 sought to determine: (i) whether the reduction 
in caffeine withdrawal symptoms observed in the Told Decaf condition in studies 1 
and 2 was a genuine placebo effect, or merely the result of non-specific experimental 
effects; and (ii) whether the reduction in withdrawal symptoms observed in the Told 
Decaf group in Studies 1 and 2 was due to unconscious conditioned responses or to 
consciously held expectancies that decaf would reduce their withdrawal symptoms. 
To test these questions two important additions were made to the design of the 
Caffeine Information arms of Studies 1 and 2. Firstly, a no-treatment group, who 
received only water, was included in the design. Secondly, participants’ expectancies 
were measured twice. The first measure of expectancies was made prior to random 
allocation, measuring participants pre-existing expectancies concerning the effects of 
consuming caffeinated coffee, decaf, and water. The second measure of expectancies 
was the inclusion in the Exit questionnaire of a question asking participants what 
effect they expected their beverage to have on their withdrawal symptoms, blood 
pressure, and performance on the RVIP test.  
  
4.2 Methods 
Design 
The flow diagram for Study 3 is presented in Figure 4.1. Study 3 used a 3 x (2) 
mixed design. There was one three-level, between-subjects factor: Group. The three 
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levels of this variable were: Told Caffeine (who received decaf but were told it was 
caffeinated coffee), Told Decaf (who received decaf and were told it was decaf) and 
the Told Water group (who received water and were told it was water). Since the Told 
Water group received a different liquid (i.e. water instead of decaf) as well as 
different instructions about the caffeine content of the liquid, this group differed from 
the other two groups in more than one respect. However, as there was no reliable way 
to provide participants with decaf and have them believe it was water, there was no 
way to cross type of liquid (water vs decaf) with beverage information (Told Caffeine 
vs Told Decaf vs Told Water). As such the Told Water group was simply a no-
treatment control group used to isolate the placebo effect from non-specific effects. 
The two-level within-subjects factor was Time, with one measurement being taken 
after 24 h abstinence from caffeine (Pre-Beverage) and the other being taken 40 min 
after a cup of decaffeinated coffee (Post-Beverage). Once again the primary outcome 
of interest was self-reported caffeine withdrawal symptoms and once again the two 
secondary outcomes, blood-pressure and the RVIP test, were also measured at both 
time points. Covariates were: (i) number of past attempts to quit or cut back caffeine 
consumption; (ii) number of years of regular (i.e. daily) caffeine use; and (iii) 
estimated total daily caffeine consumption.  
Participants 
 Seventy-two regular coffee drinkers (22 male; average age = 25.6; range = 18 
– 56) were either paid $30 (n = 47) or given 1.5 hours course credit (n = 47) in 
exchange for their participation. Participants were included in the study if they 
consumed at least 270 mg (≥3 ~200-ml cups of coffee) per day, were 18 years of age 
or over, had sufficient written and verbal English skills, and had not participated in 
any of the author’s previous studies. Participants gave 
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Fig 4.1. Flow Diagram for Study 3. Two thirds of participants received decaffeinated 
coffee. Half of these participants were told it what caffeinated and the other half were 
told that it was decaffeinated. One third of participants received water and were told it 
was water. Pre-Beverage and Post-Beverage tests were, in order: 1) Blood Pressure; 
2) Score on the Caffeine Withdrawal Symptom Questionnaire (CWSQ; Juliano et al.,
2012); 3) Score on the RVIP task, a test of concentration.
informed consent to take part in a study investigating the effect of genes on mood 
during caffeine abstinence, but were fully debriefed as to the study’s true purpose 
upon completion. 
Materials and Measures 
All materials and measures used in Study 3 were identical to those used in Study 2 
except the following: 
Demographic, Caffeine Use, and Expectancy Questionnaire: This questionnaire 
was identical to that used in Study 2 except for questions asking participants to rate on 
a 0–10 visual analog scale how much they would expect coffee, caffeinated tea, 
I
N
T
A
K
E
P
R
E
-
B
E
V
E
R
A
G
E
T
E
S
T
S
Told Caffeine
Told Water
S
A
L
I
V
A
S
A
M
P
L
E
Test Session: 90 min
P
O
S
T
-
B
E
V
E
R
A
G
E
T 
E
S
T
S
D
E
B
R
I
E
F
+
P
R
O
B
E
Given
Decaf
24-h Abstinence
45 min
Told DecafGiven
Decaf
Given
Water
 105 
caffeinated cola, energy drinks, decaffeinated coffee, caffeine strips, and water to 
affect their caffeine withdrawal symptoms (response scale: 0 – “Drinking X would 
have no effect on the way I feel”; 5 – “Drinking X would make me feel a bit better”; 
10 – “Drinking X would make me feel a much better”). Note this version of the 
questionnaire used the same non-specific questions relating to daily caffeine 
consumption used in Study 2. See Appendix 5a for the full questionnaire. 
Exit Questionnaire/Manipulation Check: A computerised exit questionnaire was 
used. This exit questionnaire was identical to the exit questionnaire used in Study 2 
except: (i) there were no questions pertaining to any genetic test; and (ii) participants 
were asked what they expected the effects of the beverage they were given (i.e. 
coffee, decaf, or water) to be on the way the felt generally, their blood pressure, and 
their performance on the RVIP test, with three response options indicating expected 
improvement, deterioration, or no change (see Appendix 5b for full questionnaire). 
Procedure 
Recruitment: Participants were recruited via the University of Sydney’s research 
participation website, online classifieds website or on the University of Sydney 
Careers website. Advertisements requested participants for a study investigating the 
effects of caffeine on cognitive performance (Appendices 5c and 5d). Since Study 3 
recruited from two different cohorts, general population and student, two different 
methods were taken to ensure participants were honest about their caffeine use. 
Student participants could only see the advertisement if they indicated in a screening 
questionnaire (see Appendix 5e) taken at the commencement of semester that they 
consumed three or more cups per day. Recruitment of participants outside the 
Psychology cohort followed the same procedure as Study 2. In the Career Hub 
advertisement no mention was made of the minimum daily consumption required for 
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inclusion in the study and interested participants were asked to email the researchers 
telling them how many cups of coffee they drank on an average weekday. If 
participants met the minimum daily coffee consumption criteria (equivalent of ≥ 3 
~200-ml cups per day), they were admitted to the study. All other recruitment 
procedures (e.g. exclusion criteria, instructions to abstain from caffeine for 24 hours, 
warning that saliva would be tested for presence of caffeine, etc) were identical to 
those in Study 1. 
Test Session: Participants were tested individually in a single 90-min test session. 
Prior to this session they were randomly allocated to either the Told Caffeine, Told 
Decaf or Told Water conditions. Upon arrival participants had saliva samples 
collected (these samples were not analysed). Following saliva collection participants 
were administered the Demographic/Caffeine Use/Expectancy questionnaire and were 
administered the primary test battery (RVIP, CWSQ, and blood-pressure). Next, 
participants were given their cup of coffee, which was prepared in front of them in the 
test room. The Told Caffeine and Told Decaf groups received decaffeinated coffee 
and the Told Water group received water. Beans used to make participants’ coffee 
were placed in the test room prior to participants’ arrival according to group 
allocation, i.e. either in original packaging or in decoy packaging of an inexpensive 
popular (caffeinated) blend. During preparation of the coffee, participants in the Told 
Decaf group were instructed that they had been allocated to a control condition of the 
study and would therefore receive decaffeinated coffee. The Told Caffeine group on 
the other hand were not given any further instructions, since all participants had been 
led to believe that they would be receiving caffeinated coffee as part of the general 
study description. Participants allocated to the Told Water group were also told that 
they had been allocated to a control group, and would be receiving water. Participants 
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then consumed their beverage, after which they were allowed a 45-min ‘caffeine 
absorption period’ in which they remained in the lab, but were free to study, browse 
the internet or use their smartphones. Those in the Told Decaf and Told Water groups 
were told this period was needed so as to match their experimental procedure to the 
group who would receive caffeine. Following the ‘absorption period’ participants had 
their blood pressure read and took the RVIP and CWSQ tests a second time. Finally, 
participants were given the exit questionnaire and debriefed as to the true nature of 
the study. As with Study 2, during the debrief participants were probed concerning: (i) 
whether they had abstained from caffeine for 24 hrs; (ii) what withdrawal symptoms, 
if any, they had experienced; and (iii) whether they had suspected at any time that the 
caffeine content of their beverage was anything other than instructed. If they 
answered in the affirmative to question (iii), they were asked whether they suspected 
before or after they read the same question in the online exit questionnaire. 
     All the procedures in this study were approved by the University of Sydney 
Human Research Ethics Committee (Protocol # 2016/681) and were conducted in 
accordance with the 1964 declaration of Helsinki. 
Data Analysis  
To determine whether there were any random pre-existing group differences, one-
way ANCOVAs with Caffeine Information (Told Caffeine vs Told Decaf vs Told 
Water), as the main predictor and covariates, (i) daily caffeine consumption, (ii) 
number of past attempts to quit or cut back caffeine consumption, and (iii) number of 
years of regular (i.e. daily) caffeine use, were performed on all dependent variables 
(CWSQ, systolic and diastolic blood-pressure, and the four RVIP metrics hit rate, 
false alarm rate, reaction time, and accuracy) at Pre-Beverage only.  
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Mixed ANCOVAs were performed on all dependent variables, with Caffeine 
Information and the three covariates as the between-subjects predictors and Time as 
the within-subjects predictor. To explore all pairwise differences between individual 
groups, linear regressions, with the predictors included in the mixed-ANCOVAs 
described above, were performed on difference scores (Pre-Beverage – Post-
Beverage) calculated for all the dependent variables. Type-I error rate for all three 
group pairwise comparisons in each regression were controlled using the Westfall 
procedure, a stepwise form of error correction which delivers equivalent protection 
against false positives across multiple pairwise comparisons, yet is more powerful 
than single-step procedures such as the Bonferroni procedure (Bretz, Hothorn, & 
Westfall, 2016; Westfall & Young, 1993). 
Pre-Post difference in participants’ CWSQ scores was first regressed on their 
strength of belief that their beverage contained caffeine, as in Studies 1 and 2. 
However, in this study, each participant also answered three questions at the outset of 
the study in the Demographic/Caffeine Use/Expectancy questionnaire, pertaining to 
their expectancies of relief from caffeine withdrawal following consumption of 
caffeinated coffee, decaffeinated coffee and water. To determine whether these 
expectancies were different on average, a repeated measures ANCOVA was 
performed, with expectancy of withdrawal relief as the dependent variable, and with 
each beverage type (caffeinated coffee vs decaf vs water) and the three between-
subjects covariates as predictors. Pairwise comparisons of differences in expectancies 
for the three beverages were performed via a hierarchical linear regression, once again 
using the Westfall procedure to control Type-1 error. 
Lastly, to determine whether there were between-group differences in the 
likelihood of participants reporting in the Exit questionnaire that they believed their 
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beverage would make them feel better vs feel worse vs no change, a chi-squared test 
of independence was performed, followed by multinomial logistic regression to 
explore the between-group differences in likelihood of choosing each of the three 
response options. 
 
4.3 Results 
Exclusions 
    Eleven participants were excluded from analyses, using the same criteria as in 
Study 2: i.e. if they were suspicious about the instruction given to them about the 
caffeine content of their beverage for any reasons other than their withdrawal 
symptoms (e.g. a general distrust of psychology experiments). One participant was 
excluded due to their Post-Beverage CWSQ score failing to be recorded. Due to a 
programming error involving a failure to force a response, a further 15 participants’ 
responses to the question in the Demographic/Caffeine Use/Expectancy questionnaire 
pertaining to expectancy of withdrawal reduction after drinking decaffeinated coffee 
were not recorded. This question was the only question in the questionnaire where a 
response was not made mandatory. Of these, eight were in the Told Decaf group, five 
in Told Water group, and two in the Told Decaf group. As this questionnaire was 
administered prior to randomisation, the between-group pattern of non-responses to 
this question was entirely random. These participants were excluded from the 
analyses pertaining to expectancy of withdrawal reduction (N=46; Told Caffeine, 
n=18; Told Decaf, n=14; Told Water, n=14) but not to other analyses where 
expectancy was not involved (N=61; Told Caffeine, n=20; Told Decaf, n=22; Told 
Water, n=19).  
 110 
Participant Characteristics  
Group mean and standard deviation of relevant participant characteristics are 
provided in Table 4.1. Mean daily caffeine consumption was 296.0 mg per day. All 
participants indicated that their primary source of caffeine was from coffee. The 
modal number of attempts at quitting caffeine prior to enrolling in the study was 0 
(average = 1.22, sd = 2.36). The mean number of years of daily caffeine use was 6.21 
(sd = 6.39).  
Table 4.1. Relevant Participant Baseline Characteristics By Group 
Group 
Years of Caffeine 
Use 
No. of Quit 
Attempts 
Per Diem 
Caffeine 
Told Caffeine  5.69 (4.9)  1.80 (3.4) 293.85 (80.8) 
Told Decaf  7.09 (8.3) 0.95 (1.6) 307.63 (64.9) 
Told Water  5.76 (5.4) 0.95 (1.7) 285.41 (62.4) 
Note: Numbers indicate means and standard deviations. Standard deviations in 
parentheses 
Effect of Genetic Information and Caffeine Information on Withdrawal 
Symptoms       Descriptive statistics for the three outcome measures are presented in Table 4.2. 
Mean Pre- and Post-Beverage CWSQ scores across groups are presented in Figure 
4.2. 
Effect of Time 
There were significant main effects of Time, with CWSQ scores (𝐹(1,58) = 54.74; p 
< 0.001, 𝜂𝑝2 = 0.486), systolic blood pressure (𝐹(1,58) = 7.53; p = 0.008, 𝜂𝑝2 = 0.115), 
and RVIP false alarm rate (𝐹(1,58) = 4.52; p = 0.037, 𝜂𝑝2 = 0.072), decreasing 
significantly from Pre- to Post-Beverage when averaged across groups. Though 
several of the other dependent variables approached significance (F range: 0.01 – 
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3.50), no reliable pattern emerged. As such, and because these variables were not 
significant predictors in Studies 1 and 2 either, these near-significant effects will not 
be discussed further. 
Effect of Group 
There were no significant differences between groups at Pre-Beverage for any of 
the dependent variables (F range: 0.11 – 1.55), nor were there any significant main 
effects of Group for any of the dependent variables when averaged across Time points 
(F range: 0.47 – 3.08).  
The interaction between Group and Time was significant for CWSQ score (𝐹(1,71) 
= 16.48; p < .001, 𝜂𝑝2 = 0.362). There were no significant interactions between Group 
and Time for blood pressure or any of the RVIP measures (F range: .470 – 1.49).  
All three pairwise comparisons revealed significant between-group differences in 
amount of reduction in CWSQ scores. The Pre-Beverage – Post-Beverage reduction 
in CWSQ scores was an estimated 11.78 points greater in the Told Caffeine group 
than the Told Decaf group (p = 0.004), an estimated 23.29 points greater in the Told 
Caffeine group than the Told Water group (p < 0.001), and an estimated 11.51 points 
lower in the Told Water group than the Told Decaf group (p = 0.005).  
Simple Effects 
As in studies 1 and 2, there was a significant reduction in scores from Pre- to Post-
Beverage in the Told Caffeine (estimate = 23.5, F(1,19) = 52.82, p < 0.001, 𝜂𝑝2 = 0.735) 
and Told Decaf (estimate = 12.91, F(1,21) = 17.19, p < 0.001, 𝜂𝑝2 = 0.450) groups. 
Unusually, the mean CWSQ score in the Told Water group at both Time points was  
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           Table 4.2. Descriptive Statistics for CWSQ Scores, Blood Pressure, and RVIP Score Across Time Points and Groups 
 Told Caffeine (n = 20) Told Decaf (n = 22) Told Water (n = 20) 
 Pre-Beverage 
M (SD) 
Post-Beverage 
M (SD) 
Pre-Beverage 
M (SD) 
Post-Beverage 
M (SD) 
Pre-Beverage 
M (SD) 
Post-Beverage 
M (SD) 
CWSQ 53.15 (15.8) 29.65 (8.0) 52.86 (17.6) 39.95 (17.6) 50.16 (15.3) 50.16 (15.8) 
Blood Pressure 
Systolic 
Diastolic 
 
104.10 (10.5) 
65.31 (7.3) 
 
100.95 (11.4) 
62.37 (9.2) 
 
108.34 (10.9) 
67.61 (7.7) 
 
107.60 (11.6) 
66.24 (6.1) 
 
109.23 (9.6) 
69.93 (8.9) 
 
106.25 (11.5) 
69.70 (8.3) 
RVIP* 
Hit rate 
False Alarm 
Reaction time 
Accuracy 
 
16.35 (6.4) 
10.05 (10.2) 
386.52 (39.4) 
0.37 (0.22) 
 
17.90 (8.7) 
7.05 (8.6) 
372.11 (66.9) 
0.43 (0.26) 
 
16.64 (7.5) 
9.91 (9.3) 
371.89 (53.0) 
0.38 (0.25) 
 
18.73 (8.7) 
7.86 (12.4) 
368.78 (60.9) 
0.44 (0.30) 
 
18.63 (6.3) 
9.0 (11.0) 
361.57 (47.3) 
0.45 (0.18) 
 
20.00 (6.3) 
5.84 (8.6) 
378.01 (51.9) 
0.50 (0.20) 
Note: ‘Hit’ refers to the number of correct responses to the target sequences in the RVIP task, ‘FA’ to the number of incorrect 
responses; ‘rt’ to the reaction time for correct responses. ‘Accuracy’ = (pHit – pFA)/(1-pFA). TW = Told Withdrawal; NTW = 
Not Told Withdrawal. *One participant in the Told Water group was excluded from all RVIP analyses due to an extreme false 
alarm score, indicating lack of understanding of task requirements. 
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exactly the same (i.e. exactly zero Pre-Post change in CWSQ scores when averaged 
across individuals even though individual participants’ scores had non-zero Pre-Post 
change) (estimate = 0.00, F(1,18) = 0.00, p > 0.999, 𝜂𝑝2 < 0.001). 
Effects of Expectancies on CWSQ Difference Scores 
Pre-Test Expectancies 
The group breakdown of participants’ expectancies concerning each beverage type 
– caffeinated coffee, decaffeinated coffee, and water – are presented in Table 4.3. The 
restricted sample of participants who completed all three expectancy questions in the 
Exit questionnaire (N = 46), expected caffeinated coffee, decaffeinated coffee, and 
water to have significantly different powers to reduce withdrawal symptoms (F(2,90) = 
98.54, p < 0.001, 𝜂𝑝2 = 0.686). When corrected for multiple pairwise comparisons 
using the Westfall procedure, the expected ability of caffeinated coffee to reduce 
withdrawal symptoms was rated 5.74 points higher than that of decaf (p < 0.001), and 
3.21 points higher than Water (p < 0.001). Unexpectedly participants expected Water 
to be more effective at reducing withdrawal symptoms than Decaffeinated coffee, 
rating it 2.53-points higher on the expectancy scale (p < 0.001). All pairwise 
comparisons were also significant when the same analyses were performed at the 
individual group level, with the same pattern of differences in mean expectancy as 
observed in the full sample (i.e. expectancy of relief from coffee > expectancy of 
relief from water > expectancy of relief from decaf; all p < 0.001).  
Figure 4.3 shows correlations between (i) expectancy of withdrawal relief from 
consumption of beverage and (ii) Pre-Post CWSQ difference scores. It shows these 
for each type of beverage expectancy – caffeinated coffee, decaf, and water – across 
all three experimental groups – Told Caffeine, Told Decaf, Told Water. 
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Fig 4.2. Effect of Time and Group on Caffeine Withdrawal Symptoms 
  
Table 4.3. Pre-Existing Expectancies of Withdrawal Reduction According to Group 
and Type of Beverage* 
  
Type of Beverage 
Group 
n Caffeinated Coffee Decaffeinated Coffee Water 
Told Caffeine  
18 7.47 (2.5)  2.11 (2.0) 4.39 (2.5) 
Told Decaf  
14 8.27 (1.3) 2.00 (2.1) 4.69 (2.9) 
Told Water  
14 7.44 (1.5) 1.71 (2.1) 4.44 (2.0) 
Total 46 7.70 (1.9) 1.96 (2.0) 4.50 (2.4) 
Note: *Fifteen participants did not offer a response to the question pertaining to expectancy 
of alleviation of withdrawal from decaffeinated coffee: eight in the Told Decaf group, five in 
the Told Water group, and 2 in the Told Caffeine group.  
 
 115 
The graphs where the type of beverage expectancy matched the beverage that the 
participants actually received have a coloured border. The only group and beverage 
expectancy combination where expectancy of withdrawal relief significantly predicted 
CWSQ difference score was the expectancy of withdrawal relief from coffee in the 
Told coffee group (top left corner graph; t = 2.94; b = 3.50; SEb = 1.19; p = 0.009), 
where a 1-unit increase in expectancy of withdrawal relief from coffee was associated 
with a 3.50-unit increase in Pre-Post CWSQ difference score (p range in other 
comparisons: 0.051 – 0.978).  
Post-Test Expectancies 
None of the 61 participants included the main analysis indicated in the Exit 
questionnaire that when they received their beverage they believed it would make 
them feel worse. There were significant between-group differences in the likelihood 
of participants indicating of indicating that they believed their beverage would make 
them feel better vs no change (χ2 (2) = 17.16, p < 0.001; see Table 4.4). Participants in 
the Told Caffeine group were 2.93 times more likely to report that they thought their 
beverage would make them feel better, than those in the Told Decaf group (p = 0.003) 
and 3.80 times more likely than those in the Told Water group (p = 0.004). 
Participants in the Told Decaf group were estimated to be 26% more likely to have 
expected to feel better after their beverage than participants in the Told Water group, 
however this difference was not significant (p = 0.647).  
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Fig 4.3 Correlation Between Expectancy and Pre-Post CWSQ Difference Scores.  
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Table 4.4 Self-Reported Expectancies of Withdrawal Reduction According to Group 
and Type of Beverage In the Exit Questionnaire 
  
Retrospective Expected Beverage Effects 
Group n Expected No Effect Expected to Feel Better 
Told Caffeine  20 4 16 
Told Decaf  22 16 6 
Told Water  19 15 4 
Total 61 35 26 
   
4.4 Discussion 
The Pre-Post reduction in withdrawal symptoms in the participants who knowingly 
received decaffeinated coffee was significantly greater than in the group who 
knowingly received water. In fact the latter group showed no change at all from Pre- 
to Post-Beverage. This indicates that the reduction observed in the Told Decaf group 
in this study and the previous two studies was a genuine placebo effect, and not due 
simply to non-specific effects of taking part in the experiment – such as increases in 
concentration and alertness caused by performing the RVIP task or being hydrated 
simply from consuming a liquid.  
By including a no-treatment group, who received and were told they received 
water, we can be certain that the reduction in withdrawal symptoms observed in the 
Told Decaf group is a placebo effect. What is less certain is what caused this placebo 
effect. If participants had indicated in the pre-test Demographic/Caffeine 
Use/Expectancy questionnaire or in the Exit questionnaire that they expected 
decaffeinated coffee to reduce their withdrawal symptoms more than water then there 
would be some grounds for concluding that the placebo effect in the Told Decaf group 
was driven by conscious expectancies. However, this was not the case. Surprisingly 
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participants both within each group and across all groups indicated in the 
Demographic/Caffeine Use/Expectancy questionnaire that they believed water would 
have a significantly greater withdrawal-reduction effect than decaf. This difference in 
the expectancy of the withdrawal relieving properties was opposite to the actual 
pattern of withdrawal reduction as indicated in change in CWSQ scores, where the 
Told Decaf group had a significantly greater reduction in reported withdrawal than the 
Told Water group. In the Exit questionnaire the proportion of participants who 
indicated that they believed their beverage would relieve their withdrawal symptoms 
somewhat versus that it would cause no change was not significantly different 
between the Told Decaf and Told Water groups – in fact it the two proportions were 
virtually equivalent. It is interesting that this is different to the pattern in the pre-test 
expectancy questions, where participants rated water a significantly more likely to 
reduce withdrawal on average than decaf. Why participants would expect water to 
have a greater withdrawal-relieving effect than decaf is unknown, as is why this 
pattern of expectancy might change from pre- to post-test. However it seems clear that 
there is little association between what withdrawal-reduction effects participants 
expect from these two beverages and what they actually report when tested. This 
dissociation could be regarded as tentative evidence for the theory that the placebo 
withdrawal-reduction effect observed in the Told Decaf group in Studies 1, 2, and 3 
was evoked unconsciously, by cues such as the heat of the cup and the liquid, the taste 
and smell of the coffee.  
There were several limitations in Study 3. With only three possible response 
options the Exit questionnaire expectancy item was possibly not subtle enough, and 
the fact that it was retrospective means that it may not have been an actual reflection 
of what participants expected when they received their beverage. The Expectancy 
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items in the Demographic/Caffeine Use/Expectancy questionnaire were more subtle, 
but could have been administered again immediately after participants received their 
beverage and potentially at the end of the study (i.e. in place of the categorical 
expectancy measure in the Exit questionnaire. The decision not to administer the 
expectancy questions contained in the pre-test questionnaire a second time, after 
participants had received their beverage/information, was informed by a desire not to 
alert participants to the true purpose of the study and possibly introduce more demand 
characteristics. 
Another explanation of the difference in withdrawal reduction between the Told 
Decaf and Told Water groups is that the small amount of caffeine in the decaffeinated 
coffee given to the Told Decaf group led to a reduction in their caffeine withdrawal 
symptoms. However, since it is ~5% of the caffeine contained in a regular cup of 
filtered, caffeinated coffee, it seems unlikely that the maximum 4 mg of caffeine in 
the decaf given to participants could, by itself, cause such a dramatic reduction in 
withdrawal symptoms in the absence of some expectancy, conscious or unconscious, 
of withdrawal reduction.              
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Chapter 5: The Effect of Expectation on Caffeine Withdrawal Symptoms During 
a Blind Dose Taper (Study 4) 
 
5.1 Introduction 
Results from Studies 1, 2, and 3 suggest that withdrawal symptoms can be 
influenced by beliefs concerning how much of a drug has been consumed. The 
remaining experiments in this thesis applied this precept to a commonly-used 
intervention for treating addiction – the tapered dose reduction – and attempted to 
model an alternative version of a tapered dose reduction that takes into account 
participants’ expectancies of withdrawal. I will first review literature that has 
examined the role of dose expectancies in tapered dose reductions, before describing 
the current experiment. 
In the last 50 years we have learned much about the way placebo effects work; 
however, it has proven challenging to translate this knowledge into improving 
existing treatments in ways that are both ethical and practical. Open-label 
administration of placebos (Kaptchuk et al., 2010), prior exposure to treatment cues 
(Quinn & Colagiuri, 2016), and selective omission of side-effect information (Wells 
& Kaptchuk, 2012) are some of the methods that have been suggested, but are yet to 
make the transition to clinical practice. Studies 4 and 5 investigated the potential of a 
new method of addiction treatment that could be used to reduce nocebo withdrawal 
effects in addicted individuals attempting to transition off drugs — the voluntary blind 
dose taper. This treatment involves only a small alteration to the procedure of 
standard dose tapers and could be implemented cheaply and easily. 
Dose tapering is a procedure where an individual who wishes to reduce their intake 
of a drug to which they are addicted has their dose lowered in stages. An example is 
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shown in Figure 1. The dose tapering procedure can be contrasted with ‘cold-turkey’ 
forms of detoxification where the drug in question is abruptly and completely 
discontinued. The rationale behind dose tapering is as follows. Withdrawal symptoms 
increase the motivation to acquire the drug from which the addicted individual is 
abstaining. Because quitting cold-turkey leads to much stronger withdrawal symptoms 
than would result from a smaller reduction, it also increases the likelihood of relapse, 
though whether this is true can depend on the drug in question (Kleber, 2007; 
Lindson-Hawley et al., 2016). Therefore, in order to increase the chances of quitting, 
doses are reduced steadily in decrements over a period of time.  
Dose tapering procedures, either medically-supervised or self-administered, are 
common procedures for transitioning off many types of addictive drugs, including 
opiates (Amato et al., 2013; Ling et al., 2009), nicotine (Greenland, Satterfield, & 
Lanes, 1998), benzodiazepam (Kaplan & Sellers, 1984; O’Brien, 2005), and anti-
depressants (Schatzberg et al., 1997). Prior to and during dose tapers, patients 
typically agree upon the dose reduction schedule with their prescribing physician or, 
if they are self-administering the taper, decide upon it themselves. As a result they 
know when and by how much their dose will be reduced. When the time for each 
scheduled reduction arrives, this knowledge may cause them to expect that they will 
experience some withdrawal symptoms immediately after the reduction (at arrows in 
Figure 1). Thus the knowledge of dose reductions could act as a type of cue that 
generates an expectancy of withdrawal, and hence, potentially, a nocebo withdrawal 
effect. Others cues signaling dose reductions can result from the dosing procedure 
itself (e.g. less methadone syrup in the dosing cup, fewer diazepam or anti-depressant 
tablets, a smaller nicotine patch), which could also elicit expectancy-induced placebo 
withdrawal effects. 
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Fig 5.1 Example of a Hypothetical Tapered Dose-Reduction Schedule  
 
A variation of the dose tapering procedure is the blinded dose tapering procedure. 
In this version the patient voluntarily surrenders their knowledge of the timing and 
magnitude of dose reductions: with their dose reduced at a schedule decided upon by 
their doctor, but unknown to the patient. Practically speaking, voluntary blinding 
involves the removal of: (i) knowledge of the precise dose-reduction schedule; and (ii) 
any environmental cues that may signal dose reductions (e.g. by diluting methadone 
syrup with strong tasting cordial to remove visual and olfactory cues signaling 
reductions in dose). The rationale behind the procedure is that removal of these 
verbal/cognitive and environmental cues that signal each dose reduction removes the 
opportunity for the patient to anticipate an increase in withdrawal directly after the 
dose reduction and hence also removes any expectancy induced placebo withdrawal 
effects.  
Blind dose taper procedures are relatively uncommon, but some patients do 
occasionally undertake them of their own volition after consulting their prescribing 
doctor (see Aegis Medical Systems special report, 2002). Furthermore, only a handful 
of studies have examined how knowledge of dose can affect withdrawal symptoms 
during a dose taper by varying the information given to participants about their dose 
reduction schedule (Senay, Dorus, & Thornton, 1977; Stitzer, Bigelow, & Liebson, 
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1982). Thus, there is limited evidence as to whether information during a dose taper 
influences the severity of withdrawal symptoms 
Benedetti and colleagues (2003) was not a study of withdrawal symptoms nor were 
participants addicted to any drug. However, its findings are relevant to the concepts of 
expectancy and negative placebo effects being examined in this thesis. Researchers 
interrupted the dose of intravenous morphine given to patients recovering from throat 
surgery. Prior to testing all patients were told that they could either be given a 
painkiller or nothing. The administration and interruption of morphine were carried 
out in such a way that they were not detectable by patients. Half of the patients were 
told when their dose was interrupted and the other half were not told. Following 
interruption of morphine, post-operative pain increased at a significantly slower rate 
in the group of patients who were not informed of the timing of the interruption than 
in the group who were informed. In the same study the same result was shown for 
perceived anxiety in patients who were informed their diazepam was interrupted vs 
those who were not (see Figure 2). The patients in the morphine arm of the study were 
not addicted to morphine; however, their symptoms could be considered comparable 
to withdrawal symptoms in the sense in that they would have had an expectancy that 
when their dose was interrupted it would lead to an aversive consequence (i.e. pain or 
anxiety). This study demonstrates that awareness of the timing of a reduction in dose 
can lead to a negative placebo effect.  
Senay, Dorus, and Thornton (1977) examined the effect of dosing information on 
withdrawal symptoms during a 30-week dose taper by varying both dose and 
information about dose. There were three groups: the Known Maintenance group (n = 
33), the Known Reduction group (n = 30), and the Blind Maintenance group (n = 31). 
The Known Maintenance group’s dose was kept constant for the entire 6 months and 
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they were aware of this fact. The Known Reduction group’s dose was reduced by 3% 
per week for the duration of the study and they were aware of the timing and 
magnitude of dose reductions fact. The Blind Maintenance group’s dose was held 
constant; however, they had no knowledge of whether their dose was being reduced 
 
Fig 5.2 Open vs Hidden Interruption of Morphine and Diazepam (from Benedetti et 
al., 2003; reproduced in accordance with Neuroscience creative commons policy)  
or being kept stable and were aware of the possibility of either occurring. The Blind 
Maintenance group reported: (i) significantly greater levels of various withdrawal 
symptoms on average across the trial than the Known Maintenance group, and (ii) 
similar levels of withdrawal symptoms to the Known Reduction group whose dose 
was actually being reduced and who were aware of the rate of reduction.  
Senay and colleagues’ (1977) findings contradict those of Benedetti and colleagues 
(2003). Being unaware of dose caused an increase in withdrawal, despite the actual 
dose being kept stable, and this increase in withdrawal was comparable to the increase 
 126 
in withdrawal brought about by an actual reduction in dose.  This suggests that 
blinding patients to dose reductions during a dose taper could actually lead to an 
increase in their withdrawal symptoms. However, the study had several limitations, 
the first being that there was no Blind Reduction group – who would have had their 
dose reduced without awareness – to compare to the Known Reduction and Blind 
Maintenance groups to, making it difficult to be certain of the precise roles of 
pharmacology, awareness, and uncertainty in the observed group differences. 
Secondly, no tests of difference in rate of change in withdrawal over time between 
maintenance groups were performed (merely difference in maximum level of 
withdrawal), making it difficult to know exactly how expectancy/uncertainty affected 
withdrawal over time. Lastly a proportion of participants across all groups tested 
positive for outside drug use, with the proportion varying across groups. While this is 
to be expected in clinical drug trials, it does make it difficult to draw reliable between-
group comparisons since actual dose of drugs was not controlled. The procedural 
limitations of Senay and colleagues (1977) study are a result of their testing on 
methadone patients, for whom deceptive administration and prohibiting interruptions 
of dose would be unethical. These findings would seem to suggest that the uncertainty 
involved in blinding patients to their dose when those patients are aware that dose 
reductions could occur leads to an increase in withdrawal symptoms. However further 
study is necessary on a sample for whom deception and imposing consistent dosing 
conditions across experimental arms is practical and ethical. 
Stitzer, Bigelow, and Liebson (1982) compared withdrawal symptoms under 
different information conditions in methadone patients undergoing a 6-week tapered 
dose reduction. They gave the same dose reduction schedule to two groups: beginning 
with a dose of 30 mg that was reduced by 5 mg per week. The Informed group was 
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aware of when and by how much their dose was being reduced, whereas the Blind 
group was given no information concerning the beginning, time-course, or end of the 
dose reduction period. Groups were compared on their daily self-reported withdrawal 
symptoms over the duration of the 6-week dose taper. There was a significant 
difference in linear trend (p = 0.02) between groups, with patients in the Blind 
group’s withdrawal symptoms increasing over the reduction period and the Informed 
group’s decreasing (see Figure 5.3). 
 
Fig 5.3 Change in Self-
Reported Methadone 
Withdrawal Symptoms Over 
Six Weeks during a dose taper 
procedure (5mg per week from 
Baseline 30 mg dose) in Blind 
and Informed Groups (from 
Stitzer and colleagues, 1982; 
reproduced with permission 
from the authors). 
 
 
Their results seem to suggest that awareness leads to lower withdrawal symptoms 
and uncertainty leads to greater withdrawal symptoms. This contradicts the rationale 
behind the blind dose taper, which is that knowledge of dose reductions increases 
withdrawal. However, there are problems with this study. First, no information was 
provided by the authors concerning whether visual or olfactory cues, that might have 
indicated the timing and magnitude of dose reduction, were concealed from patients 
in the Blind group (e.g. diluting the syrup). It is possible that having visual or 
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olfactory cues that indicated a dose reduction, but not knowing the precise amount of 
the dose reduction, could have led to a greater nocebo effect than accurate knowledge. 
Second, no detailed information was provided about the instructions given to the 
Blind group. For example, if the Blind group was told that their dose would certainly 
be reduced to 0 mg by the end of the trial this might elicit stronger expectancies of 
withdrawal than if this group was not told what their final dose would be. Third, all 
participants started the reduction period on a relatively low dose of 30 mg. Lastly, and 
most importantly, a proportion of patients included in the withdrawal symptom trend 
analyses tested positive for outside opiate use, with no information provided about 
how many participants or from which groups. Thus there are good reasons for being 
cautious about the results of Stitzer and colleagues (1982). 
Overall then, it is difficult to be certain how awareness of dose reductions affects 
withdrawal symptoms. The two studies that have actually tested this on addicted 
individuals  – Senay and Colleagues (1977) and Stitzer and Colleagues (1982) – 
found that awareness of dose reductions led to reduced withdrawal symptoms 
compared to being blinded, yet these studies had procedural issues suggest need for 
further study. Benedetti and Colleagues (2003) on the other hand had fewer 
procedural issues and found the opposite – that awareness of dose interruption led to a 
greater increase in pain – yet: (i) did not use a sample of individuals with addiction or 
measure withdrawal symptoms, and (ii) involved complete interruption of dose rather 
than gradual tapering. Despite Benedetti and Colleagues (2003) being, in a sense, in a 
different class of study to Senay and colleagues (1977) and Stitzer and colleagues 
(1982) it is worth highlighting that all three studies compared an ‘aware’ group to a 
group who were given instructions that were likely to cause uncertainty over whether 
or not they were receiving a drug, and/or what their dose of that drug was. Yet, 
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awareness and uncertainty had different effects. Some theorists suggest that being 
uncertain about the effect of a treatment may cause extra attention to be paid to bodily 
signals (Büchel, Geuter, Sprenger, & Eippert, 2014; Kirsch & Weixel, 1988). Others 
suggest that extra scrutiny of internal bodily states can lead to an amplification of 
otherwise normal symptoms and a resultant nocebo effect (Barsky, Goodson, Lane, & 
Cleary, 1988). This would imply that uncertainty could lead to a negative placebo 
effect. If this were true then it would mean that both awareness and uncertainty could 
theoretically cause a negative placebo effect.  
In summary, a placebo study by Benedetti and colleagues (2003) suggests that 
awareness leads to an increase in the negative sequelae following a dose reduction 
relative to non-awareness, whereas two flawed studies from the addiction literature 
suggest the opposite. Studies 4 and 5 attempted to combine the strengths of the three 
studies reviewed above in one design so as to clarify the relationship between 
awareness of dose and withdrawal symptoms during a dose taper, keeping the 
schedule of dose reduction identical across groups. 
 There are two forms of lack of awareness of dose. The first is uncertain non-
awareness, achieved experimentally by simply withholding dose information. The 
second is certain non-awareness, achieved by actively misinforming (i.e. deceiving) 
participants about their dose. Before comparing the effects of certain knowledge of 
dose to uncertainty about dose in Study 5, I felt that in Study 4 it would be 
advantageous to first test the effects of dose information in a ‘maximal’ way by 
comparing the effects of true dose information to dose misinformation (i.e. certain 
awareness of dose versus certain non-awareness of dose). Deceptive administration 
allows for a more accurate modeling of expectancy conditions – and hence placebo 
and negative placebo effects – as they might occur in real-world situations, where 
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people are more certain that the information given to them on the packaging of the 
drug or verbally by the dispenser is reliable (Kirsch & Weixel, 1988). Deceptive dose 
information was employed in Studies 1, 2, and 3. These studies showed that certain 
awareness of a dose of 0 mg of caffeine (the Told Decaf condition) was associated 
with more pronounced withdrawal symptoms than misinformation indicating that 
caffeine had been consumed (the Told Caffeine condition). In these studies the 
variation in dose information across conditions was binary (i.e. 0 mg vs caffeine 
contained in a cup of coffee). Furthermore the study duration was quite short. Study 4 
attempted to extend these findings by testing whether dose information would 
continue to produce significant differences in caffeine withdrawal symptoms when the 
variations in dose information were more subtle (i.e. non-binary) and across a longer 
test period. 
The goal of Study 4 was to test whether awareness of dose reductions led to an 
increase in withdrawal symptoms by applying a tapered dose reduction schedule 
under two different information conditions: one in which participants had full 
knowledge of the true dosing schedule and the other in which participants were 
misinformed about their dose reduction schedule. If it could be demonstrated that 
being informed of dose reductions led to increased withdrawal symptoms, it might 
suggest the potential of dose tapers in which knowledge of dose reductions is 
removed. 
 
5.2 Methods 
Design 
The flow diagram for Study 4 is presented in Figure 5.4. Study 4 used a mixed 
between- and within-subjects design. The between-subjects factor was a two-level 
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variable, Dose Information (Informed vs MisInformed), and the within-subjects factor 
was a four-level factor, labelled Time. The Time variable was an index of the dosing 
trajectory – the schedule of dose reductions – over the 4-day test period (Tuesday, 
Wednesday, Thursday, Friday). On each of these days participants received a different 
dose of caffeine (see Figure 5.4 below). The outcome variable in this study was 
caffeine withdrawal, as measured by the CWSQ questionnaire used in the previous 
three studies. 
Fig 5.4. Flow Diagram for Study 4. 
1Ad-libitum baseline, where participants were told to drink coffee as they normally would. 
2Abstinence baseline, where participants were asked to abstain from all sources of caffeine 
for 24 h prior to testing. White boxes indicate the dose the participant was told they were 
receiving. Actual dose of caffeine administered to all participants is indicated at top of the 
figure. 
Participants 
Thirty-one regular coffee drinkers (9 male; average age = 20.3; range = 18 – 34) 
participated in exchange for course credit (n = 23) or $100 cash (n = 8). Participants 
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were included in the study if they consumed at least 270 mg (≥3 ~200-ml cups of 
coffee) per day, were 18 years of age or over, had sufficient written and verbal 
English skills, and had not participated in any of the author’s previous studies. 
Participants gave informed consent to take part in a study investigating the effect of 
caffeine dose on mood, but were fully debriefed as to the study’s true purpose upon 
completion. 
Materials and Measures 
Demographic and Caffeine Use Questionnaire: This questionnaire was identical to 
that used in Study 2 (see Appendix 4a). 
Outcome Measures: The only outcome measures used in Study 4 were the CWSQ 
questionnaire, RVIP task, and blood pressure; all three were identical to those used in 
Study 1 (see Section 2.2, and Appendix 3b). 
Exit Questionnaire/Manipulation Check: A computerised exit questionnaire was 
used. This exit questionnaire was identical to the exit questionnaire used in Study 2, 
except it contained questions asking whether participants had thought ay any time that 
their dose of caffeine was different to what they were told (see Appendix 6a.)  
Drinks: Coffee was prepared in a DeLonghi Magnifica Automatic Coffee Machine 
using Peet’s Major Dickason’s Blend Decaffeinated coffee beans. These beans 
contain approximately 4% of the caffeine content of regular caffeinated coffee beans, 
amounting to 4 mg or less of caffeine per cup. Coffee was served in 227-ml Keji 
double wall paper coffee cups, each cup containing approximately 180 ml of liquid. 
Caffeine/Lactose Powder: Caffeine dose was administered via 100% USA 
Pharmaceutical Grade Anhydrous Caffeine Powder (1,3,7-trimethylxanthine; 
Molecular Formula–C8H10N4O2). Both caffeine and lactose powder were obtained 
from the Melbourne Food Ingredient Depot (see Appendix 1).  
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Scales: Caffeine/lactose powder was weighed on AND Brand electronic scales 
(Model GF-300). These scales have an illuminated display indicating weight easily 
visible at close range. 
Procedure 
Recruitment: Participants were recruited via the University of Sydney’s 1st-year 
Psychology Research Participation Scheme (SONA) or via the University of Sydney 
careers website (Career Hub). Advertisements invited participants to take part in a 
study testing the effect of reducing daily caffeine intake on mood (Appendices 6b and 
6c). Since Study 4 recruited from two different cohorts, the same procedures for 
ensuring honest reporting of level of daily caffeine consumption were used as in 
Studies 2 and 3. 
Baseline Sessions: The study took place over two weeks, a baseline week, and a 
test week. In the baseline week participants were required to attend an ad-libitum 
baseline session and an abstinence baseline session prior to 12pm on any two days 
during the week. The order of these two sessions was counterbalanced across the 
study. Before the ad-libitum baseline session participants were required to drink 
coffee as they normally would on an average weekday. Before the abstinence baseline 
session participants were told they were required to abstain from all sources of 
caffeine for 24 h. Once again the ‘bogus pipeline’ procedure (see Study 2, Section 
3.2–Procedure–Test Session) was used to enhance compliance with this requirement 
and saliva samples were not analysed. Participants were randomised to Dose 
Information group prior to their arrival at the first session.  
Upon arrival at the first baseline session participants were told that they were 
taking part in a study testing the effects of caffeine dose reduction on mood. 
Participants were then informed of their dose reduction schedule during the test week. 
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Participants were told that during the test week they were to consume no caffeine 
other than that supplied to them by researchers. Participants were then given one of 
the versions of the Participant Information Statement (PIS) to read, depending on the 
group they had been randomised to and whether the first session was the ad-libitum 
baseline or the abstinence baseline The PIS contained eligibility information, general 
information about the study, and a day-by-day breakdown of their dosing schedule for 
the test week (see Appendices 6d and 6e). After giving their consent to take part in the 
study participants completed the Demographic and Caffeine Use questionnaire and 
CWSQ and were allowed to leave.  
Upon arrival at the second baseline session participants completed a CWSQ 
questionnaire. They were then told the procedure (see below) for the test week and 
were allowed to leave. 
Test Week: Participants were allowed to consume caffeine ad-libitum until Sunday 
evening before the Monday of the test week, but then from when they awoke on 
Monday morning until Friday morning they were required to abstain from all sources 
of caffeine other than that provided to them by experimenters during the test week. 
Participants received their daily dose of caffeine via two cups of decaffeinated coffee 
with anhydrous caffeine powder and lactose powder added. The first dose (Morning) 
had to be consumed before 12pm and the second (Afternoon) after 12pm, with a 
minimum of 3 h between doses. Caffeine withdrawal was measured via CWSQ 
questionnaire in the morning session only.  
Figure 5.5. and Table 5.1 contain the day-by-day and visit-by-visit dose 
breakdown, as well as the  breakdown of the Dose Information participants in each 
group were given.  All participants’ dose reduction schedule was the same. In the case 
of the Informed group the dose reduction schedule they were told they would be 
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administered was their true dose reduction schedule: Mon-300 mg; Tues-200 mg; 
Wed-100 mg; Thurs-0 mg; Friday-Final Day/No Dose. The MisInformed group were 
told they would be receiving the following schedule: Mon-300 mg; Tues-300 mg; 
Wed-300 mg; Thurs-0 mg; Friday-Final Day/No Dose; however their actual dose was 
the same as the actual dose for the Informed group. 
Morning Sessions, Monday – Thursday: When participants arrived for the morning 
session they completed the CWSQ questionnaire at a computer in the lab. While 
participants were completing the questionnaire, their coffee was prepared for them. 
Coffee was prepared directly in front of participants using the decaffeinated beans and 
automatic coffee machine described in ‘Materials and Measures’ above, which grinds 
beans, filters coffee, and pours into cups automatically. Caffeine powder was weighed 
on electronic scales in full view of participants with mg displayed in bright numbers 
on the scales’ display. Powder was then poured into participant’s cup of decaffeinated 
coffee. From Monday to Friday participants in the Informed group had each session’s 
dose measured out from the same gold-coloured pouch containing 100% caffeine 
powder. The weight of the powder participants in the Informed group saw on the 
display in front of them corresponded to their actual dose (i.e. Mon-150 mg; Tues-100 
mg; Wed-50 mg; Thurs-None; Friday-None/Final visit).  Though powder was also 
weighed in full view of participants in the MisInformed group, a different procedure 
was used in order to create the impression that they were receiving a dose of caffeine 
that was different to the dose they actually received. On Monday the MisInformed 
group had their caffeine dose dispensed from the same gold-coloured pouch as the 
Informed group, and in the same quantity (150 mg of 100% caffeine powder per cup 
= 150 mg caffeine). On Tuesday an identical gold-coloured pouch was used to 
dispense 150mg of white powder into participants’ cups; however on this occasion the 
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pouch contained a blended mixture of caffeine and lactose powder in the ratio 2:1. 
Thus, although the amount of white powder dispensed and the readout on the 
electronic scales’ display was the same as the previous day (i.e. 150 mg), the actual 
amount of caffeine dispensed was 100 mg (150 mg of 67% caffeine powder per cup = 
100 mg). On Wednesday the same amount of white powder was dispensed from an 
identical gold-coloured pouch, but with caffeine-to-lactose ratio 1:2, and the amount 
of actual caffeine dispensed 50 mg (150 mg of 33% caffeine powder per cup = 50 
mg). To ensure consistency of the mixture powders were mixed via adding lactose 
and caffeine in the appropriate ratio in a large Tupperware container and then 
repeatedly sifting the mixture through a sieve. On Thursday morning participants 
completed a questionnaire but received no coffee.  
Afternoon Sessions, Monday – Wednesday: In the afternoon sessions no 
questionnaires were completed. Participants simply had their coffee prepared for them 
and were allowed to leave. In afternoon sessions participants received their second 
dose of caffeine using the same techniques as in the morning sessions. As participants 
received 0 mg on Thursday they were not required to attend a session on Thursday 
afternoon. 
Final Session, Friday Morning: At the final session on Friday participants 
completed a CWSQ questionnaire and the Exit Questionnaire. When they had 
completed the Exit questionnaire, participants were asked: (i) if they had complied 
with the ‘no outside caffeine request’ during the test week; (ii) if they suspected at 
any time before completing the Exit questionnaire that their true dose of caffeine was 
different from the dose they were told they were receiving, and, if so, why they 
suspected it; and (iii) general thoughts about the experiment and the withdrawal 
symptoms they experienced. Participants were then debriefed concerning the true 
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purpose of the experiment and, if they were in the MisInformed group, were then told 
their true dose reduction schedule and allowed to leave. 
Data Analysis 
The purpose of this study was to observe change in caffeine withdrawal symptoms 
over multiple days due to information and reduced dose. This study was designed 
with the assumption that each participant’s morning levels of caffeine withdrawal 
would reflect the previous day’s total caffeine dose. Therefore Monday morning’s 
CWSQ is a measure of Sunday’s total caffeine dose, Tuesday morning a measure of 
Monday’s total dose, Wednesday morning a measure of Tuesday’s and so on. Thus, 
caffeine withdrawal was expected to increase across mornings as the previous day’s 
dose decreases. Because there was no control over the amount of caffeine consumed 
by participants on Sunday, Monday morning’s CWSQ was not included in analyses. 
Descriptive statistics were performed for biohistorical variables that were used as 
covariates: Total Daily Caffeine Consumption, Duration of Caffeine Use, and Number 
of Previous Quit Attempts. Participants received the instructions about their test-week 
dosing schedule during the first baseline session. These instructions differed 
depending on which group participants had been allocated to. Because these differing 
instructions may have created differences in CWSQ scores from the abstinence and 
baseline sessions, these scores were not used as covariates in statistical analyses.  
Differences at baseline were tested in two ways. First, in order to verify how 
withdrawal varied across the two baseline sessions and on Monday morning, a multi-
level linear regression was performed on CWSQ scores across these three days, with 
Time as the primary predictor (ad-libitum vs abstinence vs Monday morning) and the 
three covariates (Duration of Daily Caffeine Use, Number of Previous Quit Attempts, 
and Total Estimated Daily Caffeine Use) as secondary predictors. 
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Table 5.1. Day-by-Day and Visit-by-Visit Breakdown of Dose Reduction Schedule According to Actual Dose and Dosing Information  
 Dose All Participants Received  
Dose Participants Were Told 
Informed Group MisInformed Group 
       Day             Visit Requirements Caffeine Per Cup Total Caffeine Per Day 
Time 
Taken Per Cup Daily Total Per Cup Daily Total 
Monday 
Morning 
 
Afternoon 
 
Questionnaire + Coffee 
 
   Coffee 
 
150mg 
 
150mg 
 
 
300mg 
 
10 min 
 
5 min 
 
150mg 
 
150mg 
 
 
300mg 
 
150mg 
 
150mg 
 
 
300mg 
Tuesday 
Morning 
 
Afternoon 
 
Questionnaire + Coffee 
 
   Coffee 
 
100mg 
 
100mg 
 
 
200mg 
 
10 min 
 
5 min 
 
100mg 
 
100mg 
 
 
200mg 
 
150mg 
 
150mg 
 
 
300mg 
Wednesday 
Morning 
 
Afternoon 
 
Questionnaire + Coffee 
 
   Coffee 
 
50mg 
 
50mg 
 
 
100mg 
 
10 min 
 
5 min 
 
50mg 
 
50mg 
 
 
100mg 
 
150mg 
 
150mg 
 
 
300mg 
Thursday 
Morning 
 
Questionnaire Only 
 
 
No Coffee* 
 
0mg 
 
5 min 
 
No Coffee 
 
0mg 
 
No Coffee 
 
0mg 
Friday 
 
Morning 
 
 
Questionnaire Only 
 
    
   Final Session/ 
End of Experiment Final Session/ End of Experiment 
 
 
10 min 
    
   Final Session/ 
End of 
Experiment 
Final Session/ 
End of 
Experiment 
    
   Final Session/ 
End of 
Experiment 
Final Session/ 
End of 
Experiment 
* No coffee was given to participants during this visit.  
Fig 5.5 Actual Dose Trajectory and Dosing Information Trajectory 
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The three pairwise comparisons of different days’ average CWSQ scores were 
controlled for type-1 error using the Westfall method (Bretz, Hothorn, & Westfall, 
2016). The second set of baseline tests was designed to examine between-group 
differences in CWSQ scores at each of the three baseline sessions – ad-libitum, 
abstinence, and Monday morning. These were designed to assess whether there were 
any pre-existing between-group differences in CWSQ scores that may have biased 
later analyses during the test week. Between-subjects linear regressions were 
performed on CWSQ scores on each of these days, with Dose Information and the 
three covariates as the predictors.  
A multi-level linear regression was used to examine the influence of Dose 
Information on CWSQ scores over Time. This model included Dose Information, 
Time, the Dose Information x Time interaction, and the three covariates as the 
primary fixed effects, and participant ID as the random effect. This was a random-
slopes model, which generates estimates of each individual’s unique intercept and 
slope. The advantage of this approach over the traditional mixed-ANCOVA are:  
(i) it uses generalized least-squares estimation rather than ordinary least 
squares, which allows for the relaxing of assumptions of independence 
and homoscedasticity of residuals that are inappropriate for longitudinal 
data (Singer & Willett, 2003). 
(ii) because it is a form of regression, it generates maximum-likelihood 
estimates as well as estimates of statistical significance.  
Traditional measurements of effect size (e.g. partial eta-squared) cannot be 
generated for multi-level models, and hence will not be presented. 
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Within the multi-level regression model tests of simple effects were performed at 
each level of Time to determine whether there were difference in CWSQ scores on 
each day.  
 
5.3 Results 
Exclusions     Seven participants were excluded from analyses, leaving 24 participants in total (12 
in both Informed and MisInformed groups). Participants were excluded if they gave 
any indication, either in the post-test in-person debrief or in the computer-based exit 
questionnaire, that (i) they had not complied with the request to abstain from outside 
sources of caffeine during the test period or 24 hours prior to the abstinence baseline 
(n = 1); (ii) if they doubted the caffeine content of their beverage for any reasons other 
than their withdrawal symptoms (e.g. a general distrust of psychology experiments (n 
= 3) and the taste of the coffee (n = 1)); or (iii) other reasons, e.g. experimenter error 
(n = 1) or debriefed by a friend who had finished the experiment (n = 1). 
Participant Characteristics  
Mean daily caffeine consumption was 281.3 mg per day (SD = 85.7). All 
participants indicated that their primary source of caffeine was from coffee, with an 
average consumption of 3.0 cups per day (SD = 0.78). The modal number of attempts 
at quitting caffeine prior to enrolling in the study was 0 (average = 0.5, SD = 0.9). The 
mean number of years of daily caffeine use was 4.1 (SD = 3.1). Group breakdown of 
participants’ biohistorical characteristics by group is presented in Table 5.2. 
 
 141 
Baseline Differences 
Ungrouped Difference Across Baseline Sessions: When ignoring the influence of 
group allocation there was a highly significant difference in average CWSQ scores 
between the abstinence and ad-libitum baselines (estimated mean difference = 27.00; 
t(46) = 7.02, p < 0.001), indicating the sensitivity of the CWSQ to differences in 
withdrawal symptoms under opposite caffeine consumption states (see Figure 5.6– 
Table 5.2 Relevant Participant Bio-historical Characteristics By Group 
Group Years of Caffeine 
Use 
No. of Quit 
Attempts 
Per Diem 
Caffeine 
Informed (n = 12) 4.52 (3.4)  0.67 (1.1) 286.00 (117.1) 
MisInformed (n = 12) 3.68 (2.7) 0.33 (0.7) 276.47 (39.8) 
Note: Numbers indicate means and standard deviations. Standard deviations in 
parentheses 
left). There was also a highly significant difference in average CWSQ scores between 
the first measurement of the test week, Monday morning, and the ad-libitum baseline 
(mean difference = 25.04; t(46) = 6.51, p < 0.001) and a non-significant difference 
between Monday morning and the abstinence baseline (mean difference = -1.96; t(46) 
= -0.51, p = 0.611). 
Group Differences Across Baseline Sessions: There were no significant between-
group differences in CWSQ scores on any of the baseline sessions nor on Monday 
morning (Figure 5.6). 
Test week 
Average raw CWSQ scores for each group are presented in Figure 5.7 (Left). 
Between-group differences in linear trajectory of change in CWSQ scores across test 
days are presented in Figure 5.7 (Right). Though the estimated initial CWSQ score on 
Tuesday was higher in the Informed group (47.61) than the MisInformed group 
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Note: Error bars indicate standard error. The number of milligrams on x-axis labels refers to the 
total amount of caffeine consumed the previous day.  
Note: Error bars indicate standard error 
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(38.72), this difference ('Intercept = 8.89) was not significant (p = 0.141). There was 
a significant between-group difference in rate of increase across the test days, with 
CWSQ scores increasing an estimated 4.86 points per day in the MisInformed group, 
Fig 5.6. Mean CWSQ Score Across Baseline Sessions Grouped by Dose Information 
 
 
Fig 5.7 Means of Raw CWSQ Scores (left) and Fitted Slopes (right) During the Test 
Week, According to Dose Information and Time  
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but only 0.81 points per day in the Informed group ('b = 4.05; p = 0.031). Tests of 
simple effects revealed no significant between-group differences in CWSQ scores on 
any of the four test days (Tuesday - Wednesday: t range = 1.52, 0.89, 0.14, -0.52; p 
range = 0.142, 0.383, 0.889, 0.609.  
 
5.4 Discussion 
When examined day-by-day it does not seem as if manipulating information about 
dose had a pronounced effect on withdrawal symptoms. There were no significant 
differences in CWSQ scores between the Informed and MisInformed group on any of 
the test days. However, the analysis of differences in linear trend over time indicated 
that there were differences in rate of linear increase in withdrawal symptoms over the 
four-day test period. In theory, because the rate of actual caffeine dose reduction was 
identical across groups, any differences in rate of change in withdrawal must have 
been due solely to the information provided to participants about their dose. The 
Informed group were told their true rate of dose decrease (300 mg, 200 mg, 100 mg, 0 
mg). Thus they should have expected their withdrawal symptoms to increase across 
the four days. The MisInformed group on the other hand were told their dose was 
remaining stable on the first three days and then being completely discontinued (300 
mg, 300 mg, 300 mg, 0 mg). Thus, they should have expected their withdrawal 
symptoms to stay approximately the same for the first three test days then to increase 
dramatically. The raw scores and fitted slopes seem to tell a different story, with the 
Informed group’s CWSQ scores showing very little change across the days, but the 
MisInformed group’s scores increasing. If awareness of the true dose reduction 
schedule leads to expectancy-induced placebo withdrawal effects we would expect the 
opposite pattern.  
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At first glance these results are similar to the results of Stitzer and colleagues 
(1982), who found that awareness of timing and magnitude of dose reductions during 
a 6-week methadone dose taper produced little or no increase in withdrawal 
symptoms, whereas being blinded to the timing of dose reductions was associated 
with increasing withdrawal symptoms over time. This was interpreted by the authors 
as an indication either that awareness caused a placebo withdrawal-reduction effect or 
that uncertainty induced a negative placebo withdrawal effect (or possibly both). They 
went on to state that “informed detoxification procedures may result in improved 
levels of subjective comfort for detoxifying patients.” (Stitzer et al., 1982, p244). 
However, inspection of the pattern of results from the present study suggest caution 
before interpreting these data as supporting the conclusions of Stitzer and colleagues 
(1982). Though there were no significant differences between groups on any of the 
days in isolation the MisInformed group’s CWSQ scores were numerically lower than 
the Informed group’s for the first three days of the test period. Only on Friday 
morning did the MisInformed group have a numerically higher average CWSQ score 
than the Informed group. Thus it would seem that the MisInformed group’s greater 
linear rate of increase in withdrawal across the days is driven primarily by a 
numerically lower level of withdrawal on the first three days. Had the groups started 
on a near identical level of withdrawal and then the MisInformed group had a greater 
rate of increase there would be some grounds for saying that awareness of dose 
reductions led to lower withdrawal symptoms.  
Since the ‘non-Aware’ group in Stitzer and colleagues (1982) received different 
instructions to those given non-Aware group in Study 4 (i.e. the MisInformed group), 
the results of the two studies cannot be directly compared. In the Stitzer study the 
Non-Aware group were operating under conditions of uncertainty, while having a 
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general awareness of impending dose reductions. Thus, they may have been operating 
under two conditions that have been known to result in negative placebo effects: 
uncertainty and an expectancy of impending withdrawal. In contrast the non-Aware 
group in the present study (the MisInformed group) were actively deceived about their 
dose. Active deception has been demonstrated to lead to more pronounced placebo 
effects (Kirsch & Weixel, 1988) and is thought to more accurately mimic expectancy 
conditions in the real-world, where people are generally have less doubt about having 
received an active agent.  
There were several potential problems with the present study that cast doubt on the 
reliability of these results and limit their interpretability.  
The most important issue is that a different procedure was used in each group to 
control the dose of caffeine. This may have meant that the two Dose Information 
groups did not have identical dose reduction schedules. The Informed group received 
100% caffeine powder for the entire test week, whereas the MisInformed group 
received 100% caffeine powder on Monday, a 2:1 Caffeine-/Lactose-powder blend on 
Tuesday, and a 1:2 Caffeine-/Lactose-powder blend on Wednesday. The 
Caffeine/Lactose blend was created by repeatedly sifting the weighed mixtures of the 
two powders together to achieve a consistent blend. When the particles that make up 
different powders have different density, size, shape, surface properties, friction 
coefficients and other physical parameters – as caffeine powder and lactose powder 
do – achieving a homogenous blend of mixtures is very difficult, for two reasons. The 
first is that the powders may not be blended homogeneously in the first place. The 
homogenous blending of powders requires a considerable amount of time and 
industrial machines designed specifically for the purpose (Poux et al., 1991). Though 
the process used in this study was all that was available at the time, in hindsight it was 
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not adequate to be assured of homogeneity. Second, if powders are not bound together 
via a compression process (e.g. shaping them into a pill), over time segregation or 
demixing can occur (Scheibelhofer et al., 2013). The blended powders used in Study 4 
were stored as loose powder in soft pouches, thus there was a strong possibility 
demixing occurred. No tests (e.g. multipoint NIR spectroscopy) were performed on 
samples of the blended powders to ensure homogeneity, either at time of mixing or 
subsequently. Thus the possibility must be seriously entertained that amount of 
caffeine received by members of each group on Tuesday and Wednesday was not 
identical, limiting the ability to make judgements about the relative role of actual 
caffeine dose versus dose information on the pattern of withdrawal symptoms 
reported.  
A further consequence of the difference in dosing procedure is that the two Dose 
Information groups’ coffee would have tasted different on Tuesday and Wednesday: 
the Informed group receiving only caffeine and the MisInformed group receiving 
lactose powder mixed with caffeine. Whether the combination of lactose with caffeine 
resulted in a more or less aversive flavour is unknown; however, the difference may 
have had unknown follow-on effects on withdrawal symptoms.  
An additional limitation mentioned above is that participants were informed of 
their supposed dose reduction schedule in the PIS given to participants at the 
beginning of the first baseline session. This was done so as to increase the salience of 
the instructional manipulation about the dose schedule. Though this did not produce 
any significant differences in withdrawal ratings at either of the baselines or on 
Monday morning, it did prevent these baseline session scores from being used as 
covariates. 
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These procedural issues mentioned above were addressed in the design of Study 5, 
which will be discussed in the next chapter.  
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Chapter 6: The Effect of Expectation on Caffeine Withdrawal Symptoms During 
a Blind Dose Taper (Study 5) 
 
6.1 Introduction 
The results of Study 4 were inconclusive, notably because of potential problems 
with caffeine dosing in the MisInformed group that may have undermined the 
integrity of the instructional manipulation. Study 5 had an almost identical design to 
Study 4, except it attempted to address the procedural issues with Study 4: (i) by 
devising a way of ensuring that actual dose reduction schedule was identical across all 
groups, while still maintaining the illusion of maintenance of dose from Monday to 
Wednesday in the MisInformed group; and (ii) by trying to match the taste differences 
caused by the presence of lactose powder in the MisInformed group’s coffee.  
One of the aims of this thesis was to model the dose-expectancy processes 
involved in a dose taper procedure, with a view to testing a modified version of the 
procedure where participants are blinded to timing and magnitude of dose reductions. 
The Informed group in Study 4 represented the dose-expectancy conditions under the 
existing standard procedure for dose tapers, where participants are aware of the timing 
and magnitude of dose reductions. Theoretically the Informed group should 
experience the pharmacological effect of the dose reduction plus a negative placebo 
effect, brought about by the expectancy that their withdrawal symptoms would 
increase over the five-day test period. The MisInformed group on the other hand 
should experience the pharmacological effect of the dose reduction counteracted by a 
placebo effect on Wednesday and Thursday, brought about by the instructions that 
their dose was remaining the same from Monday to Wednesday. If the purpose of the 
study was to model a blind dosing tapering procedure as it might occur in practice, the 
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MisInformed group is not an analogue of the dose-expectancy conditions in such a 
procedure. In such a procedure participants would not be Misinformed (i.e. deceived) 
about their dose. Instead they would merely have dosing information removed. To 
model these conditions more faithfully a third group was added to the design of Study 
4: the NonInformed group. This group had their dose reduced at the same rate as the 
Informed and MisInformed groups, but were given no information about their dose 
whatsoever. Conceptually this group was an ‘uncertain non-awareness’ group, who, 
like the MisInformed group, were not aware of the true dosing schedule, but who, 
unlike the MisInformed group, had no alternative sources of dosing information 
available to them. 
An additional change to the procedure of Study 4 was to include an extra measure 
of withdrawal on each day from Monday to Thursday. There are well-known ‘time of 
day’ effects involved in the psychodynamics of caffeine use (e.g. Hindmarch et al., 
2000). Since participants were attending twice each day to receive their coffee 
anyway – once in the morning and once in the afternoon – it made sense from a 
practical standpoint to measure caffeine withdrawal in the afternoon as well. Two 
separate parallel analyses would be performed for scores measured on these two times 
of day.  
Like Study 4, Study 5 tested the effect of information about dose on caffeine 
withdrawal symptoms over the course of a 5-day caffeine dose taper procedure. 
Actual daily dose of caffeine was reduced by 100 mg per day from a starting dose of 
300 mg. This dose reduction schedule was the same for all participants, but was 
administered under three information conditions, true dose information (the Informed 
group), false dose information (the MisInformed group), and no dose information (the 
NonInformed group). Caffeine withdrawal was measured once in the morning and 
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once in the afternoon on every day except Friday, when there was only a single 
morning session. 
The following results were hypothesised. 
Informed vs MisInformed group: based on the dose information given to them it 
was hypothesized that the MisInformed Group’s reported withdrawal symptoms 
would remain approximately stable: across mornings from Tuesday to Thursday and 
across afternoon from Monday to Wednesday. However, on Friday morning, when 
the MisInformed group were instructed their dose was dropping from 300 mg to 0 mg, 
their withdrawal symptoms were expected to increase significantly compared with 
Thursday morning. It was expected that the Informed group’s withdrawal trajectory to 
increase in a steady fashion. Reflecting the difference between groups in the change 
in supposed dose from Wednesday to Thursday (100 mg reduction in the Informed 
group compared to 300 mg reduction in the MisInformed group), it was expected that 
the change in withdrawal symptoms from Thursday morning to Friday morning would 
be greater in the MisInformed group than the Informed group. A similar pattern was 
expected for the afternoon sessions, except that, due to their being no Friday 
afternoon session, the four-day test period would be from Monday to Thursday 
instead of Tuesday to Friday. 
Informed vs NonInformed vs MisInformed group: It was anticipated that, due to the 
absence of any instructions about dose, the NonInformed group would exhibit a less 
steep increase in withdrawal trajectory across the morning and afternoon sessions than 
the Informed group, but that, overall, their linear trajectory would be steeper than the 
MisInformed group.  
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6.2 Methods 
Design 
The design for Study 5 was identical to that of Study 4 save for: (i) the addition of 
an extra group to the Dose Information variable: the NonInformed group; and (ii) 
random allocation to Dose Information group occurring after the second baseline 
session rather than before, so that the two baseline CWSQ scores could be used as 
covariates in statistical analysis. The flow diagram in Figure 6.1 shows the order of 
events through the study. 
Fig 6.1. Flow Diagram for Study 5. 
Note: White boxes indicate the dose the participant was told they were receiving. Actual dose 
of caffeine administered to all participants is indicated at top of figure. 
Participants 
Participants were 48 adults (31 female; mean age = 20.8, age range = 17 to 40) 
who participated in exchange for course credit (n = 44) or for $100 cash (n = 4). 
Ad-libitumCaffeineConsumption
 Numbers in the white boxes below the horizontal arrow refer to daily caffeine intake participants in each group will beinformed they are receiving during the test phase. On each day of the test phase participants will be given a CWSQ questionnair  to complete. 1 – At this session particip ts will complet  a CWSQ questionnaire on a day when they are consuming caffeine as normal. 2 – At this session participants will complete a CWSQ questionnaire after 24 h or total caffeine abstinence.  
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g
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Exclusion criteria were identical to Study 4. Participants gave informed consent to 
take part in a study investigating the effect of caffeine dose on mood, but were fully 
debriefed as to the study’s true purpose upon completion. 
Materials and Measures 
Materials and measures were identical to those used in Study 4. 
Procedure 
Recruitment: Participants were recruited via the University of Sydney’s 1st-year 
Psychology Research Participation Scheme (SONA) or via the University of Sydney 
careers website (Career Hub). The advertisements in Study 4 mentioned dose 
reduction in the advertisement. In Study 5 no mention was made of dose reductions. 
Instead advertisements simply requested participants for a study testing the effect of 
caffeine dose on mood (Appendices 7a and 7b). This ensured that the NonInformed 
group had no expectation of having their dose reduced. The same screening 
procedures for ensuring honest reporting of level of daily caffeine consumption were 
used as in Study 4. 
Baseline Sessions: The procedure for the baseline sessions was the same as in 
Study 4 except that participants were not randomised to group prior to the first 
session. As a result, instructions about the study and the PISs given to participants 
were all the same, making no mention of dose reduction (see Appendix 7c).  
Test Week: As in Study 4, participants in Study 5 were allowed to consume 
caffeine ad-libitum until Sunday evening before the Monday of the test week. They 
received their daily dose of caffeine via two cups of decaffeinated coffee with 
anhydrous caffeine powder and lactose powder added. Once again the first dose 
(Morning) had to be consumed before 12pm and the second (Afternoon) after 12pm, 
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with a minimum 3-hr gap between doses. Caffeine withdrawal was measured via 
CWSQ questionnaire in both the morning and afternoon sessions. Table 6.1 contains 
the day-by-day and visit-by-visit dose breakdown, as well as the breakdown of the 
Dose Information participants in each group were given. As in Study 4, all 
participants’ actual dose reduction schedule was the same: Mon-300 mg; Tues-200 
mg; Wed-100 mg; Thurs-0 mg; Friday-Final Day/No Dose. On Monday morning 
upon arrival at their first test session participants were informed of their dose schedule 
for the week. If they had been randomly allocated to the Informed group, their 
instructed dose reduction schedule matched the true dose reduction schedule. The 
MisInformed group were told they would be receiving the following schedule: Mon-
300 mg; Tues-300 mg; Wed-300 mg; Thurs-0 mg; Friday-Final Day/No Dose. If they 
were allocated to the NonInformed group they were told that they had been allocated 
to a control group and would receive no information about their dose.  
As mentioned previously, in Study 4 there were problems with the dosing procedure 
that may have led to discrepancies in the amount of caffeine received by the Informed 
and MisInformed groups, and also differences in the taste of the beverage due to the 
absence of lactose powder added to the coffee given to the Informed group. In order 
to control for these differences a new system of surreptitious dosing was devised. At 
the beginning of each day, before participants arrived, the requisite caffeine powder 
for each day’s dose – which was the same regardless of group allocation – was 
measured and added to the bottom of empty coffee cups stacked on the table in the 
test room (see Figure 6.2). The cups had white bottoms and the powder was white. 
This fact, combined with the height and position of the stack of cups, meant that 
participants would have had to lean over the desk and peer into the cups at very close 
range in order to see the powder at the bottom of the cups. No participants were seen 
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to do this. This method ensured that, unlike Study 4, 100% caffeine powder could be 
used to control the daily dose, ensuring that dosing schedule was exactly the same 
across groups.  
Figure 6.2. Room in which testing was performed 
 
The procedure for controlling dose information relative to actual dose was 
different across the three groups, as follows: 
Informed and MisInformed Group, Monday to Thursday: When participants 
arrived for each session and began to complete their CWSQ questionnaire, their cup, 
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containing the caffeine powder, was taken from the top of the stack and placed on the 
drip tray under the coffee dispenser. The machine was turned on and the automated 
process of grinding, filtering, and pouring the coffee initiated. While this process was 
taking place, lactose powder, which participants were told was caffeine powder, was 
taken from a gold-coloured pouch (labeled ‘Caffeine Anhydrous, 200 gms’) on top of 
the coffee machine and measured into a plastic ramekin sitting on the electronic scales 
in the testing room. The amount of lactose powder measured out in each cup on each 
day corresponded to the dose of caffeine participants were informed they were 
receiving (see Table 6.1 for breakdown of amount of caffeine and lactose powder 
added to each cup on each day). The weighing procedure took place in full view of 
participants. The electronic scales used were very close to participants and displayed 
weight in bright, easily visible numbers.  
On Thursday participants came in twice as usual and filled out a questionnaire, but 
were given no coffee.  
NonInformed Group, Monday to Thursday: The NonInformed group also visited 
twice each day and completed their questionnaires. However, once they had 
completed their questionnaire they left the test room, and sat on a chair outside while 
their coffee was prepared. In order to match as closely as possible the taste of the 
coffee given to the other groups the NonInformed group had lactose powder added to 
their coffee in amounts matching the amounts given to the MisInformed group (i.e. 
150 mg lactose per day). On Thursday they were given coffee containing no caffeine 
powder and 150 mg lactose powder.  
All Groups, Friday Morning: At the final session on Friday participants completed 
a CWSQ questionnaire and the Exit Questionnaire. When they had completed the Exit 
questionnaire, participants were asked: (i) if they had complied with the ‘no outside 
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caffeine request’ during the test week; (ii) if they suspected at any time before 
completing the Exit questionnaire that their true dose of caffeine was different from 
the dose they were told they were receiving, and, if so, why they suspected it; and (iii) 
general thoughts about the experiment and about the withdrawal symptoms they 
experienced. Participants were then debriefed concerning the true purpose of the 
experiment and, if they were in the MisInformed or NonInformed groups, were then 
told their true dose reduction schedule and allowed to leave. 
Data Analysis 
Like Study 4, Study 5 was designed with the assumption that each participant’s 
morning levels of caffeine withdrawal would reflect the previous day’s total caffeine 
dose. In Study 5 withdrawal was also measured in the afternoon, with the assumption 
that each participant’s afternoon levels of caffeine withdrawal would reflect the 
morning’s dose for that day, and that change in afternoon scores would reflect change 
on each morning’s dose. Therefore Monday afternoon’s CWSQ is a measure of 
Monday morning’s total caffeine dose, Tuesday afternoon a measure of Tuesday 
morning’s total dose, Wednesday afternoon a measure of Wednesday’s and so on. 
Thus we would expect caffeine withdrawal to increase across mornings as the 
previous day’s dose decreases and to increase across afternoons as the morning’s dose 
decreases across days. The CWSQ score data for afternoon and morning sessions 
were analysed separately. As in Study 5, because we had no control over the amount 
of caffeine consumed by participants on Sunday, Monday morning’s CWSQ was not 
included in analyses. Therefore, the test period for the morning sessions was from 
Tuesday to Friday morning, and the test period for the afternoon was from Monday to 
Thursday afternoon. 
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Table 6.1. Day-by-Day and Visit-by-Visit Breakdown of Dose Reduction Schedule During Test Week by Actual Dose and Dosing Information  
 Dose All Participants Received  
Dose Participants Were Told 
Informed Group MisInformed Group NonInformed Group 
       Day           Visit Requirements Caffeine Per Cup 
Total Caffeine 
Per Day Time Taken Per Cup Daily Total Per Cup Daily Total Per Cup Daily Total 
Monday 
Morning 
 
Afternoon 
 
Questionnaire + Coffee 
 
Questionnaire + Coffee 
 
150mg 
 
150mg 
 
 
300mg 
 
10 min 
 
5 min 
 
150mg 
 
150mg 
 
 
300mg 
 
150mg 
 
150mg 
 
 
300mg NA NA 
Tuesday 
Morning 
 
Afternoon 
 
Questionnaire + Coffee 
 
Questionnaire + Coffee 
 
 
100mg 
 
100mg 
 
 
200mg 
 
10 min 
 
5 min 
 
100mg 
 
100mg 
 
 
200mg 
 
150mg 
 
150mg 
 
 
300mg NA NA 
Wednesday 
Morning 
 
Afternoon 
 
Questionnaire + Coffee 
 
Questionnaire + Coffee 
 
 
50mg 
 
50mg 
 
 
100mg 
 
10 min 
 
5 min 
 
50mg 
 
50mg 
 
 
100mg 
 
150mg 
 
150mg 
 
 
300mg NA NA 
Thursday 
 
Informed and 
MisInfomed 
Groups 
Morning 
 
Afternoon 
 
NonInformed 
Group 
Morning 
 
Afternoon 
 
 
 
 
 
Questionnaire Only 
 
Questionnaire Only 
 
 
 
Questionnaire + Coffee 
 
Questionnaire + Coffee 
 
 
 
 
 
No Coffee* 
 
No Coffee* 
 
 
 
0mg 
 
0mg 
 
 
 
 
 
0mg 
 
0mg 
 
 
 
0mg 
 
0mg 
 
 
 
 
 
5 min 
 
5 min 
 
 
 
5 min 
 
5 min 
 
 
 
 
 
0mg 
 
0mg 
 
 
 
0mg 
 
0mg 
 
 
 
 
0mg 
 
 
 
 
 
0mg 
 
 
 
 
 
0mg 
 
0mg 
 
 
 
0mg 
 
0mg 
 
 
 
 
0mg 
 
 
 
 
 
0mg 
NA NA 
Friday 
 
Morning 
 
 
Questionnaire Only 
 
 
Final Session 
 
 
 
Final Session 
 
 
 
10 min 
 
Final 
Session 
 
Final 
Session 
 
 
Final 
Session 
 
Final 
Session 
 
 
Final 
Session 
 
Final 
Session 
 
* Participants in the Informed and MisInformed groups were given no coffee on Thursday morning or Thursday Afternoon. The NonInformed group were 
given coffee on these days but it had 0 mg of caffeine added. 
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The same approach for descriptive and inferential statistics used in Study 4 was 
also used in Study 5 (see ‘Data Analysis’ section of Study 4). Repeated-measures 
multi-level linear regression was used to compare pairwise differences between ad-
libitum baseline, abstinence baseline, and Monday morning CWSQ scores. Linear 
regressions were used to test group differences in CWSQ scores at each level of the 
two baseline measures and on Monday morning. Between-group differences in 
change in CWSQ scores over the test week were explored using two multi-level linear 
regressions, one for the morning scores and one for the afternoon. Tests of simple 
effects, performed within each multi-level regression, were conducted in order to 
estimate group differences in CWSQ scores on each day of the test week. All 
regressions included Duration of Caffeine Use, Number of Previous Quit Attempts, 
and Total Daily Caffeine Use as covariates. Because Ad-Libitum and Abstinence 
Baseline CWSQ scores were recorded prior to randomisation in the present study 
(unlike in Study 4), these were also included as covariates in the multi-level 
regressions performed on the test week data. All pairwise comparisons testing 
differences across the three Dose Information groups were corrected for Type-1 error 
using the Westfall method (Bretz, Hothorn, & Westfall, 2016). In addition, because 
there were two measures on each day (except Friday) a repeated-measures 
hierarchical linear regression was performed on CWSQ scores, with Time of Day 
(Morning vs Afternoon) and Time (Days 1 to 4) as the two within-subjects predictors, 
the three covariates as between-subjects predictors, and participant ID as the random 
effect. To determine whether initial CWSQ score and rate of change in CWSQ scores 
were different from the morning to the afternoon, Tuesday morning and Monday 
afternoon were both coded as Day 1 in the regression, Wendnesday morning and 
Tuesday afternoon as Day 2 etc.  
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6.3 Results 
Exclusions 
Three participants were excluded, either because they did not read the pre-screen 
question correctly (e.g. several answered for the number of cups of coffee they 
consumed per week instead of each day) or because they indicated in the exit 
questionnaire or in-person debrief: (1) that they were suspicious before testing even 
began (e.g. one participant indicated that they doubted their dose ‘because 
psychologists are sneaky’); or (2) that they had consumed caffeine in some form. This 
left 45 participants upon whose data analyses were performed.  
Participants’ average daily caffeine consumption was 305.2mg per day. All 
participants’ indicated that their principle source of caffeine was coffee. Average 
duration of daily caffeine use prior to enrolling in the study was 4.9 years and the 
modal number of quit attempts was 1 (mean = 1.9). Participants’ biohistorical 
characteristics are presnted in Table 6.2. 
Table 6.2 Relevant Participant Biohistorical Characteristics By Group 
Group Years of Caffeine 
Use 
No. of Quit 
Attempts 
Per Diem 
Caffeine 
Informed (n = 15) 6.30 (6.7)  2.47 (3.5) 368.00 (170.7) 
MisInformed (n = 15) 4.82 (5.3) 1.40 (2.6) 286.93 (68.7) 
NonInformed (n = 15) 4.01 (3.2) 1.93 (2.7) 289.27 (68.1) 
Note: Numbers indicate means and standard deviations. Standard deviations in 
parentheses 
Baseline Differences 
Ungrouped Difference Across Baseline Sessions: When ignoring the influence of 
group allocation, and correcting for multiple comparisons, there was a highly 
significant difference in average CWSQ scores between the abstinence and ad-libitum 
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Note: Error bars indicate standard error 
baselines (mean difference = 23.73; t(88) = 7.63, p < 0.001), once again indicating the 
sensitivity of the CWSQ to differences in withdrawal symptoms at different levels of 
caffeine consumption (see Figure 6.3–Left). There was also a highly significant 
difference in average CWSQ scores between the first measurement of the test week, 
Monday morning, and the ad-libitum baseline (mean difference = 15.69; t(88) = 5.04, p 
< 0.001). Unlike Study 4, there was a significant difference between Monday morning 
and the abstinence baseline, with participants scoring 8.04 points lower on Monday 
morning (t(44) = -2.59, p = 0.010), suggesting that participants were experiencing 
lower withdrawals on Monday morning, following a day of ad-libitum coffee 
consumption, than they were following 24 hours of total caffeine abstinence. 
Group Differences Across Baseline Sessions: There were no significant between-
group differences in CWSQ scores for any of the baseline sessions nor on Monday 
morning. Mean differences between groups at each of the two baselines and on 
Monday morning, as well as p-values for omnibus main effects of Dose Information 
are presented in Figure 6.3 (Right). 
Fig 6.3 Mean CWSQ Scores Across Baseline Sessions Grouped by Dose Information 
 Ad-Libitum Abstinence Monday
20
30
40
50
60
Informed
MisInformed
p = 0.355
NonInformed
p = 0.117
p = 0.224
p < 0.001
p < 0.001
p = 0.006
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Morning vs Afternoon 
Mean CWSQ scores over the test week for the morning and afternoon sessions 
averaged across groups are presented in Figure 4. The initial CWSQ score on Tuesday 
morning was an estimated 8.37 points higher than on Monday afternoon (p < 0.001). 
When averaged across groups there was a significant increase in withdrawal 
symptoms of 2.20 points per day across mornings (p = 0.016). The increase in the 
afternoons was 1.75 points per day greater, but this difference was not significant (p = 
0.126).  
Fig 6.4 Mean CWSQ Scores in Morning and Afternoon Session Averaged Across 
Groups 
 
 
 
 
 
 
 
 
 
Multi-Level Models 
The results of the morning and afternoon multilevel linear regressions are 
presented in Table 6.3 and Figures 6.5 and 6.6. These are results are summarized as 
follows: 
Note: Error bars indicate standard error 
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Morning: There were no significant between-group differences either in initial 
value of CWSQ scores on Tuesday morning (i.e. intercept) or in change in CWSQ 
scores across the four-day test period (i.e. slope).  
Afternoon: There were no significant between-group differences in initial value 
of CWSQ scores on Monday afternoon (i.e. intercept). However there were 
significant differences in rate of change in CWSQ scores across the four-day test 
Table 6.3 Multi-level Linear Regression Coefficients For Initial Value and Rate of  
Change in CWSQ Scores Over Time 
 Estimate t p p (corrected) 
Morning 
 
Intercept 
Informed 
 
MisInformed - Informed 
NonInformed - Informed 
NonInformed - MisInformed 
 
Slope 
Informed 
 
MisInformed - Informed 
NonInformed - Informed 
NonInformed - MisInformed 
 
 
 
37.27 
 
1.67 
6.87 
5.20 
 
 
2.68 
 
-0.64 
-0.75 
0.11 
 
 
 
11.02 
 
-0.34 
1.44 
1.12 
 
 
1.85 
 
-0.32 
-0.37 
-0.05 
 
 
 
<0.001 
 
0.732 
0.158 
0.271 
 
 
0.071 
 
0.753 
0.720 
0.960 
 
 
 
 
 
0.731 
0.321 
0.321 
 
 
 
 
0.928 
0.928 
0.958 
Afternoon 
 
Intercept 
Informed 
 
MisInformed - Informed 
NonInformed - Informed 
NonInformed - MisInformed 
 
Slope 
Informed 
 
MisInformed - Informed 
NonInformed - Informed 
NonInformed - MisInformed 
 
 
 
28.81 
 
1.79 
7.26 
5.46 
 
 
6.85 
 
-4.70 
-4.12 
0.58 
 
 
 
8.61 
 
0.38 
1.53 
1.17 
 
 
4.85 
 
-2.35 
-2.08 
0.29 
 
 
 
<0.001 
 
0.710 
0.133 
0.247 
 
 
<0.001 
 
0.024 
0.044 
0.772 
 
 
 
 
 
0.708 
0.275 
0.275 
 
 
 
 
0.049 
0.049 
0.776 
Note: p-values <.10 in italics, <.05 in bold, <.001 in bold italics. Corrected p-values were 
adjusted using the Westfall method.  
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period (i.e. slope). The rate of increase in CWSQ scores in the Informed group was an 
estimated 6.85 points per day (t(40) = 4.85, p < 0.001). The rate of increase in the 
MisInformed group was 2.15 points per day, a significant difference in rate of 
increase of 4.70 points per day (t(40) = -2.35, p = 0.049) compared to the Informed 
group. The rate of increase in the NonInformed group was 2.73 points per day, a rate 
of increase that was also significantly lower than the Informed group (estimated 
difference = -4.12, t(40) = -2.08, p = 0.049). The difference in rate of increase between 
the NonInformed and MisInformed groups was non-significant (estimated difference 
= 0.58, t(40) = 0.29, p = 0.776).  
Fig 6.5 Fitted Slopes for CWSQ Scores During the Test Week, for Morning (left) and 
Afternoon (right) Sessions. 
 
 
 
 
 
 
 
 
  
 
Tests of simple effects comparing group means at each level of Time are presented 
in Table 6.4 and Figure 6.6. In the morning sessions there were no significant 
differences between groups on any day during the test period. In the afternoon, after 
correcting for multiple comparisons, the only significant differences were between the 
Note: p-values have been adjusted for type-1 error.  
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Informed and MisInformed group: on Wednesday (estimated difference = -6.57, t = -
2.47, p = 0.039) and Thursday (estimated difference = -6.40, t = -2.41, p = 0.045). 
Fig 6.6 Mean CWSQ Scores in Morning (Left) and Afternoon (Right) According To 
Day and Group 
 
 
 
 
 
 
 
 
 
analyses. Simple coding was used on the Dose Information and Time factors so as to 
obtain the same estimates of main effects of Dose Information, Time, and their 
interaction as would be obtained from a traditional 2 x (2) ANCOVA. When averaged 
There was main effect of Dose Information, with the Informed group reporting 
CWSQ scores an estimated 11.64 points higher than the MisInformed group (p = 
0.004). There was also a main effect of Time, with Thursday’s scores an estimated 
8.30 points higher than Wednesday’s (p = 0.007). The interaction between Dose 
Information and Time was not significant, with an estimated difference in rate of 
increase between the groups of 0.33 points (p = 0.954). 
Note: Error bars indicate standard error. Single-sided error bars were chosen for clarity. The number of 
milligrams on x-axis labels refers to: Morning – the total number of milligrams of caffeine consumed the 
previous day; Afternoon –milligrams of caffeine in the cup of coffee consumed in the morning of the same 
day. p-values have been adjusted for type-1 error.  
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Table 6.4. Group Mean Difference in CWSQ Score at Each Level of Time 
 
 Estimated 
Difference t 
p-value 
 Uncorrected Corrected 
Morning 
 
Tuesday-300mg 
MisInfo – Info 
NonInfo – Info 
NonInfo – MisInfo 
Wednesday-200mg 
MisInfo – Info 
NonInfo – Info 
NonInfo – MisInfo 
Thursday-100mg 
MisInfo – Info 
NonInfo – Info 
NonInfo – MisInfo 
Friday-0mg 
MisInfo – Info 
NonInfo – Info 
NonInfo – MisInfo 
 
 
 
-0.27 
3.47 
3.20 
 
-1.87 
8.07 
9.93 
 
-6.40 
0.40 
6.80 
 
-0.07 
3.87 
3.93 
 
 
 
-0.04 
0.56 
0.52 
 
-0.31 
1.30 
1.60 
 
-1.03 
0.07 
1.10 
 
-0.01 
0.62 
0.63 
 
 
 
0.966 
0.577 
0.607 
 
0.764 
0.196 
0.112 
 
0.304 
0.949 
0.275 
 
0.991 
0.534 
0.527 
 
 
 
0.966 
0.842 
0.842 
 
0.764 
0.249 
0.249 
 
0.518 
0.949 
0.518 
 
0.991 
0.802 
0.802 
Afternoon 
 
Monday-150mg 
MisInfo – Info 
NonInfo – Info 
NonInfo – MisInfo 
Tuesday-100mg 
MisInfo – Info 
NonInfo – Info 
NonInfo – MisInfo 
Wednesday-50mg 
MisInfo – Info 
NonInfo – Info 
NonInfo – MisInfo 
Thursday-0mg 
MisInfo – Info 
NonInfo – Info 
NonInfo – MisInfo 
 
 
 
-0.73 
5.53 
6.26 
 
-1.00 
-0.40 
-0.60 
 
-13.33 
-3.20 
9.93 
 
-12.80 
-7.27 
5.53 
 
 
 
-0.14 
1.04 
1.18 
 
-0.19 
-0.08 
-0.11 
 
-2.47 
-0.60 
1.87 
 
-2.41 
-1.37 
1.04 
 
 
 
0.890 
0.299 
0.240 
 
0.851 
0.940 
0.910 
 
0.015 
0.548 
0.064 
 
0.017 
0.174 
0.299 
 
 
 
0.890 
0.467 
0.467 
 
0.981 
0.981 
0.981 
 
0.039 
0.548 
0.064 
 
0.045 
0.175 
0.299 
Note: p < .10 in italics, p < .05 in bold. Numbers of milligrams refers to the period prior to 
the measure; the morning measures to the total dose the day before, the afternoon period to 
the dose the morning of the same day.
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6.4 Discussion 
Like Studies 1, 2, and 3, Study 5 demonstrates that withdrawal symptom severity is 
affected by the beliefs of individuals concerning how much of a drug they have in 
their body.  
Although withdrawal symptoms as a whole increased as the dose the previous day 
decreased, the different instructions given to the different groups produced no 
significant differences in reported withdrawal symptoms in the mornings. The pattern 
of withdrawal symptoms across the afternoons was quite different. Caffeine takes 6-8 
hours to clear the body (Juliano & Griffiths, 2004). It is possible that in the mornings, 
before their first cup of coffee for the day, when they had not consumed caffeine for 
over 12 hours, withdrawal was at a ceiling level upon which instructions about dose 
had very little effect.  
In contrast to the morning sessions, in the afternoon sessions instructions about 
dose did have a differential effect on the pattern of withdrawal symptoms across the 
four-day test period.  
Informed vs MisInformed: The day-by-day analysis revealed a pattern of 
withdrawal over the four days in the Informed and MisInformed groups that was quite 
consistent with the information they were given about their dose each morning across 
the four-day test period. The dose information given to participants in these two 
groups is shown in Figure 7. Given that we would expect an inverse relationship 
between dose and withdrawal, we could broadly expect that, if dose information has a 
significant effect on withdrawal, the Informed group should exhibit a roughly linear 
increase in withdrawal from Monday to Thursday afternoon, and the MisInformed 
group should show a relatively stable level of withdrawal from Monday to 
Wednesday, then significant increase from Wednesday to Thursday. Inspection of the 
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pattern of withdrawal in these two groups across the four days, combined with the 
day-by-day analysis of group differences, reveals that this expected pattern is matched 
to some extent by the data (see Figure 6.7).  
Fig 6.7 Dose Information Trajectory 
(in mg of caffeine per cup in 
morning of same day) and Afternoon 
CWSQ Score Trajectory Across Test 
Days in Informed and MisInformed 
Groups 
On Monday afternoon the dose 
that the Informed group and 
MisInformed group were told was in 
their morning session’s cup of coffee 
was identical: 150mg (the true dose). 
Their CWSQ score in this session 
reflected this, with an estimated difference of 0.73 of a point (p = 0.890). On Tuesday 
afternoon the dose each group was informed was in their morning’s coffee began to 
diverge: 100 mg for the Informed group (the true dose) as opposed to 150mg for the 
MisInformed group. However, this small difference was insufficient to produce any 
detectable difference in CWSQ scores. On Wednesday afternoon the difference in 
informed dose had widened to 100 mg, with the Informed group being told their 
morning’s dose was 50mg (the true dose), and the MisInformed group being told it 
was 150mg. This wider difference in dose information was reflected in a now 
significant difference in the CWSQ scores, with the MisInformed group reporting an 
average score 13.33 points lower than the Informed group (p = 0.039). This difference 
could be termed ‘the cost of being informed’, and could be considered either a 
placebo withdrawal-reduction effect in the MisInformed group caused by their 
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expectation of their dose remaining stable, or alternatively an enhanced negative 
placebo effect in the Informed group, caused by their expectation of having their dose 
reduced and therefore experiencing an increase in withdrawal. On Thursday afternoon 
the two groups’ dose information converged again, with both groups being told that 
their dose was 0 mg. For the MisInformed group this represented a reduction in 
informed dose from Wednesday to Thursday of 150 mg, whereas in the Informed 
group this reduction was only 50 mg. While this greater reduction from Wednesday to 
Thursday in the MisInformed group could theoretically have resulted in a greater 
increase in CWSQ scores from Wednesday afternoon to Thursday afternoon in the 
MisInformed group than in the Informed group, it appeared as if the between-group 
difference in CWSQ scores on Wednesday was largely preserved with a significant 
difference of 12.8 points (p = 0.045). This was confirmed by multi-level regression, 
which revealed a negligible difference in change in CWSQ scores between the two 
groups from Wednesday to Thursday (p = 0.954).  
The longitudinal analysis examining rates in linear change in withdrawal scores 
across the days revealed a significantly lower rate of linear increase in withdrawal 
across afternoons in the Misinformed group than in the Informed group (corrected p = 
0.049). However, due to the design of the experiment, the meaningfulness of a linear 
regression analysis for comparison of rate of change across the MisInformed and 
Informed groups is questionable since the Dose Information provided to the 
MisInformed group was discontinuous, with a sharp change on Thursday. Had the 
dose information the MisInformed group received on Thursday also been 150 mg this 
analysis may have been more appropriate.  
NonInformed vs Informed and MisInformed: The day-by-day analysis revealed no 
significant differences in reported withdrawal between the NonInformed group and 
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either the two other groups on any of the four afternoons. The longitudinal analysis 
was more appropriate in the case of the comparison between the NonInformed and the 
other two groups, since both of the latter had information about dose that could be 
considered continuous in some sense across all four days: in the Informed group 
because their informed morning dose dropped by 50mg each day (mirroring the true 
dose) and in the NonInformed group because they received no information about dose 
at any point. If we view the expectancy conditions in the Informed group as 
representing the true pharmacological effect of the dose reduction plus the negative 
placebo effect accompanying the knowledge of this dose reduction, there were 
grounds for thinking that removing awareness of dose reductions would lead to a 
reduced rate of increase in withdrawal (e.g. Benedetti et al., 2003). However, studies 
have also shown that the uncertainty caused by removing knowledge of a dose 
reduction is associated with an increase in rate of withdrawal increase (e.g. Stitzer, 
Bigelow, & Liebson, 1982). The results of Study 5 tentatively favour the former 
interpretation, with the NonInformed group showing a significantly shallower rate of 
increase in withdrawal than the Informed group (estimated difference in rate of 
increase = 4.13, p = 0.049). This finding is important since the NonInformed group 
most closely represents the conditions under which a blind dose taper might occur in 
the real world, where participants volunteer to have verbal and contextual information 
about dose removed. There was no significant difference in the initial level of 
withdrawal or the rate of increase in withdrawal between the NonInformed and 
MisInformed groups.  
In summary, Study 5’s results were consistent with the theory that withdrawal 
symptoms are affected by the information individuals receive concerning the amount 
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of a drug they have in their body. The broader implications of this for clinical practice 
in treatment of addiction will be discussed in Chapter 7.  
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Chapter 7: General Discussion 
 
7.1 Summary 
The goals of this thesis were twofold: to examine the role of expectancies in drug 
withdrawal and to explore the withdrawal-reduction potential of interventions that 
integrate expectancies into their design. All studies used caffeine to model withdrawal 
processes. Studies 1 and 2 tested the relative impact of two types of verbal 
instructions on withdrawal symptoms: (i) instructions concerning the likelihood of 
experiencing withdrawal symptoms during abstinence, (ii) instructions concerning 
whether or not a drug had been ingested. The results of these studies indicated that 
instructions relating to the likelihood of experiencing withdrawal had no effect on 
withdrawal symptoms, whereas instructions concerning whether or not the drug had 
been ingested did have an effect. Study 3 examined an intriguing phenomenon that 
occurred in Studies 1 and 2, whereby participants given decaffeinated coffee who 
were instructed they were receiving decaffeinated coffee (the Told Decaf group) 
experienced a significant reduction in caffeine withdrawal symptoms. Studies 1 and 2 
did not contain a natural history group, making it difficult to know whether the 
reduction in the Told Decaf group was a genuine placebo effect or some artefact of 
the test procedure. Therefore a no-treatment control group – the Told Water group, 
who were given water instead of decaf and were instructed it was water – was 
included in Study 3. In addition participants were given a questionnaire to determine 
whether they had conscious expectancies that decaf would reduce their withdrawal 
symptoms. Once again a significant reduction in withdrawal symptoms was observed 
in the Told Decaf group, and this reduction was significantly greater than the Told 
Water group, suggesting that the placebo effect was genuine. Furthermore participants 
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endorsed expectancies that decaf would not reduce their withdrawal symptoms, 
suggesting that the observed placebo effect was mediated unconsciously. The results 
of Study 3 suggest that placebo effects can take place even in the absence of 
conscious expectancies and that conscious and unconscious expectancies likely 
combine to produce greater placebo effects than unconscious expectancies alone. 
Studies 4 and 5 tested the potential of a blind dose tapering procedure – where 
participants are not aware of timing and magnitude of dose reductions – for reducing 
withdrawal symptoms compared with a standard dose taper. These studies suggest: (i) 
that beliefs about dose can have a significant impact on withdrawal symptoms 
independently of actual dose, (ii) that withdrawal symptoms are increased by being 
aware of the timing and magnitude of dose reductions, (iii) that lack of awareness of 
dose reductions reduces the intensity of withdrawal symptoms, (iv) that being 
misinformed about dose produces stronger placebo effects than simply being blinded, 
but that (v) even under blind conditions, when there is uncertainty about dose, the rate 
of increase in withdrawal symptoms during a dose taper is reduced by removing 
awareness of dose reductions.  
7.2 Theoretical Implications 
The results of the studies in this thesis have some important theoretical 
implications for placebo withdrawal specifically and placebo effects generally. These 
will be discussed below. 
7.2.1 Implications for Placebo Withdrawal 
The Effect of Knowledge of Dose on Withdrawal Symptoms 
The studies in this thesis all tested whether caffeine withdrawal was affected by 
knowledge of dose by comparing a condition that had accurate knowledge of their 
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dose of caffeine to another condition (or conditions) that did not have accurate 
knowledge. In all but one study this comparison condition was actively misinformed 
about their dose. In Study 5 a group that had accurate knowledge of dose was 
compared against two other groups: one that was actively misinformed about their 
dose, and another that had all external cues that might indicate their dose removed. 
These two comparison conditions – misinformation and no information – were 
operating under different types of expectancies and will therefore be discussed 
separately. 
Accurate Dose Information vs Inaccurate Dose Information: As mentioned above, 
all studies in this thesis tested a group receiving accurate information about their dose 
of caffeine against a group who were given inaccurate information, i.e. who were 
actively misinformed about their dose. In Studies 1 and 2 the Told Decaf condition 
were given accurate information that they had received close to 0 mg of caffeine (4 
mg or less of caffeine in each cup). In Study 3 the conditions receiving accurate 
information were the Told Decaf group and the Told Water group. In Studies 1, 2, and 
3, the conditions that were given inaccurate dose information were the Told Caffeine 
conditions. In Studies 4 and 5 the Informed group were given accurate information 
about their dose reduction schedule, whereas the MisInformed group were given a 
false dose reduction schedule. Because the conditions that received inaccurate 
information were actively misinformed about their dose, theoretically they should 
have been operating under conditions of relative certainty about what dose they were 
receiving each day. In Studies 1, 2 and 3 the differential dose information was binary, 
i.e. the simple presence or absence of caffeine in their beverage, whereas in studies 4 
and 5 the information was more specific, given in the form of number of milligrams 
of caffeine in each cup and on each day. In Studies 1, 2, 3, and 5 participants reported 
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change in caffeine withdrawal symptoms that was consistent with the information 
they received – accurate or inaccurate – about their caffeine dose. This occurred 
despite all participants in each study receiving identical doses of caffeine. In Studies 
1, 2, and 3 caffeine withdrawal reduction was significantly greater when people were 
told they had received caffeine. In Study 5 being told their true dose schedule led to 
participants in the Informed group to report greater withdrawal symptoms on 
Wednesday and Thursday afternoon of the test week, and faster overall rate of 
increase in withdrawal symptoms across the test week, than participants who were 
misinformed that their dose was remaining stable for three days and then dropping to 
0 mg on the final day.  In combination, results from these studies strongly suggest that 
when people receive unequivocal information about the dose of a drug, it leads to 
strong placebo withdrawal and placebo withdrawal-reduction effects. 
Accurate Dose Information vs No Dose Information: The only study to compare 
the effect of accurate dose information to no dose information was Study 5. The 
NonInformed group were given no information, verbal or contextual, to indicate the 
dose schedule that they received. The overall rate of increase in the NonInformed 
group was significantly lower than that of the Informed group, suggesting that even 
when participants are given no information about dose – i.e. are operating under 
conditions of uncertainty about dose – it still leads to lower withdrawal symptoms 
than being aware of dose reductions.  
These results contradict the results from previous studies such as Stitzer and 
colleagues (1982) and Senay and colleagues (1977) who found that uncertainty about 
dose reduction schedule led to more pronounced withdrawal symptoms than when 
people were aware of their true reduction schedule. Some theories of placebo effects 
suggest that uncertainty might cause an increase in anxiety about and in scrutiny of 
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bodily sensations, which can lead to an amplification of incidental, existing symptoms 
(Barsky, Goodson, Lane, & Cleary, 1988; Barsky, Saintfort, Rogers, & Borus, 2002; 
Barsky, Wyshak, & Klerman, 1990). Other theories (e.g. Benedetti et al., 2003) 
suggest the opposite, that awareness of a reduction or interruption in dose of a drug 
that is relied upon for keeping negative sequelae at bay will lead to expectancies of 
these negative sequelae occurring, which in turn will lead to a negative placebo effect. 
Benedetti and Colleagues (2003) found that awareness of dose of morphine being 
interrupted led to a more rapid increase in pain than uncertain non-awareness and that 
awareness of diazepam interruption led to a more rapid increase in anxiety. 
Comparison of the Informed and NonInformed groups in Study 5 supports Benedetti 
and colleagues’ (2003) theory that awareness of an event that is expected to lead to 
negative sequelae can evoke a negative placebo effect, and suggests that this same 
principle applies to withdrawal symptoms. 
Inaccurate Dose Information vs No Dose Information: Study 5 was the only study 
where these two forms of dose information were compared directly against each 
other. There was no significant difference between the MisInformed or NonInformed 
groups in the morning or afternoon on any of the test days, nor was there a significant 
difference in rate of increase in withdrawal symptoms between these two groups. 
Despite the absence of any significant differences between the MisInformed and 
NonInformed groups on any of the test days, there is evidence that the MisInformed 
group (who received inaccurate but unequivocal dose information) experienced a 
stronger placebo effect than the NonInformed group (who received no information). 
The MisInformed group’s withdrawal symptoms were significantly lower than the 
Informed group’s on Wednesday and Thursday afternoon. In contrast there were no 
days when the NonInformed group’s withdrawal symptoms were significantly lower 
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than the Informed group’s. This suggests, perhaps, that the relative certainty of the 
information given to the MisInformed group led to a stronger placebo withdrawal-
reduction effect than the uncertainty under which the NonInformed group was 
operating. 
Placebo effects and negative placebo effects are not absolute: they can only be 
demonstrated via comparison of one condition to another. It is to be expected that 
misinformation leads to stronger placebo effects. However in Study 5 receiving no 
dose information also led to reduced withdrawal symptoms. This suggests that the 
reason why having accurate information about dose reductions leads to greater 
withdrawal symptoms is that it creates expectancies of withdrawal increases that lead 
to a placebo withdrawal (i.e. a negative placebo) effect. This has important practical 
implications for dose tapers, which will be discussed below. 
Instructions About Withdrawal vs Instructions About Dose  
This thesis tested the ability of two types of verbal instruction to affect caffeine 
withdrawal symptoms: instructions concerning the likely effects of abstinence and 
instructions concerning how much caffeine participants had consumed. In terms of the 
former, neither a warning contained in a PIS (Study 1) nor a more elaborate bogus 
DNA test (Study 2) had any effect on caffeine withdrawal symptoms, demonstrated 
by Bayes Factors of 3.78 and 4.78 respectively in favour of the null hypothesis of no 
effect of instruction. In contrast, instructions concerning how much caffeine had been 
consumed did have an effect on withdrawal symptoms. The question then arises why 
one type of verbal instruction affected withdrawal symptoms when the other did not. 
The answer to this question may lie in the difference between the sorts of beliefs each 
type of verbal instruction was attempting to manipulate.   
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Individuals with addiction have extensive first-hand experience with the effects of 
both using and abstaining from their drug. Through this experience they acquire 
strong beliefs about what symptoms they are likely to experience and how likely they 
are to experience them. As a result, any information provided to them by an 
unfamiliar researcher or clinician (even one wearing a white lab-coat) concerning 
what effects to expect or how likely those effects are will likely do little to alter those 
expectancies. Supporting this notion, past experiments where instructions concerning 
the effects of a drug have elicited placebo effects have mainly been with drugs or 
effects that are in some way novel (e.g. appetite change following a novel anti-
insomnia drug in Colagiuri et al., 2012, or specific effects of caffeine use on a motor 
performance task in Fillmore and Vogel-Sprott, 1992). The participants in Studies 1 
and 2 were moderate to heavy coffee users, who were likely to be very well 
acquainted with the symptoms they would experience during abstinence. As such, it 
seems quite plausible that they had such strong prior knowledge of the likelihood of 
experiencing withdrawal symptoms that neither the PIS in Study 1 nor the genetic 
information in Study 2 could alter those beliefs. Studies 1 and 2 support the idea that 
expectancies surrounding the contingency between events and their outcomes will be 
relatively resistant to alteration by verbal instruction if the individual in question has 
sufficient first-hand experience with those outcomes.  
 The verbal instructions concerning how much caffeine had been consumed also 
attempted to use participants’ beliefs about the likely effects of abstinence on 
withdrawal to produce placebo effects. However instead of attempting to change those 
pre-existing beliefs the instructions about dose simply sought to activate those beliefs. 
This may explain why instructions concerning dose produced placebo effects when 
the instructions about likelihood of experiencing withdrawal failed. 
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The difference in the ability of the two types of verbal instructions to affect 
withdrawal symptoms suggests that: (i) individuals with addiction have such 
extensive experience with their withdrawal symptoms that their beliefs about 
withdrawal are relatively impervious to instructions that attempt to change those 
beliefs, (ii) placebo manipulations that activate participants’ existing expectancies will 
be more successful than those that attempt to change those expectancies via 
instruction, and, (iii) that beliefs acquired through extensive first-hand experience are 
only likely to be altered by further first-hand experience. 
7.2.2. Implications for Placebo Effects Generally 
Conscious vs Unconscious Expectancies 
Though it was not the central goal of this thesis to explore the relative contribution 
of conscious and unconscious expectancies in placebo effects, the unexpected result in 
Studies 1 and 2, where the Told Decaf condition had a significant reduction in 
withdrawal was worthy of exploration. Study 3, therefore, included an additional no-
treatment control group – who received all the same experimental procedures but 
were given water – to compare the Told Decaf group against. The results of Study 3 
indicated that the Pre- to Post-Beverage reduction in withdrawal symptoms in the 
Told Decaf group was significantly greater than in the Told Water group, whose mean 
withdrawal score in fact stayed exactly the same from Pre- to Post-Beverage. This 
suggests that the reduction in withdrawal symptoms in the Told Decaf group, in this 
and the previous two studies, was due to a genuine placebo effect. Critically, the 
expectancies of withdrawal reduction endorsed by participants for the three different 
beverages – caffeinated coffee, decaf, and water – showed a different pattern. 
Unsurprisingly caffeinated coffee was rated as having the highest caffeine-withdrawal 
reduction potential; however, unexpectedly, water was rated as having the second 
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highest, and decaf the lowest. This pattern was the same across the entire sample and 
within each group, including the Told Decaf group. That participants who received 
decaffeinated coffee would show a significant reduction in withdrawal symptoms 
after consuming it, despite (i) knowing it was decaffeinated coffee, (ii) holding 
conscious expectancies that decaffeinated coffee would not reduce their withdrawal 
symptoms, suggests the presence of an unconsciously mediated placebo effect.  
There is already some evidence that placebo effects can be conditioned when the 
effects of the drug with which the neutral stimuli are paired cannot be perceived by 
patients, for example with respiratory depression following exposure to opiates 
(Benedetti et al., 1998), secretion of human growth hormone following conditioning 
with sumatriptan (Benedetti, Pollo, et al., 2003), and immune activation after 
conditioning with Interferon-γ (Longo et al., 1999). However, in most cases where the 
effect of a drug or procedure is perceptible by the organism it is difficult to separate 
the effects of conscious and unconscious processes. One study design has made it 
possible to study the differential effects of conscious and unconscious expectancies 
even when the effects can be perceived: the ‘reveal’ design. In this design participants 
have a cream applied that they are told is a topical analgesic. All participants are then 
administered shocks during a conditioning phase, both with and without the cream. 
On the trials when the cream is applied, the shock level is reduced by experimenters 
by reducing the amplitude of the current being administered to participants. When the 
cream is wiped off the shock level is increased. Participants are then told that the 
reduction in pain experienced during the placebo trials is due to experimenters 
reducing the intensity. If the placebo effects brought about by conditioning procedures 
were entirely mediated by conscious awareness then the revelation that the pain 
reduction was not due to the cream should abolish the placebo effect. However if the 
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placebo effect persists after the revelation, this indicates that unconscious 
expectancies (or conditioning) can elicit placebo effects unmediated by conscious 
expectancies. Unfortunately results from the experiments using variants of this design 
are not consistent. In one study where the reveal was performed prior to the 
conditioning procedure, a group who were told the true reason for the reduction in 
pain on trials where the cream was applied showed no placebo effect whereas a group 
who were not told did exhibit placebo analgesia (Montgomery & Kirsch, 1997). In 
another study the reveal was made after the conditioning procedure. In this study the 
placebo effect persisted after the reveal (Schafer, Colloca, & Wager, 2015). In both 
studies participants’ conscious expectancies were measured and it was found that 
participants who were aware of the true source of the pain reduction did not expect 
that the cream would have any effect. These two studies present conflicting results 
concerning whether or not conscious expectancies are necessary for placebo effects to 
occur. In Study 3 a placebo ‘withdrawal-reduction’ effect occurred in the Told Decaf 
condition despite participants expressing no conscious expectancies that decaf would 
reduce their withdrawal. This is consistent with the results of Schafer and colleagues 
(2015), supporting the idea that placebo effects can be evoked by stimuli surrounding 
drug use even in the absence of conscious expectancies, and that conscious and 
unconscious expectancies can cause placebo effects independently of one another.  
Compensatory Effects  
The fact that caffeine withdrawal symptoms were reduced by stimuli associated 
with consumption of coffee is also interesting because the opposite effects have 
been observed in other drugs of addiction. As discussed in Chapter 1, often when 
abstinent addicted individuals are exposed to cues associated with drug 
consumption it produces symptoms that are opposite in direction to the effects of 
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the drug, that is, conditioned tolerance responses (Childress, McLellan, & 
O'Brien, 1986; O'Brien et al., 1977; Sideroff & Jarvik, 1980; Teasdale, 1973; 
Ternes et al., 1979; Vaillant, 1988). This did not occur in studies 1, 2, and 3, 
where being presented with the stimuli surrounding caffeine consumption, in the 
form of a cup of decaffeinated coffee, produced a placebo withdrawal-reduction 
effect rather than a placebo withdrawal effect. Opiate addiction has a much more 
pronounced withdrawal syndrome than caffeine, with many more outward, 
physical signs of withdrawal. It may be that, when the withdrawal syndrome for a 
certain drug is less pronounced or consists of mostly subjective symptoms, as does 
caffeine withdrawal, stimuli associated with drug use elicit placebo responses that 
are in the same direction as the unconditioned effects of consuming the drug, 
which in this case is withdrawal reduction.  
 
7.3 Practical Implications 
While the results of the studies in this thesis did have interesting theoretical 
implications, the primary goal of this project was to explore the potential of methods 
for integrating drug withdrawal expectancies into clinical addiction interventions. As 
discussed in detail above, it seems likely that addicted individuals have such strong 
beliefs about withdrawal and abstinence that any attempts to influence these beliefs 
purely by verbal means (e.g. in psychotherapy) would have little effect on the 
experience of withdrawal symptoms. However some of the results from this project 
did have practical implications for addiction interventions that are worth discussing.  
7.3.1 Dose Tapering 
The findings from Study 5 have important implications for dose tapering practices 
in a clinical setting. First, they indicate that standard dose tapering practices– where 
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patients are made aware of any dose reductions via verbal and contextual cues – are 
likely to lead to greater withdrawal symptoms via the creation of expectancies of 
withdrawal that actually exacerbate withdrawal symptoms. Second, they suggest that 
blinding patients to dose reductions may be effective at reducing these placebo 
withdrawal symptoms. These findings are noteworthy because withdrawal symptoms 
are an important predictor of relapse to illegal drugs, dropout during a dose taper, or  
cessation of tapering (Calsyn, Malcy, & Saxon, 2006; San et al., 1989). As such, any 
procedure which could reduce withdrawal symptoms could potentially improve the 
chances of patients undergoing a dose taper of successfully transitioning to a drug-
free state.  
One way to implement these findings in clinical practice would be to offer patients 
who are considering undertaking a dose taper the option of voluntary blinding. 
Voluntary blinding would involve the patient electing to have their dose reduction 
schedule hidden from them. Their prescribing doctor could decide on the exact details 
of the dose reduction schedule and give instructions to dosing staff in the pharmacy, 
clinic, or dispensary where the patient is collecting their dose not to make patients 
aware of their dose or any dose changes during the dose taper procedure. 
Furthermore, contextual cues that would otherwise indicate dose reductions could be 
removed.  For example, by diluting methadone syrup with a strong-tasting cordial or 
fruit juice, taste cues and cues relating to volume of liquid in each dose could be 
masked from participants. This would remove all signals that their dose was being 
reduced and therefore would also remove the opportunity to generate any 
expectancies of withdrawal that might lead to placebo withdrawal effects. Such a 
procedure has two advantages. First it would be ethical: patients would be voluntarily 
surrendering knowledge of dose reductions, with the understanding that they can end 
 186 
the blinding at any time and find out their dose. Second it would be a very simple and 
inexpensive procedure to carry out. 
Another advantage of this procedure is that patients could be transitioned to a 
completely drug-free state under blind conditions. For people who have been on a 
drug-replacement therapy like methadone for a long time the drug can hold a central 
place in their lives, to the point where the idea of not taking it is difficult to imagine, 
and a source of great anxiety (Syvertsen et al., 2010; Vaillant, 1988). For these 
patients the expectancy of negative effects upon discontinuation is very high, which is 
perhaps one of the reasons why patients often relapse at the final stages of a dose 
taper (Calsyn et al., 2006), despite the fact that their dose of methadone they are 
maintained at is so small that discontinuation should cause only mild physical 
withdrawal symptoms (Schweizer, Rickels, Case, & Greenblatt, 1990). With blind 
dose tapering these issues could be removed. The patient could be transitioned to 0 
mg and kept on a 0-mg dose for several weeks. They could then be informed that they 
have been totally drug free for several weeks. Provided that they had been coping 
normally during those weeks of oblivious abstinence, this could potentially be 
empowering, and could help to demystify the over-inflated importance of the drug in 
the minds of the users.  
7.3.2 Open Label Interventions 
The fact that caffeine withdrawal reduced significantly in the Told Decaf 
conditions in Studies 1, 2, and 3 in the absence of conscious expectancies suggests 
that relief from withdrawal can be conditioned to neutral stimuli associated with 
consumption of an addictive drug. In recent years much research attention has been 
devoted to investigating open-label placebo effects, where placebo effects are 
observed when participants are given a placebo and are told openly that it is a 
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placebo. In most cases open-label placebos are administered with an accompanying 
‘rationale’, that is, with instructions that indicate that placebo effects can lead to 
clinical improvement, rather than that the placebo will do nothing (e.g. Kaptchuk et 
al., 2010). Administering a placebo with this form of instruction may create conscious 
expectancies of symptom improvement in the mind of patients similar to the 
expectancies generated by a regular (i.e. ‘non-open-label’) placebo. In Study 3 
participants indicated that they believed there was little chance that decaf would 
reduce their withdrawal symptoms. Yet when they were given decaf, it did reduce 
withdrawal. Thus Study 3 suggests that presenting addicted individuals with stimuli 
associated with drug use may reduce withdrawal symptoms even without verbally 
instructing participants that it will do so. This raises the possibility that open-label 
placebo interventions – where patients are exposed to the stimuli surrounding drug 
use – may be effective at reducing withdrawal even without an accompanying 
rationale. However, as mentioned in Chapter 1 and above, there are studies where 
exposure to stimuli surrounding drug consumption lead to compensatory effects that 
actually make withdrawal symptoms more pronounced. Further research into which 
drugs are amenable to open-label procedures is necessary to determine whether these 
procedures have any clinical utility.  
7.4 Limitations 
There are several limitations to the studies conducted in this thesis. Some of these 
limitations were due to broader conceptual issues and others were due to procedural 
issues. These will be discussed below. 
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7.4.1 Conceptual Issues 
Self-Report Data 
The caffeine withdrawal symptoms measured in all five studies in this thesis were 
measured by self-report. As with any research that relies on self-report, there is the 
possibility that participants based their responses on what they believed the research 
was trying to achieve rather than what they actually experienced. Efforts were made 
to reduce such demand characteristics by, for example, telling participants in Studies 
1 and 3 that the variable of interest was cognitive performance rather than withdrawal 
symptoms, or by not informing participants in Studies 4 and 5 about the dose 
reduction schedule of other conditions. However, it is possible that participants still 
perceived the experimental demands, causing them to either under- or over-report 
their symptoms. 
Unfortunately there are no proven psychophysiological markers of caffeine 
withdrawal other than cerebral blood flow (Jones, Herning, Cadet, & Griffiths, 2000) 
and the procedure involved to measure this is too invasive to be practical in a study 
with a large sample size or involving many visits. Self-report is the only way to 
measure many psychological variables, and unfortunately caffeine withdrawal is one 
of these variables. However it should be noted that, in the case of individuals with 
addiction, they way they feel is likely to be the primary determinant of their decision 
to relapse. Hence, in the case of withdrawal, objective measurements of symptoms are 
arguably less important than subjective measurements of participants’ internal bodily 
states and mood. 
Generalisability 
Generalising from caffeine to other addictive drugs: A central assumption of this 
thesis is that findings related to placebo caffeine withdrawal can plausibly be 
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generalised to the withdrawal syndromes of other addictive drugs.  The effects of 
caffeine use and caffeine withdrawal are milder than those of drugs such as heroin, 
cocaine, benzodiazepam, and alcohol. Just as important, caffeine use is free of the 
usual societal prohibitions surrounding more serious drugs. This means that most 
caffeine users face neither the financial problems involved with regularly obtaining 
their drug of choice nor the social ostracism and sense of shame that often accompany 
use of illegal, class-A drugs. As a result, caffeine users generally do not experience 
strong outside pressure to quit their drug the way users of illegal drugs do.  
Despite these differences there are similarities between caffeine and more serious 
drugs that allow for cautious generalisation. First, caffeine possesses the essential 
criteria for a drug to be considered addictive, that is, with regular use tolerance 
develops to its acute effects and withdrawal symptoms emerge following dose 
reduction or discontinuation (American Psychiatric Association & American 
Psychiatric, 2013). Caffeine has a well-established withdrawal syndrome across a 
range of individual symptoms that has been proven and replicated in double-blind 
studies that compared regular users to caffeine-naive users (see Juliano & Griffiths, 
2004, for a review). Second, like users of more serious drugs, caffeine users have 
robust and accurate knowledge (and hence expectancies) of caffeine withdrawal 
symptoms (Huntley & Juliano, 2012). Third, caffeine has abuse potential, reflected in 
the fact that caffeine withdrawal has been added to the DSM-5 list of substance abuse 
disorders (American Psychiatric Association & American Psychiatric, 2013).  
There is general agreement that all addictions have common features and there are 
several general models of addiction that are based on this idea, such as the Syndrome 
model (Shaffer et al., 2004), the Components model (Griffiths, 2005) and the 
Affective Processing model (Baker et al., 2004). Furthermore, while physical 
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withdrawal symptoms tend to be characteristic of the individual drug in question, 
psychological withdrawal symptoms tend to be the same across all addictive drugs 
(West & Gossop, 1994). As such, caffeine and caffeine withdrawal do share sufficient 
features in common with other addictive drugs that the current studies should be 
considered to at least provide proof of concept for other types of addictive drugs.  
Generalising to Real-World Dose Tapers: Another issue relating to generalisability 
of the results is that the NonInformed group in Study 5 – who received no information 
about their dose schedule across the five test days – was not a proper analog of the 
expectancy conditions in a blind dose taper as it occurs in a clinical setting. 
Participants in this group were given no information about their dose schedule, and 
thus had no external indicators of whether their dose was increasing, decreasing or 
remaining stable. In a clinical setting participants undergoing a voluntary dose taper 
would have a general expectancy that their dose will be reduced over time (after all 
that is the purpose of the taper) but no specific expectancy of when or by how much. 
It may be that a general expectancy of dose reductions but with some uncertainty 
about timing of these reductions creates a negative placebo effect similar to that 
observed in the Informed group, or even greater. Such an effect was observed in 
Stitzer and colleagues (1982; discussed in detail in section 5.1). To simulate the real-
world conditions of a blind dose taper properly, participants in the NonInformed 
group in Study 5 would have had to be told that their dose was being reduced but not 
told the rate of reduction. Unfortunately such a manipulation would require a much 
longer intervention period than that of Study 5. This is because of the likelihood that, 
for practical purposes, over a five day reduction period, instructing the NonInformed 
group that their dose would be reduced but not telling them when would generate 
expectancies similar to the informed group – i.e. participants would just assume their 
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dose was dropping every day and probably dropping to zero. In other words, it is 
likely that over such a short reduction period a general expectancy of withdrawal and 
a specific expectancy of withdrawal would amount to much the same thing. Dose 
tapers for drugs like methadone and diazepam typically take much longer and have 
much smaller reductions in dose for each titration (typically around 5-10% of existing 
dose; Calsyn et al. 2006). Accurate experimental simulation of these real-world 
conditions was not practical in these experiments, limiting the ecological validity of 
the results. 
7.4.2 Procedural Issues 
Single-Blinding 
All of the studies in this thesis were single-blind only. Single-blind studies, where 
participants are blinded to treatment allocation but experimenters are not, are 
particularly prone to the observer-expectancy effect, which is a form of bias 
introduced when researchers’ cognitive biases cause them to unconsciously influence 
the participants of an experiment. These unconscious experimenter biases are of 
particular concern in placebo experiments, where the instructions given to participants 
are so important in generating the effects being studied. While efforts were made to 
standardise all procedures and instructions given to participants (e.g. via creating 
scripts for the delivery of instructions or administering questionnaires electronically), 
this lack of blinding on my part may have introduced unconscious biases that may 
have affected results. While double-blinding is the gold-standard for unbiased 
experimentation it requires significant additional resources that are generally not 
available to PhD students, and certainly not available to myself. 
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Testing of Abstinence 
In all the studies in this thesis there was no objective test of abstinence from 
caffeine, making it difficult to be certain that participants abstained from caffeine for 
24 hours prior to testing. In Studies 1, 2, and 3, and in the abstinence baseline session 
of Studies 4 and 5, a bogus pipeline procedure was used to increase compliance 
(Murray, O'Connell, Schmid, & Perry, 1987). This consisted of warning participants 
that their saliva would be tested for presence of caffeine, and then collecting saliva 
when they arrived. In addition, in all studies participants were asked during the 
debrief and in the exit questionnaire whether they had consumed outside sources of 
caffeine. Several participants in Study 4 and 5 indicated that they had consumed 
caffeine at some point during the test week. As a result these participants were 
excluded from analyses. Despite these precautions there is a possibility that some 
participants may have consumed caffeine and not reported the fact, which may have 
affected their withdrawal symptoms and biased results. 
Pharmacological Effect of Decaf 
Participants in all studies were given decaffeinated coffee, which, in this case 
amounted to ~ 4 mg of caffeine per cup. While this cannot explain the differences 
between the Told Caffeine and Told Decaf groups in studies 1, 2, and 3, which both 
received decaf, in Study 3 the Told Water group was given water containing no 
caffeine whatsoever, meaning that there was a pharmacological difference in caffeine 
consumed between the Told Decaf and Told Water groups of approximately 4 mg. 
While it is possible that this small amount of caffeine caused the Told Decaf group to 
experience a greater reduction in withdrawal than the Told Water group, it seems 
unlikely that it would, on its own, be sufficient to produce a difference of the size that 
was observed. Future studies comparing decaf to water should add an equivalent 
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amount of caffeine to the water condition providing that the taste of the caffeine 
powder is unnoticeable.  
 
7.5 Conclusion 
The level of withdrawal experienced by people influences their decisions about 
whether to use a drug or not. The processes that contribute to an addicted individual’s 
decision to use drugs are far more automated than those of people who are not 
addicted. As a result, in this vulnerable population, very small effects, events, or 
emotional states can trigger a decision to relapse. Any attempts to develop procedures 
that minimise the chances of this happening are certainly worth undertaking. If a 
person’s expectancies about how much of a drug they have consumed can affect that 
person’s perceived withdrawal symptoms, as the studies in this thesis indicate, then it 
is important to develop addiction interventions that minimise the impact of these 
expectancies so as to improve the chances of sufferers of addiction regaining a normal 
life. 
The central idea guiding the studies in this thesis was that knowledge of dose 
reductions creates placebo withdrawal effects that impede addicted individuals' efforts 
to transition off drugs. This was born out by the results of these studies. When dose 
was held constant participants’ beliefs about how much caffeine they had in their 
body had a significant effect on their self-reported caffeine withdrawal symptoms. 
This suggests that adjusting the way in which information is delivered during a dose 
reduction can have an effect on the withdrawal symptoms experienced by patients. 
Furthermore, if beliefs about dose can have an effect on caffeine withdrawal then it is 
plausible that they also affect withdrawal from other drugs.  
 
 194 
7.6 References 
American Psychiatric Association, D. S. M. T. F., & American Psychiatric, A. (2013). 
Diagnostic and statistical manual of mental disorders: DSM-5. Arlington, Va: 
American Psychiatric Association. 
Baker, T. B., Piper, M. E., McCarthy, D. E., Majeskie, M. R., & Fiore, M. C. (2004). 
Addiction motivation reformulated: an affective processing model of negative 
reinforcement. Psychological review, 111(1), 33-51.  
Barsky, A. J., Goodson, J. D., Lane, R. S., & Cleary, P. D. (1988). The amplification 
of somatic symptoms. Psychosomatic medicine, 50(5), 510-519.  
Barsky, A. J., Saintfort, R., Rogers, M. P., & Borus, J. F. (2002). Nonspecific 
medication side effects and the nocebo phenomenon. JAMA, 287(5), 622-627.  
Barsky, A. J., Wyshak, G., & Klerman, G. L. (1990). The somatosensory 
amplification scale and its relationship to hypochondriasis. Journal of 
psychiatric research, 24(4), 323-334.  
Benedetti, F., Amanzio, M., Baldi, S., Casadio, C., Cavallo, A., Mancuso, M., . . . 
Maggi, G. (1998). The specific effects of prior opioid exposure on placebo 
analgesia and placebo respiratory depression. PAIN, 75(2), 313-319.  
Benedetti, F., Maggi, G., Lopiano, L., Lanotte, M., Rainero, I., Vighetti, S., & Pollo, 
A. (2003). Open versus hidden medical treatments: The patient's knowledge 
about a therapy affects the therapy outcome. Prevention & Treatment, 6(1), 
1a.  
Benedetti, F., Pollo, A., Lopiano, L., Lanotte, M., Vighetti, S., & Rainero, I. (2003). 
Conscious expectation and unconscious conditioning in analgesic, motor, and 
hormonal placebo/nocebo responses. The Journal of Neuroscience, 23(10), 
4315-4323.  
Calsyn, D. A., Malcy, J. A., & Saxon, A. J. (2006). Slow tapering from methadone 
maintenance in a program encouraging indefinite maintenance. Journal of 
Substance Abuse Treatment, 30(2), 159-163.  
Childress, A. R., McLellan, A. T., & O'Brien, C. P. (1986). Abstinent opiate abusers 
exhibit conditioned craving, conditioned withdrawal and reductions in both 
through extinction. British Journal of Addiction, 81(5), 655-660.  
Fillmore, M. T., & Vogel-Sprott, M. (1992). Expected effect of caffeine on motor 
performance predicts the type of response to placebo. Psychopharmacology, 
106(2), 209-214.  
Griffiths, M. (2005). A ‘components’ model of addiction within a biopsychosocial 
framework. Journal of Substance Use, 10(4), 191-197.  
Huntley, E. D., & Juliano, L. M. (2012). Caffeine Expectancy Questionnaire 
(CaffEQ): Construction, psychometric properties, and associations with 
caffeine use, caffeine dependence, and other related variables. Psychological 
assessment, 24(3), 592-607. doi:10.1037/a0026417 
Jones, B., Corbin, W., & Fromme, K. (2001). A review of expectancy theory and 
alcohol consumption. Addiction, 96(1), 57-72. doi:10.1046/j.1360-
0443.2001.961575.x 
Jones, H. E., Herning, R. I., Cadet, J. L., & Griffiths, R. R. (2000). Caffeine 
withdrawal increases cerebral blood flow velocity and alters quantitative 
electroencephalography (EEG) activity. Psychopharmacology, 147(4), 371-
377.  
Juliano, L. M., & Griffiths, R. R. (2004). A critical review of caffeine withdrawal: 
empirical validation of symptoms and signs, incidence, severity, and 
 195 
associated features. Psychopharmacology, 176(1), 1-29. doi:10.1007/s00213-
004-2000-x 
Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, 
J. P., . . . Lembo, A. J. (2010). Placebos without deception: a randomized 
controlled trial in irritable bowel syndrome. PloS one, 5(12), e15591.  
Longo, D. L., Duffey, P. L., Kopp, W. C., Heyes, M. P., Alvord, W. G., Sharfman, W. 
H., . . . Rosenstein, D. L. (1999). Conditioned Immune Response to Interferon-
γ in Humans. Clinical Immunology, 90(2), 173-181. 
doi:10.1006/clim.1998.4637 
Montgomery, G. H., & Kirsch, I. (1997). Classical conditioning and the placebo 
effect. PAIN, 72(1), 107-113.  
Murray, D. M., O'Connell, C. M., Schmid, L. A., & Perry, C. L. (1987). The validity 
of smoking self-reports by adolescents: A reexamination of the bogus pipeline 
procedure. Addictive behaviors, 12(1), 7-15. 
doi:http://dx.doi.org/10.1016/0306-4603(87)90003-7 
O'Brien, C. P., Testa, T., O'Brien, T. J., Brady, J. P., & Wells, B. (1977). Conditioned 
Narcotic Withdrawal in Humans. Science, 195(4282), 1000-1002. 
doi:10.2307/1743735 
San, L., Camí, J., Peri, J. M., Mata, R., & Porta, M. (1989). Success and failure at 
inpatient heroin detoxification. Addiction, 84(1), 81-87.  
Schafer, S. M., Colloca, L., & Wager, T. D. (2015). Conditioned placebo analgesia 
persists when subjects know they are receiving a placebo. The Journal of Pain, 
16(5), 412-420.  
Schweizer, E., Rickels, K., Case, W. G., & Greenblatt, D. J. (1990). Long-term 
therapeutic use of benzodiazepines: II. Effects of gradual taper. Archives of 
General Psychiatry, 47(10), 908-915.  
Senay, E. C., Dorus, W., & Thornton, W. (1977). Withdrawal From Methadone 
Maintenance: Rate of Withdrawal and Expectation. Archives of General 
Psychiatry, 34(3), 361-367. doi:10.1001/archpsyc.1977.01770150119014 
Shaffer, H. J., LaPlante, D. A., LaBrie, R. A., Kidman, R. C., Donato, A. N., & 
Stanton, M. V. (2004). Toward a syndrome model of addiction: Multiple 
expressions, common etiology. Harvard review of psychiatry, 12(6), 367-374.  
Sideroff, S. I., & Jarvik, M. E. (1980). Conditioned responses to a videotape showing 
heroin-related stimuli. Substance Use and Misuse, 15(4), 529-536. 
doi:10.3109/10826088009040035 
Stitzer, M. L., Bigelow, G. E., & Liebson, I. A. (1982). Comparison of three 
outpatient methadone detoxification procedures. NIDA Res Monogr, 41, 239-
245.  
Syvertsen, J., Pollini, R. A., Lozada, R., Vera, A., Rangel, G., & Strathdee, S. A. 
(2010). Managing la malilla: Exploring drug treatment experiences among 
injection drug users in Tijuana, Mexico, and their implications for drug law 
reform. International Journal of Drug Policy, 21(6), 459-465.  
Teasdale, J. D. (1973). Conditioned Abstinence in Narcotic Addicts. International 
Journal of the Addictions, 8(2), 273-292. doi:10.3109/10826087309057475 
Ternes, J. W., O'Brien, C. P., Grabowski, J., Wellerstein, H., & Jordan-Hayes, J. 
(1979). Conditioned drug responses to naturalistic stimuli. NIDA research 
monograph, 27, 282-288.  
Vaillant, G. E. (1988). What can long-term follow-up teach us about relapse and 
prevention of relapse in addiction? British Journal of Addiction, 83(10), 1147-
1157.  
 196 
West, R. J., & Gossop, M. (1994). Overview: A comparison of withdrawal symptoms 
from different drug classes. Addiction, 89(11), 1483-1489. doi:10.1111/j.1360-
0443.1994.tb03747.x 
 
 
(http://www.melbournefooddepot.com)
Authorised Reseller? Your
New Support Page
(http://www.melbournefooddepot.com
/wholesale-support)
Home (http://www.melbournefooddepot.com) /  Health (/shop/health/05)
/  Health Powders (/shop/health/health-powders/0503)
/  Ca"eine Anhydrous Powder 400g (/buy/ca"eine-anhydrous-powder-400g/F00511)
(/assets/full/F00511.jpg)
(/assets
/alt_1
/F00511.jpg)
Calculate Shipping
Ca"eine powder is used stimulant and diuretic. It is also used in
the treatment of shock, asthma and heart disease. The most
stable form is ca"eine anhydrous.
Ca"eine
Anhydrous
Powder 400g
Share: 
AUD$525.00
In Stock
This product is
available but only
available for
purchase with
payment via direct
bank deposit. Please
create an account
with all your details.
Delivery must be to
a street address and
have a person
present to sign for
the goods. Use the
contact form on the
website to start the
process. NO
EXCEPTIONS
Compliment your order with the
below
Lactose
Powder
(Standard) 200g
AUD$24.50
 Add to my order
Menthol
Crystals
(Food/Pharma
Grade) 20g
AUD$31.90
 Add to my order
1
 Add To Cart
 Add To Wishlist
Qty
Australia
Post Code
 Calculate
What does Ca!eine do?
Ca"eine is used as a stimulant and diuretic. It is also used in the treatment of
shock, asthma and heart disease. This product is used in commercially
available fat blaster formulations (appetite suppression). Vets also use
ca"eine for cardiac irritation, as a respiratory stimulant and diuretic.
Description Speci#cations Reviews 
product search eg Agar, Colour, Gum... - 0 Items (https://www.melbournefooddepot.com/_mycart?tkn=cart&ts=150442397316!
" #$+
&
⋆
(
⋆⋆⋆ ⋆⋆
&
Caffeine Anhydrous Powder - The Melbourne Food Depot, M... http://www.melbournefooddepot.com/buy/caffeine-anhydrous...
1 of 5 3/09/2017, 5:34 PM
This product is 100% USP (USA Pharmaceutical standard) Grade Ca!eine
powder
It contains no other ingredients (#llers, dextrose, anything)
IUPAC
1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione,
Also know as:
1,3,7-trimethylxanthine
trimethylxanthine
theine
methyltheobromine
Molecular formula:
C8H10N4O2
 
(F00511)
You May Also Like
Others Also Bought
Lactose Powder (Standard) 200g
(http://www.melbournefooddepot.com
/buy/lactose-powder-standard-200g/F05719)
Not yet rated
AUD$24.50
See Options (http://www.melbournefooddepot.com/buy/lactose-powder-standard-200g/F05719)
(http://www.melbournefooddepot.com/buy/lactose-
powder-standard-200g/F05719)
Menthol Crystals (Food/Pharma Grade) 20g
(http://www.melbournefooddepot.com
/buy/menthol-crystals-food-pharma-grade-
Not yet rated
AUD$31.90
See Options (http://www.melbournefooddepot.com/buy/menthol-crystals-food-pharma-grade-20g/M0
(http://www.melbournefooddepot.com
/buy/menthol-crystals-food-pharma-grade-
20g/M01974)
Caffeine Anhydrous Powder - The Melbourne Food Depot, M... http://www.melbournefooddepot.com/buy/caffeine-anhydrous...
2 of 5 3/09/2017, 5:34 PM
(http://www.melbournefooddepot.com)
Authorised Reseller? Your
New Support Page
(http://www.melbournefooddepot.com
/wholesale-support)
Home (http://www.melbournefooddepot.com) /  Culinary (/shop/culinary/06)
/  Modernist Cooking (/shop/culinary/modernist-cooking/0621)
/  Lactose Powder (Standard) 200g (/buy/lactose-powder-standard-200g/F05719)
(/assets/full/F05719.jpg)
Available Options
Product
Certi!cates
Not Required
Calculate Shipping
This product is mainly used for experimental cooking in
combination with kaolin clay.
Lactose
Powder
(Standard)
200g
Share: 
AUD$24.50
In Stock
Compliment your order with the
below
Kaolin Clay
200g
AUD$22.00
 Add to my order
Sushi Tweezers
(Stainless Steel)
200mm
AUD$26.10
 Add to my order
1
 Add To Cart
 Add To Wishlist
Qty
Australia
Post Code
 Calculate
This product is mainly used for experimental cooking in combination with
kaolin clay. The main practitioner of this style is The Royal mail in Dunkeld. It
can also be used by practitioners to test for lactose intolerence.
(F05719)
We Also Recommend
Description Speci"cations Reviews 
product search eg Agar, Colour, Gum... - 0 Items (https://www.melbournefooddepot.com/_mycart?tkn=cart&ts=150441766865!
"#$+
&
⋆
(
⋆⋆ ⋆⋆ ⋆
&
Lactose Powder (standard) - The Melbourne Food Depot, Me... http://www.melbournefooddepot.com/buy/lactose-powder-sta...
1 of 5 3/09/2017, 5:45 PM
Major Dickason's Blend® -
DECAF
Flavor Notes:
All the rich complexity and body of the original. A surprisingly bold
decaf.
Our most popular blend, without caffeine. Quite possibly the most
flavorful cup of decaf you’ll ever have.
 per lb.$16.95
ADD TO CART ADD TO SUBSCRIPTION
Select a grind 1
COFFEE STORY
A loyal customer of our original Berkeley store, retired army officer Key Dickason brought the idea
for our most beloved blend to Mr. Peet in 1969. Intrigued, our founder worked with the local
gourmand and coffee aficionado to refine it. They sampled countless combinations before arriving
at what is now our all-time bestseller. The result was so good, Alfred Peet decided naming it after
his friend wasn't enough — Dickason's rich, complex blend also deserved a promotion from
sergeant to major.
Major Dickason's combines the best origin coffees from the world's premier growing regions, each
imparting its distinctive regional characteristics while still effortlessly rounding into a smooth,
balanced cup. Over the years, it has become the coffee that epitomizes Peet's: flavorful, deeply
roasted, and unsurpassingly satisfying. But for us, Major D's is just like a relationship with an old
friend. We'll always remember it as the story of a customer's passion, an expert's palate, and a
shared love of coffee.
For a decaf version of the best-loved Peet's coffee to earn the Major Dickason's name, we felt it
had to brew the absolute finest decaf cup in the world. So we used the exact same premium beans
as the original to create a blend just as full of flavor, body, and aroma, but without any caffeine. The
mellow, satisfying richness stands alone among decafs, whether prepared in a press, by drip, or as
espresso. It's the boldest of its kind. We think Major D would be proud.
REVIEWS (8)ABOUT THIS COFFEE
Featured Category
Top Sellers
Limited Editions
People & Planet
Reserve Coffees
All Coffees
Bottled Cold Brew
By Type
Espresso
Cold Brew
Single-Origin
Signature Blends
Decaf & Half-Caf
By Roast
Light
Medium
Dark
By Region
The Americas
Africa & Arabia
Indo-Pacific
K-cup® Packs
All K-Cup® Packs
Reusable Single Cup
Gifts & Samplers
Coffee Samplers
Coffee Gift
Subscription
Coffee Gifts
Sweets & Treats
© 2017 PEET’S COFFEE PRIVACY POLICY TERMS OF SERVICE
Newsletter Sign-up
My Account
Customer Service
Find Peet’s
At Peet’s Stores
Peet’s Cards
Peetnik Rewards
SHOP
Peet’s Cards
Coffee
Tea
Gear
Subscriptions
Gifts & Goods
Sale
ABOUT US
Careers
Our History
Our People
Social Responsibility
Newsroom
Company Info
Contact Us
FOR BUSINESS
Submit a Site
Corporate Gifting
Office Coffee
Food Service
JOIN US ON
Youtube
Twitter
Facebook
Instagram
SEARCHCRAFT COFFEE TEA GEAR COLD BREW SUBSCRIPTIONS GIFTS COFFEEBARS
Find Peet's Sign in or register
$5 flat rate now available on all orders & Free Shipping on orders $59 and up! CALL (800) 999-2132 EMAIL 24/7
Major Dickason's Blend® - DECAF | Peet's Coffee & Tea https://www.peets.com/coffee/by-type/decaf-half-caf-coffee/d...
1 of 1 3/09/2017, 5:49 PM
 Research Integrity 
Research Portfolio 
Level 6, Jane Foss Russell 
The University of Sydney  
NSW 2006 Australia 
T +61 2 8627 8111 
F +61 2 8627 8177 
E ro.humanethics@sydney.edu.au 
sydney.edu.au 
ABN 15 211 513 464 
CRICOS 00026A 
 
 
Research Integrity 
Human Research Ethics Committee 
 
 
Wednesday, 15 January 2014 
 
Dr Ben Colagiuri 
Psychology; Faculty of Science 
Email: ben.colagiuri@sydney.edu.au 
 
Dear Ben 
 
I am pleased to inform you that the University of Sydney Human Research Ethics Committee (HREC) 
has approved your project  An experimental model of expectancy and withdrawal 
# !$.  
 
Details of the approval are as follows: 
 
Project No.:  2013/1034 
 
Approval Date:  13 January 2014 
 
First Annual Report Due: 13 January 2015 
 
Authorised Personnel: Colagiuri Ben; Mills Llewellyn; 
 
Documents Approved:  
 
Date Uploaded Type Document Name 
31/12/2013& Participant&Info&
Statement&
PIS&for&Students&in&the&Info&Condition&
31/12/2013& Participant&Info&
Statement&
PIS&for&Students&in&the&No&Info&Condition&
31/12/2013& Participant&Info&
Statement&
PIS&for&General&Population&in&the&No&Info&
Condition&
31/12/2013& Participant&Info&
Statement&
PIS&for&General&Population&in&the&Info&Condition&
18/12/2013& Advertisements/Flyer& Ad&for&SONA&
14/11/2013& Advertisements/Flyer& Study&Advertisement&for&General&Public&
14/11/2013& Other&Type& Final&Email&to&Participants&
14/11/2013& Advertisements/Flyer& Advertisement&for&Students&
14/11/2013& Questionnaires/Surveys& Mood&Questionnaire&
14/11/2013& Questionnaires/Surveys& Online&Screening&Questionnaire&
14/11/2013& Questionnaires/Surveys& Post&Test&Questionnaire&Caffeinated&Version&
14/11/2013& Questionnaires/Surveys& Post&Test&Questionnaire&Decaffeinated&Version&
14/11/2013& Other&Type& Participant&Debrief&Statement&
 
HREC approval is valid for four (4) years from the approval date stated in this letter and is granted 
pending the following conditions being met: 
 
Special Condition/s of Approval 
In revising the consent form, please include a section for postal address. The format has been 
changed to 2 pages. Please either amend spacing so it fits on one page or change page number in 
the version that is provided to participants so that the page numbers match the number of pages. If 
changes are made to the document, please submit these using the "Compliance with special 
conditions of approval" coversheet so that they are on file in the IRMA record. 
 
 
 Page 2 of 2 
 
Condition/s of Approval 
 
 Continuing compliance with the National Statement on Ethical Conduct in Research Involving 
Humans.  
 
 Provision of an annual report on this research to the Human Research Ethics Committee from the 
approval date and at the completion of the study. Failure to submit reports will result in withdrawal 
of ethics approval for the project.  
 
 All serious and unexpected adverse events should be reported to the HREC within 72 hours. 
 
 All unforeseen events that might affect continued ethical acceptability of the project should be 
reported to the HREC as soon as possible. 
 
 Any changes to the project including changes to research personnel must be approved by the 
HREC before the research project can proceed.  
 
 
 	
	 
   

thesis. 
 
"  !"%  
 
1. You must retain copies of all signed Consent Forms (if applicable) and provide these to the HREC 
on request. 
 
2. It is your responsibility to provide a copy of this letter to any internal/external granting agencies if 
requested. 
 
 
Please do not hesitate to contact Research Integrity (Human Ethics) should you require further 
information or clarification. 
 
Yours sincerely 
 
 
 
 
Dr Stephen Assinder 
Chair 
Human Research Ethics Committee 
 
 
 
This HREC is constituted and operates in accordance with the National Health and Medical 
!%
    	 ! 
!
(2007), NHMRC and Universities Australia Australian Code for the Responsible Conduct of 
Research (2007) and the CPMP/ICH Note for Guidance on Good Clinical Practice. 
 
 Research Integrity 
Research Portfolio 
Level 6, Jane Foss Russell 
The University of Sydney  
NSW 2006 Australia 
T +61 2 8627 8111 
F +61 2 8627 8177 
E ro.humanethics@sydney.edu.au 
sydney.edu.au 
ABN 15 211 513 464 
CRICOS 00026A 
 
 
Research Integrity 
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Wednesday, 17 December 2014 
 
 
Dr Ben Colagiuri 
Psychology; Faculty of Science 
Email: ben.colagiuri@sydney.edu.au  
 
 
Dear Ben 
 
I am pleased to inform you that the University of Sydney Human Research Ethics Committee (HREC) 
has approved your project entitled “The Effect of Receiving Genetic Information on Negative 
Mood States During Caffeine Abstinence.”  
 
Details of the approval are as follows: 
 
Project No.:  2014/974 
 
Approval Date:  17 December 2014  
 
First Annual Report Due: 17 December 2015  
 
Authorised Personnel: Colagiuri Ben; Dar-Nimrod Ilan; Mills Llewellyn 
 
Documents Approved:  
 
Uploaded Type Document Name 
13/11/2014  Other Type  Consent Form to Test for Specific Genes_Used as prop only   
13/11/2014  Other Type  Debrief_Gen Pop_Genes and Caffeine Abstinence  
13/11/2014  Other Type  Debrief_Student_Genes and Caffeine Abstinence  
13/11/2014  Advertisements/ Flyer  Gen Pop Advertisement_Genes and Caffeine Abstinence  
13/11/2014  Participant Consent Form  PCF_Genes and Caffeine Abstinence  
11/12/2014 Participant Info Statement  PIS_Caffeine and Genes_Gen Pop PIS_2014_974 
11/12/2014 Participant Info Statement  PIS_Caffeine and Genes_Student PIS_2014_974 
13/11/2014  Other Type  Post Test Questionnaire_Genes and Caffeine Abstinence  
13/11/2014  Other Type  Script for Delivery of Results_Negative_Genes and Caffeine  
13/11/2014  Other Type  Script for Delivery of Results_Positive_Genes and Caffeine  
13/11/2014  Other Type  Statement of Comprehension of Debrief_Genes and Caffeine  
13/11/2014  Advertisements/ Flyer  Student Advertisement_Genes and Caffeine Abstinence  
11/12/2014 Safety Protocol  Risk Assessment Form_Saliva and Swab_2014_974 
11/12/2014 Safety Protocol  Safe Work Procedure_Saliva and Swab Collection_2014_974 
 
 
HREC approval is valid for four (4) years from the approval date stated in this letter and is granted 
pending the following conditions being met: 
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Condition/s of Approval 
 
x Continuing compliance with the National Statement on Ethical Conduct in Research Involving 
Humans.  
 
x Provision of an annual report on this research to the Human Research Ethics Committee from 
the approval date and at the completion of the study. Failure to submit reports will result in 
withdrawal of ethics approval for the project.  
 
x All serious and unexpected adverse events should be reported to the HREC within 72 hours. 
 
x All unforeseen events that might affect continued ethical acceptability of the project should be 
reported to the HREC as soon as possible. 
 
x Any changes to the project including changes to research personnel must be approved by the 
HREC before the research project can proceed.  
 
x Note that for student research projects, a copy of this letter must be included in the 
FDndidDte¶V tKeViV 
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1. You must retain copies of all signed Consent Forms (if applicable) and provide these to the HREC 
on request. 
 
2. It is your responsibility to provide a copy of this letter to any internal/external granting agencies if 
requested. 
 
 
Please do not hesitate to contact Research Integrity (Human Ethics) should you require further 
information or clarification. 
 
Yours sincerely 
 
 
 
 
Professor Glen Davis 
Chair 
Human Research Ethics Committee 
 
 
 
This HREC is constituted and operates in accordance with the National Health and Medical 
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(2007), NHMRC and Universities Australia Australian Code for the Responsible Conduct of 
Research (2007) and the CPMP/ICH Note for Guidance on Good Clinical Practice. 
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Dr Ben Colagiuri 
Psychology; Faculty of Science 
Email: ben.colagiuri@sydney.edu.au 
 
 
 
Dear Ben 
 
The University of Sydney Human Research Ethics Committee (HREC) has considered your 
application. 
 
After consideration of your response to the comments raised your project has been approved. 
 
 
Approval is granted for a period of four years from 22 August 2016 to 22 August 2020 
 
Project title:  Factors Influencing Reduction of Negative Mood and Physical 
Symptoms Following Placebo Caffeine Administration. 
 
Project no.:  2016/681 
 
First Annual Report due: 22 August 2017 
 
Authorised Personnel: Colagiuri Ben; Mills Llewellyn; 
 
Documents Approved:  
Date Uploaded Version number Document Name 
15/08/2016 Version 2 adForGenPop_CaffeineAndCognition_V2_untracked 
15/08/2016 Version 2 description for SONA_CaffeineAndCognition_V2 
12/07/2016 Version 1 ad_Student_FactorsInfluencingCaffeineAbstinenceSymptoms 
12/07/2016 Version 1 ad_GenPop_FactorsInfluencingCaffeineAbstinenceSymptoms 
15/08/2016 Version 2 debrief_CaffeineAndCognition_V2_untracked 
12/07/2016 Version 1 studyDesign_FactorsInfluencingCaffeineAbstinenceSymptoms 
12/07/2016 Version 1 debrief_FactorsAffectingCaffeineAbstinenceSymptoms 
09/08/2016 Version 2 PCF_CaffeineAndCognition_V2_untracked 
12/07/2016 Version 1 PCF_FactorsInfluencingCaffeineAbstinenceSymptoms 
09/08/2016 Version 2 PIS_GenPop_CaffeineAndCognition_V2_untracked 
09/08/2016 Version 2 PIS_Student_CaffeineAndCognition_V2_untracked 
12/07/2016 Version 1 PIS_Student_FactorsInfluencingCaffeineAbstinenceSymptoms 
12/07/2016 Version 1 PIS_GenPop_FactorsInfluencingCaffeineAbstinenceSymptoms 
12/07/2016 Version 1 exitQuestionnaire_CoffeeGroups_CaffeineAbstinenceFactors 
12/07/2016 Version 1 exitQuestionnaire_WaterGroup_CaffeineAbstinenceFactors 
12/07/2016 Version 1 demographicQuestionnaire_FactsAffectingCaffAbsSymptoms 
12/07/2016 Version 1 CWSQ_FactorsAffectingCaffeineAbstinenceSymptoms 
15/08/2016 Version 2 1stEmailToParticipants_CaffeineAndCognition_V2_untracked 
12/07/2016 Version 1 secondResponseEmail_included_FactsAffCaffAbsSymp 
12/07/2016 Version 1 firstResponseEmail_excluded_FactsAffCaffAbsSymp 
12/07/2016 Version 1 firstResponseEmail_included_FactsAffCaffAbsSymp 
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 Condition/s of Approval 
 
• Research must be conducted according to the approved proposal. 
 
• An annual progress report must be submitted to the Ethics Office on or before the anniversary 
of approval and on completion of the project.  
 
• You must report as soon as practicable anything that might warrant review of ethical approval 
of the project including: 
¾ Serious or unexpected adverse events (which should be reported within 72 hours). 
¾ Unforeseen events that might affect continued ethical acceptability of the project. 
 
• Any changes to the proposal must be approved prior to their implementation (except where 
an amendment is undertaken to eliminate immediate risk to participants). 
 
• Personnel working on this project must be sufficiently qualified by education, training and 
experience for their role, or adequately supervised. Changes to personnel must be reported 
and approved.  
 
• Personnel must disclose any actual or potential conflicts of interest, including any financial or 
other interest or affiliation, as relevant to this project. 
 
• Data and primary materials must be retained and stored in accordance with the relevant 
legislation and University guidelines. 
 
• Ethics approval is dependent upon ongoing compliance of the research with the National 
Statement on Ethical Conduct in Human Research, the Australian Code for the Responsible 
Conduct of Research, applicable legal requirements, and with University policies, procedures 
and governance requirements. 
 
• The Ethics Office may conduct audits on approved projects. 
 
• The Chief Investigator has ultimate responsibility for the conduct of the research and is 
responsible for ensuring all others involved will conduct the research in accordance with the 
above.  
 
 
This letter constitutes ethical approval only.  
 
Please contact the Ethics Office should you require further information or clarification. 
 
Sincerely 
 
 
Associate Professor Rita Shackel 
Chair 
Human Research Ethics Committee 
 
The University of Sydney HRECs are constituted and operate in accordance with the National 
Health and Medical Research Council’s (NHMRC) National Statement on Ethical Conduct in 
Human Research (2007) and the NHMRC’s Australian Code for the Responsible Conduct of 
Research (2007). 
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Friday, 21 November 2014 
 
 
Dr Ben Colagiuri 
Psychology; Faculty of Science 
Email: ben.colagiuri@sydney.edu.au 
 
 
 
Dear Ben 
 
I am pleased to inform you that the University of Sydney Human Research Ethics Committee (HREC) 
has approved your project entitled “The Role of Expectancy in the Negative Mood States 
Experienced by Abstinent Caffeine Consumers.”.  
 
 
Details of the approval are as follows: 
 
Project No.:  2014/887 
 
Approval Date:  19 November 2014  
 
First Annual Report Due: 19 November 2015  
 
Authorised Personnel: Colagiuri Ben; Mills Llewellyn; 
 
Documents Approved:  
 
Date Uploaded Type Document Name 
14/11/2014 Advertisements/Flyer Advertisement for Gen Pop_Caffeine 
Reduction PLan_Version 2 
14/11/2014 Advertisements/Flyer Advertisement for Students_Caffeine 
Reduction Plan_Version 2 
19/10/2014 Other Type Debrief_Caffeine Reduction 
Plan_Version 1 
19/10/2014 Participant Consent Form PCF_Caffeine Reduction Plan_Version 1 
14/11/2014 Participant Info Statement PIS_Caffeine Reduction Plan_Gen 
Pop_Aware_Version 2 
14/11/2014 Participant Info Statement PIS_Caffeine Reduction Plan_Gen 
Pop_Blind_Version 2 
14/11/2014 Participant Info Statement PIS_Caffeine Reduction 
Plan_Student_Aware_Version 2 
14/11/2014 Participant Info Statement PIS_Caffeine Reduction 
Plan_Student_Blind_Version 2 
19/10/2014 Questionnaires/Surveys Exit Questionnaire_Caffeine Reduction 
Plan_Version 1 
19/10/2014 Questionnaires/Surveys MAPSS Questionnaire_Caffeine 
Reduction Plan_Version 1 
19/10/2014 Questionnaires/Surveys Screening Questionnaire_Caffeine 
Reduction Plan_Version 1 
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HREC approval is valid for four (4) years from the approval date stated in this letter and is granted 
pending the following conditions being met: 
 
Condition/s of Approval 
 
• Continuing compliance with the National Statement on Ethical Conduct in Research Involving 
Humans.  
 
• Provision of an annual report on this research to the Human Research Ethics Committee from 
the approval date and at the completion of the study. Failure to submit reports will result in 
withdrawal of ethics approval for the project.  
 
• All serious and unexpected adverse events should be reported to the HREC within 72 hours. 
 
• All unforeseen events that might affect continued ethical acceptability of the project should be 
reported to the HREC as soon as possible. 
 
• Any changes to the project including changes to research personnel must be approved by the 
HREC before the research project can proceed.  
 
• Note that for student research projects, a copy of this letter must be included in the 
candidate’s thesis. 
 
Chief Investigator / Supervisor’s responsibilities: 
 
1. You must retain copies of all signed Consent Forms (if applicable) and provide these to the HREC 
on request. 
 
2. It is your responsibility to provide a copy of this letter to any internal/external granting agencies if 
requested. 
 
 
Please do not hesitate to contact Research Integrity (Human Ethics) should you require further 
information or clarification. 
 
Yours sincerely 
 
 
 
 
Professor Glen Davis 
Chair 
Human Research Ethics Committee 
 
 
 
This HREC is constituted and operates in accordance with the National Health and Medical 
Research Council’s (NHMRC) National Statement on Ethical Conduct in Human Research 
(2007), NHMRC and Universities Australia Australian Code for the Responsible Conduct of 
Research (2007) and the CPMP/ICH Note for Guidance on Good Clinical Practice. 
 
 
 
 
 
 
Appendix 3: Study 1 
 
Appendix 3a – Demographics and Caffeine Use Questionnaire for Study 1 
 
Author’s Note: The following is a demographics and caffeine-use questionnaire given to 
participants when they first arrived for testing. The questionnaire was administered online 
via Qualtrics survey software.  All tests were completed by participants in the labs at the 
School of Psychology. 
 
Online Caffeine Use and Demographics Screening Questionnaire 
 
1. Demographic Information  
 
Please indicate your gender 
m Male 
m Female 
m Other (please indicate) ____________________ 
 
Please enter your age (in years)  
 
Please indicate your employment status 
m Full time 
m Part time 
m Volunteer 
m Unemployed 
m Student 
m Retired 
m Other (please indicate) ____________________ 
 
 
 
 
 
 
Please indicate your highest level of education 
m Primary 
m Secondary 
m College / University 
m Other (please indicate) ____________________ 
 
Please indicate your marital status 
m Single 
m In a relationship 
m Cohabitating 
m Married 
m Divorced 
m Widowed 
m Other (please indicate) ____________________ 
 
Please indicate your predominant ethnicity ____________________ 
 
 
2. Caffeine Use 
 
Do you drink coffee every day? 
m Yes 
m No 
 
If you indicated ‘Yes’ above, please indicate how many standard cups (approximately 
200ml) or shots you would consume each day (Note: one shot is the equivalent to one 
standard 200ml cup). 
 
Instant Coffee 
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brewed Coffee bought from a Café, Coffee Cart or Restaurant eg. Cappuccino, flat 
white, latte, long black, short black, espresso, mocha, macchiato, Vienna etc. (Note. If 
you regularly order double shots of any of these, please count this as 2 cups towards 
your average total daily use).  
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
Home made brewed coffee eg. Cappuccino, flat white, latte, long black, short black, 
espresso, mocha, macchiato, Vienna etc. 
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
Home made ‘capsule’ coffee eg. Nespresso, Lavazza, Senseo etc. 
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
Do you drink tea every day? 
m Yes 
m No 
 
 
 
 
 
 
 
 
 
 
If you indicated ‘Yes’ above, please indicate what type of tea and how many cups you 
would consume on an average weekday. If you do not consume any of that type please 
leave the answer blank.  
 
Black Tea eg.  
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
Green Tea 
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
Herbal Tea eg. Ginseng, chamomile, Jasmine, Lemongrass, Ginger. 
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
Do you drink cola every day? 
m Yes 
m No 
 
If you indicated ‘Yes’ above, please indicate what type of cola and how many cans or 
bottles you would consume on an average weekday. If you do not consume any of that 
type please leave the answer blank. If you consume cola from large 1.25-, 2-, or 3-Litre 
bottles please estimate how many cans per day this would translate to.  
 
 
 
 
 
 
 
 
 
 
 
Coke eg. Regular Coke, Coke Zero, Diet Coke.  
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
Pepsi eg. Regular Pepsi, Pepsi Max. 
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
Extra-Strength Cola eg. Mother, Pepsi Double.  
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
Please indicate which brand you drink if not listed above, and how many you drink per 
weekday on average.                                                                                                       
 
 
Do you energy drinks every day? 
m Yes 
m No 
 
If you indicated ‘Yes’ above, please indicate what type of energy drink and how many 
cans or bottles you would consume on an average weekday. If you do not consume any 
of that type please leave the answer blank. (Note. If you regularly order large cans of 
any of these, please count this as 2 cans towards your average total daily use)  
 
 
 
 
 
 
 
 
 
Red Bull eg. Regular Red Bull, Sugar-Free Red Bull  
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
V  
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
Please indicate which brand you drink if not listed above, and how many you drink per 
weekday on average.                                                                                                        
 
 
End of Survey 
 
Thankyou for completing this questionnaire. Please indicate your email address 
in the box below and we will send you an information sheet.  
 
 
 Appendix 3b – Primary Outcome Measure: The Caffeine Withdrawal Symptom Questionnaire 
 
Author’s Note: The following are items in the Caffeine Withdrawal Symptom Questionnaire 
(CWSQ) which was developed by Laura M. Juliano, Edward D. Huntley, Paul T. Harrell, and 
Ashley T. Westerman. Response scale omitted at the request of the authors. For details 
concerning the CWSQ’s development, psychometric properties, instructions and response scale 
of the CWSQ see Development of the Caffeine Withdrawal Symptom Questionnaire: Caffeine 
Withdrawal Symptoms Cluster into 7 Factors (2012) published in Drug and Alcohol 
Dependence, 124 (3). 
 
The original 23-item CWSQ consisted of seven factors: Drowsiness/Fatigue; Decreased 
Alertness/Difficulty Concentrating; Mood Disturbances; Decreased Sociability/Motivation to 
Work; Nausea/Upset Stomach; Flu-like Feelings, and Headache. On the advice of Professor 
Juliano the 9 ‘additional items for consideration’ listed overleaf were added to the original 23-
item version of the CWSQ. These items added three items (Queasy, Naseous, Vomiting) to the 
exisitng Nausea/Vomiting factor, a single item (‘Headachey’) to the Headache factor, three items 
(Anxious, Nervous, Jittery) pertaining to the acute effects of caffeine which formed a new factor 
termed Acute Effects of Caffeine, and two items pertaining to craving (‘Craving for caffeine’ 
and ‘Craving for coffee’) which also formed a separate additional factor. The test was 
administered online via Qualtrics survey software.  All tests were completed by participants in 
the labs at the School of Psychology.  
 
Questions 2, 4, 6, 12, 15, 18, 19, and 20 of the CWSQ are reverse-worded. These items were 
reverse-scored prior to analysis. 
 Participants were asked to rate to what extent they were experiencing each symptom at the time 
of taking the test, on a 5-item response scale from 0 (‘not at all’) to 4 (‘extremely’). The 
maximum possible score is. 128. 
  
  
CWSQ Items 
 
 
        
1. Drowsy/sleepy    
2. Self-confidence    
3. Yawning     
4. Alert     
5. Tired/Fatigued    
6. Content     
7. Difficulty Concentrating   
8. Irritable     
9. Heavy feelings in arms and legs  
10. Depressed Mood    
11. Grouchy     
12. Urge to do work related activity  
13. Flu-like feelings    
14. Headache     
15. Talkative     
16. Sluggish     
17. Upset stomach    
18. Clearheaded    
19. Desire to socialize    
20. Energetic     
21. Nausea/vomiting    
22. Muscle pain/stiffness/aches  
23. Discouraged    
 
Additional items for consideration:  
24. Queasy      
25. Nauseous     
26. Vomiting      
27. Headachy     
28. Anxious     
29. Nervous     
30. Jittery       
31. Craving for caffeine    
32. Craving for coffee    
     
* These symptoms have not been empirically validated as caffeine withdrawal symptoms.  The items anxious, 
nervous and jittery are acute effects of caffeine. 
 
 
 
 
Appendix 3c – Participant Information Statement: Told Withdrawal Group 
 
Author’s Note: The following is the Participant Information Statement (PIS) sent out to 
participants allocated to the Told Withdrawal group as an attachment on an initial-contact 
email. Participants were instructed to read this as it contained important information 
pertaining to their participation in the experiment. Participants were also instructed to read 
this upon arrival at their test session.  Their reading of the statement was supervised by the 
researcher. The crucial statement concerning the withdrawal symptoms they were likely to 
experience is contained in the black box on page 1.
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NSW 2006 AUSTRALIA 
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EFFECT OF CAFFEINE ON SUSTAINED ATTENTION: PARTICIPANT INFORMATION STATEMENT 
 
Thankyou for indicating your interest in participating in this study into the effects of caffeine  
intake on sustained attention. Here is some information about the study. Please read it carefully.  
 
(1) What is the study about? 
 
The study involves completing a computer-based test of attention before and after you have drunk a strong 
cup of coffee. The computer-based test will require you to detect consecutive strings of odd or even numbers 
in amongst random numbers. 
 
(2) Who is carrying out the study? 
 
The study is being conducted by Llew Mills from the University of Sydney as part of research that will be 
presented as part of his PhD, under the supervision of Dr Ben Colagiuri 
 
(3) What does the study involve? 
 
If you choose to take part in the study you will be asked to attend a single 90 min test session. During this 
session you will be asked to complete two sets of tests; one set before you have drunk a cup of strong coffee 
and one after. Each set of tests will contain: a 5-minute computer-based task measuring sustained attention, 
a 2-minute questionnaire to assess your mood, and a blood-pressure reading.  
 
To be eligible to participate in this study you need to: 
 
a) be 18 yrs-old or over 
b) not have been told by your doctor to stop consuming caffeine for any medical reason, such as 
cardiovascular disease 
c) not be pregnant 
d) not be addicted to any drug other than nicotine 
 
If you do not meet all these criteria please tell researchers as consuming caffeine could be dangerous for 
you. 
 
So that the dose of caffeine in the blood can be controlled across many participants we require that you do 
not consume any products that contain caffeine (coffee, tea, energy drinks, chocolate, caffeine strips) for 24 
hours prior to your appointment. So if your appointment is scheduled for 2pm on a Tuesday, we require that 
you do not consume any caffeine products from 2pm Monday. When you arrive we will ask you to provide a 
small saliva sample (~1 ml) by spitting into a sterile saliva collection container. This will later be tested for the 
presence of caffeine as a way of confirming your abstinence from caffeine.  
. 
 
 
 
 
 
 
(3) (continued) 
IMPORTANT: Because caffeine withdrawal symptoms become stronger over time it is likely that you will 
experience some withdrawal symptoms due to abstaining from coffee. These withdrawal symptoms can 
include headache, fatigue, difficulty concentrating, irritability, depression, flu-like feelings, nausea, upset 
stomach etc. If any of these withdrawal symptoms become too severe please contact the researchers 
 
 
 
 
Please refrain from eating, drinking milk, or brushing your teeth in the 60 min prior to testing, as this 
may contaminate your saliva sample. 
 
(4) How much time will the study take? 
 
You will be asked to attend a single 90-min test session at the University of Sydney 
 
 
(5) Can I withdraw from the study? 
 
Being in this study is completely voluntary - you are not under any obligation to consent and - if you do 
consent - you can withdraw at any time without affecting your relationship with The University of 
Sydney  
 
 
(6) Will anyone else know the results? 
 
All aspects of the study, including results, will be strictly confidential and only the researchers will have 
access to information on participants. A report of the study may be submitted for publication, but 
individual participants will not be identifiable in such a report. Other researchers may also be granted 
access to de-identified data for the purpose of further analysis. This data will not include participant 
names or any other information that could identify you. 
 
(7) Will the study benefit me? 
 
You will receive 1.5 hours credit as part of the School of Psychology’s Research Participation Scheme 
 
(8) Can I tell other people about the study? 
 
You are welcome to discuss the study with other people, such as your family and friends. However we 
do ask that you try to avoid discussing it with other participants as sometimes this can affect the 
study’s results.  
 
(9) What if I require further information about the study or my involvement in it? 
 
When you have read this information, Llew MIlls will discuss it with you further and answer any 
questions you may have.  If you would like to know more at any stage, please feel free to contact him 
via email at lmil8126@unisydney.edu.au or via phone on 04212 032 614.    
 
(10) What if I have a complaint or any concerns? 
 
Any person with concerns or complaints about the conduct of a research study can contact The 
Manager, Human Ethics Administration, University of Sydney on +61 2 8627 8176 (Telephone); +61 2 
8627 8177 (Facsimile) or ro.humanethics@sydney.edu.au (Email). 
 
 
This information sheet is for you to keep 
  
 
Appendix 3d – Participant Information Statement: Not Told Withdrawal Group  
 
Author’s Note: The following is the Participant Information Statement (PIS) sent out to 
participants allocated to the Not Told Withdrawal group as an attachment on an initial-contact 
email. Participants were instructed to read this as it contained important information pertaining 
to their participation in the experiment. Participants were also instructed to read this upon 
arrival at their test session.  Their reading of the statement was supervised by the researcher. 
Note that the passage concerning the withdrawal symptoms they were likely to experience 
contained in the Told Withdrawal group’s PIS is not present in this version.
 1
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          EFFECTS OF CAFFEINE ON SUSTAINED ATTENTION: PARTICIPANT INFORMATION STATEMENT 
 
Thankyou for indicating your interest in participating in this study into the effects of caffeine  
Intake on sustained attention. Here is some information about the study. Please read it carefully.  
 
(1) What is the study about? 
 
You are invited to participate in a study of the effects of caffeine on sustained attention. The study involves 
completing a computer-based test of attention before and after you have drunk a strong cup of coffee. The 
computer-based test will require you to detect consecutive strings of odd or even numbers amongst random 
numbers. 
 
(2) Who is carrying out the study? 
 
The study is being conducted by Llew Mills from the University of Sydney as part of research that will be 
presented as part of his PhD, under the supervision of Dr Ben Colagiuri 
 
(3) What does the study involve? 
 
If you choose to take part in the study you will be asked to attend a single 2-hr test session. During this 
session you will be asked to complete two sets of tests; one set before you have drunk a cup of strong coffee 
and one after. Each set of tests will contain: a 5-minute computer-based task measuring sustained attention, 
a 2-minute questionnaire to assess your mood, and a blood-pressure reading.  
 
To be eligible to participate in this study you need to: 
 
a) be 18 yrs-old or over 
b) not have been told by your doctor to stop consuming caffeine for any medical reason, such as 
cardiovascular disease 
c) not be pregnant 
d) not be addicted to any drug other than nicotine 
 
If you do not meet all these criteria please tell researchers as consuming caffeine could be dangerous for 
you. 
 
So that the dose of caffeine in the blood can be controlled across many participants we require that you do 
not consume any products that contain caffeine (coffee, tea, energy drinks, chocolate, caffeine strips) for 24 
hours prior to your appointment. So if your appointment is scheduled for 2pm on a Tuesday, we require that 
you do not consume any caffeine products from 2pm Monday. When you arrive we will ask you to provide a 
small saliva sample (~1 ml) by spitting into a sterile saliva collection container. This will later be tested for the 
presence of caffeine as a way of confirming your abstinence from caffeine. Please refrain from eating, 
drinking milk or brushing your teeth for 1 hour before testing commences as this may contaminate 
the saliva sample. 
 
    (4) How much time will the study take? 
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           You will be asked to attend a single 90-min test session at the University of Sydney 
 
 
(4) Can I withdraw from the study? 
 
Being in this study is completely voluntary - you are not under any obligation to consent and - if you do 
consent - you can withdraw at any time without affecting your relationship with The University of 
Sydney  
 
 
(5) Will anyone else know the results? 
 
All aspects of the study, including results, will be strictly confidential and only the researchers will have 
access to information on participants. A report of the study may be submitted for publication, but 
individual participants will not be identifiable in such a report. Other researchers may also be granted 
access to de-identified data for the purpose of further analysis. This data will not include participant 
names or any other information that could identify you. 
 
(6) Will the study benefit me? 
 
        You will receive 1.5 hours credit as part of the School of Psychology’s Research Participation Scheme 
 
(7) Can I tell other people about the study? 
 
You are welcome to discuss the study with other people, such as your family and friends. However we 
do ask that you try to avoid discussing it with other participants as sometimes this can affect the 
study’s results.  
 
(8) What if I require further information about the study or my involvement in it? 
 
When you have read this information, Llew MIlls will discuss it with you further and answer any 
questions you may have.  If you would like to know more at any stage, please feel free to contact him 
via email at llew.mills@sydney.edu.au or via phone on 04212 032 614.    
 
(9) What if I have a complaint or any concerns? 
 
Any person with concerns or complaints about the conduct of a research study can contact The 
Manager, Human Ethics Administration, University of Sydney on +61 2 8627 8176 (Telephone); +61 2 
8627 8177 (Facsimile) or ro.humanethics@sydney.edu.au (Email). 
 
 
This information sheet is for you to keep 
			
Appendix 3e – Exit Questionnaire Study 1  
 
Author’s Note: The following is the online Exit questionnaire given to participants 
after they had completed the final CWSQ questionnaire but before they were 
debriefed to the true purpose of the study. Its purpose it to check for awareness of the 
experimental manipulation (i.e. deception). This questionnaire was administered 
online via Qualtrics survey software.  All tests were completed by participants in the 
labs at the School of Psychology. 
 
Caffeine Study Exit Questionnaire 
 
Did	you	think	the	experimental	procedures	differed	in	any	way	from	what	
you	had	been	told?	
m Yes	
m No	
	
Tell	us	what	you	think	the	purpose	of	the	study	was.		
	
	
	
	
Do	you	have	any	other	comments	on	the	testing	or	procedure?	
	
	
	
	
	
		
Do	you	think	that	there	was	caffeine	in	your	coffee?	
m Yes	
m No	
	
	
	
	
	
	
	
	
Estimate	how	likely	it	was	that	the	coffee	you	drank	was	caffeinated?	
m Certainly	decaffeinated	
m Probably	decaffeinated	
m Possibly	decaffeinated	
m Do	not	know	
m Possibly	caffeinated	
m Probably	caffeinated	
m Certainly	caffeinated	
		
  
 
Appendix 3f – Debrief Statement for Participants 
 
Author’s Note: The following is a debrief statement given to all participants upon 
completion of the Exit Questionnaire.  
 
 
 
 
 
 
 
School of Psychology 
 
  
ABN 15 211 513 464 
 
 Dr Ben Colagiuri 
Lecturer 
Room 444  
Brennan MacCallum, A18 
The University of Sydney  
NSW 2006 AUSTRALIA 
Telephone:   +61 2 9351 4589         
Facsimile:  +61 2 9351 5223 
Email: ben.colagiuri@sydney.edu.au 
Web: http://www.sydney.edu.au/ 
 
THE EFFECTS OF CAFFEINE ON SUSTAINED ATTENTION 
 
DEBRIEF STATEMENT 
 
Thankyou for participating in this study. The aim of this study was to examine the cognitive processes 
involved in negative placebo effects. A placebo effect refers to when a drug or procedure causes effects 
that aren’t due to the drug or procedure itself. Placebo effects can be positive (e.g. the pain relief a patient 
feels when they are told a simple sugar pill is morphine) or negative (e.g. the nausea a patient receiving 
chemotherapy feels when they are given an injection of water in the same room as the chemotherapy 
drugs were injected with in the past). Placebo effects are mostly caused by the expectation of receiving a 
particular treatment. These expectations are generated when we receive information that causes us to 
believe a particular drug or treatment is about to happen. We were interested in two questions: 1) does 
providing information about the likelihood of experiencing negative mood symptoms during caffeine 
abstinence increase these symptoms? and; 2) Does the belief that caffeine has been consumed then 
reduce these symptoms? 
 
In this study, some people were led to believe that they had a high chance of experiencing negative 
symptoms if they did not consume any caffeine for 24-hours, whereas others received no information about 
these symptoms at all. Then, some people were told that they had been given caffeinated coffee while 
others were told they had been given decaffeinated coffee. In fact no participants actually received 
caffeinated coffee: all participants received decaffeinated coffee. We were interested in how the information 
about the withdrawal symptoms and about the type of coffee you received affected your mood state.    
 
Because research into the effect of expectations on treatment outcomes requires that people believe they 
are receiving an active treatment, it was necessary for us to keep the true purpose of the study hidden from 
you until after you had completed all of the required tests. We apologise for the deception and for not 
revealing the study’s true aims. After reading this you have the right to withdraw your data from the study. 
Please inform one of the researchers if you wish to do this. Please be assured that there will be no 
repercussions if you choose to do this. 
 
If you would like to know more about the study, your performance in any of the tests, or the results of the 
study please contact Llew Mills on 0421 032 614 or at llew.mills@sydney.edu.au and he will arrange to 
make these available to you. 
 
Meanwhile, because it is important that other participants do not know precisely what we are looking for 
before they are tested, we ask for your help by not telling other people that might participate in this study in 
future.  
 
Once again, thankyou for participating.  
 
 
 
 
 
 
 
 
Appendix 4: Study 2 
 
Appendix 4a – Demographics and Caffeine Use Questionnaire for Study 2 
 
Author’s Note: The following is a demographics and caffeine-use questionnaire given to 
participants when they first arrived at the baseline session. The questionnaire was 
administered online via Qualtrics survey software.  All tests were completed by 
participants in the labs at the School of Psychology. The main change from the similar 
questionnaire administered in Study 1 is that there is only one question about the type of 
coffee consumed (e.g. filter vs capsule vs ground etc).  
 
Caffeine Use and Demographics Screening Questionnaire 
 
1. Demographic Information  
 
Please indicate your gender 
m Male 
m Female 
m Other (please indicate) ____________________ 
 
 
Please enter your age (in years) __________________________ 
 
Please indicate your employment status 
m Full time 
m Part time 
m Volunteer 
m Unemployed 
m Student 
m Retired 
m Other (please indicate) ____________________ 
 
 
 
 
 
 
Please indicate your highest level of education 
m Primary 
m Secondary 
m College / University 
m Other (please indicate) ____________________ 
 
Please indicate your current marital status 
m Single 
m In a relationship 
m Cohabitating 
m Married 
m Divorced 
m Widowed 
m Other (please indicate) ____________________ 
 
Please indicate your predominant ethnicity ____________________ 
 
Do you speak a language other than English at home 
m Yes  
m No 
if you answered yes above please indicate what language______________ 
 
 
If you speak a language other than English at home, is English your first 
language? 
m Yes  
m No 
 
 
2. Caffeine Use 
 
Do you drink coffee regularly (i.e. every weekday?) 
m Yes 
m No 
 
If you indicated ‘Yes’ above, please indicate how many standard cups 
(approximately 200ml) or shots you would consume each day (Note: one shot is 
the equivalent to one standard 200ml cup). 
 
 
 
 
 
 
Since weekend consumption of caffeine can sometimes differ from consumption 
during the week, we are only interested in the number of cups you would drink ON 
AN AVERAGE WEEKDAY.  
 
m 1 
m 2 
m 3 
m 4 
m 5 
m More than 5 
 
 
 
Do you drink tea every weekdayday? 
m Yes 
m No 
 
If you indicated ‘Yes’ to the previous question, please indicate how many cups of 
CAFFEINATED TEA you would consume on an average weekday, (i.e. if you only 
drink herbal tea with no caffeine in it, answer '0'). 
 
Again, since weekend consumption of caffeine can sometimes differ from 
consumption during the week, we are only interested in the number of cups you 
would drink ON AN AVERAGE WEEKDAY.  
 
m 1 
m 2 
m 3 
m 4 
m 5 
m More than 5 
 
 
Do you drink cola every weekday? 
m Yes 
m No 
 
If you indicated ‘Yes to the previous question’, please indicate below how much 
cola, based on a single unit equivalent to 1 375ml can, you would consume ON AN 
AVERAGE WEEKDAY.  
 
 
 
 
 
For example one 600ml bottle of coke is the equivalent of 1.6 cans. Therefore two 
600ml bottles is 3.2 cans. Below is a conversion table to help you. 
Please round your answers down or up, so if you drink the equivalent of 3.2 cans 
just answer 3 below, whereas if you drink the equivalent of 1.6 cans just answer 2.  
Size of 
Bottle 
Equivalent, in 
375 ml cans, of 1 
per day 
Equivalent, in 
375 ml cans, of 2 
per day 
3 per day 4 per day 5 per day 
300 ml 0.8 1.6 2.4 3.2 4 
600 ml 1.6 3.2 4.8 6.4 8 
1.25 L 3.3 6.6 10 13.3 16.6 
2 L 5.3 10.6 15.9 21.2 26.5 
3 L 8 16 24 32 40 
Please list how much cola, in cans, you would drink ON AN AVERAGE WEEKDAY 
(please answer using numbers not text) 
_______________________________________ 
Please list what type of cola you usually drink_____________________________ 
 
Do you energy drinks every weekday? 
m Yes 
m No 
 
If you indicated ‘Yes’ above, please indicate in the box below what type of energy 
drink you most regularly consume 
_____________________________________________ 
 
How many cans or bottles you would consume on an average weekday. (Note. If 
you regularly consume large cans (i.e. >500 ml) please count this as 2 cans 
towards your average total daily use)  
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
 
 
 
 
 
 
 
End of Survey 
Thankyou for completing this questionnaire. Please indicate your email address in the 
box below. 
Your Univeristy of Sydney address is preferable. This address usually takes the form of 
your unikey followed by @uni.sydney.edu.au  (e.g. lmil8126@uni.sydney.edu.au). if you 
do not have a Sydney University email address just enter your primary email address. 
IMPORTANT:  whatever address you enter below please make sure to enter THE SAME 
EMAIL ADDRESS on all the questionnaires you complete for this study 
 
 
 Appendix 4b – Exit Questionnaire for Study 2 
 
Author’s Note: The following are items in the Exit Questionnaire given to all 
participants. The chief purpose of this questionnaire was to determine whether 
participants knew or suspected that either a) the genetic test was fake, or b) the coffee 
they were given was decaf. All questions appeared separately (i.e. they were not 
visible until the previous question had been answered). This was important as the 
order of questions goes from general to more specific. 
 Caffeine	Study	Exit	Questionnaire	
	
How	long	have	you	been	a	regular	(i.e.	daily	use	of	caffeine?	Please	answer	
in	years	and	months	
	
	
Before	taking	part	in	this	study	had	you	ever	attempted	to	quit	or	cut	back	
on	your	use	of	caffeine?	
m Yes	
m No	
	
If	you	answered	yes	to	the	previous	question,	how	many	times	have	you	
attempted	to	quit	or	cut	back	your	caffeine	use?	
m Yes	
m No	
	
Did	you	comply	with	the	request	to	abstain	from	all	sources	of	caffeine		
m Yes	
m No	
	
If	you	answered	‘No’	to	the	above	question,	please	tell	us	what	form	of	
caffeine	you	consumed	in	the	24-h	prior	to	the	test	session,	how	much	of	it	
you	consumed,	and	when	approximately	you	consumed	it.	
	
	
	
	
Did	you	think	the	experimental	procedures	differed	in	any	way	from	what	
you	had	been	told?	
m Yes	
m No		
	
Tell	us	what	you	think	the	purpose	of	the	study	was.		
	
	
	
	
Do	you	have	any	other	comments	on	the	testing	or	procedure?	
	
	
	
	
	
	
Do	you	think	that	there	was	caffeine	in	your	coffee?	
	
If	possible,	when	answering	please	refer	to	what	you	thought	DURING	the	
test	BEFORE	reading	this	question	
	
m Yes	
m No	
	
Estimate	how	likely	it	was	that	the	coffee	you	drank	was	caffeinated?	
m Certainly	decaffeinated	
m Probably	decaffeinated	
m Possibly	decaffeinated	
m Do	not	know	
m Possibly	caffeinated	
m Probably	caffeinated	
m Certainly	caffeinated	
	
	
	
	
Did	you	become	aware	or	come	to	suspect	at	any	stage	during	the	study	
that	either	:	a)	the	genetic	test	results	might		be		fake	or;	b)	that	the	coffee	
you	drank	might	not	have	contained	caffeine?		Please	indicate	below	by	
ticking	the	bullet	point	if	either	or	both	of	these	was	the	case.		(Note:	Please	try	to	answer	about	what	you	thought	at	the	time	rather	than	what	you	think	now	after	reading	this	question).	
	
m During	the	study	I	thought/suspected	the	genetic	results	might	be	fake.		If	you	ticked	the	bullet	point	above,	please	indicate	approximately	when	you	became	aware	
	
	 	
m During	the	study	I	thought/suspected	my	coffee	may	not	have	contained	caffeine	
	If	you	ticked	the	bullet	point	above,	please	indicate	approximately	when	you	became	aware	
	
	 	
		
Did	a	friend	or	anyone	else	tell	you	before	you	took	part	in	the	study	either	
a)	that	the	genetic	test	was	not	real;	and/or	b)	that	you	may	be	deceived	
about	the	caffeine	content	of	your	beverage?	Please	indicate	below	by	
ticking	the	bullet	point	if	either	or	both	of	these	was	the	case.		(Note:	there	will	be	no	penalty	if	you	did	know	either	of	these	facts	beforehand.	We	just	want	to	know	the	truth).	
	
m I	knew	beforehand	that	the	genetic	test	was	fake	
m I	knew	I	beforehand	might	receive	decaffeinated	coffee		
	
Appendix 4c – Advertisement for Participants for Study 2 
 
Author’s Note: The following is an advertisement for recruitment of participants. 
The advertisement appeared on the online classifieds website Gumtree or on the 
University of Sydney careers Website.  	
	
Regular daily caffeine drinkers 18 years or older are 
wanted to take part in a research study investigating the 
effects of genes on mood during caffeine abstinence. 
 
The study will involve attending two test sessions 3 days 
apart, the first lasting 25 min and the second 90 min. You 
will be required to abstain from caffeine for 24 hours prior 
to the second test session. 
The study is being conducted at the School of 
Psychopharmacology, located at the Camperdown 
Campus of the University of Sydney. 
Note: You will be reimbursed for the costs associated with 
participating. 
If you are interested in participating please email the head 
researcher Llew Mills at: 
genesandcaffeine@gmail.com 
 
In the email please indicate how many cups of coffee you 
consume on a regular weekday 
  
Are you a regular coffee drinker? 
 Appendix 4d – Participant Information Statement for Study 2 
 
Author’s Note: The following is an information sheet given to participants at the baseline 
session. Its purpose is to convey the background information necessary to set up the 
genetic result prime when it was delivered by phone 2+ days after this session. The only 
citation in the references list that is not authentic is the Osborn et al. paper, as no proven 
link has been established between the A1 allele and withdrawal, from caffeine or any other 
drug. 
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EFFECT OF GENES ON NEGATIVE MOOD DURING CAFFEINE ABSTINENCE: Information Sheet 
 
Dear Participant 
 
Research has shown a strong positive association between presence of of the heterozygous dominant Taq 1 A1 (A1) 
allele of the Dopamine D2 Receptor Gene (DRD2) and both severity and duration of alcohol, cocaine, and tobacco 
addiction (Blum et al. 1995; Ponce et al. 2003; Bannon et al. 2014). Furthermore it has been shown that possessing 
this allele is associated with more severe withdrawal symptoms during abstinence from tobacco, alcohol, and caffeine 
(Osborn et al. 2006), and that this may be the mechanism which maintains continued use of addictive substances and 
makes successful quit attempts less likely (Pato et al. 2011). Approximately 10-15% of the population carry the A1 
allele. 
 
What this means is that carriers of the A1 allele may have heightened risk for withdrawal symptoms during abstinence 
from caffeine and other drugs.  
 
The psychological symptoms of withdrawal – fatigue, headache, tension, irritability and certain negative mood states – 
are very similar across all drugs of addiction, which is why it is suggested that the neural mechanism behind these 
psychological withdrawal symptoms may also be common across all drugs. However caffeine is unusual in that its 
withdrawal symptoms are almost entirely subjective. Caffeine is also unusual in that it is widely used (80-90% of 
adults), widely available, and free of the stigma attached to other addictive drugs. Thus many caffeine users, including 
carriers of the Taq A1 DRD2 allele, may not go without the drug for sufficiently long periods of time to become fully 
aware of the range and extent of their withdrawal symptoms, or may mistake these symptoms for common everyday 
symptoms resulting from stress, overwork, lack or sleep, or dehydration. 
 
Thank you for taking part in this experiment and helping us to explore the relationship between this gene and caffeine 
withdrawal. Researchers will attempt contact you to explain the results of this DNA test, however if you have any 
queries or concerns please do not hesitate to call Llew Mills on 0421 032 614 or email him at 
llew.mills@sydney.edu.au. 
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Appendix 4e – Script for ‘Gene Positive’ genetic test results for Study 2 
 
Author’s Note: The following is the script read out over the phone to participants allocated to 
the Gene + condition. 
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EFFECT OF GENES ON NEGATIVE MOOD DURING CAFFEINE ABSTINENCE: Results of DNA Test 
 
Dear  ________ 
 
I am calling to inform you that the buccal mouth swab you provided on the ______ of ______ tested positive for 
presence of the heterozygous dominant Taq 1 A1 (A1) allele of the Dopamine D2 Receptor Gene (DRD2). 
 
Studies show that 10-15% of the population carry the A1 allele (Ponce et al. 2003). Research has shown a strong 
positive association between presence of this gene and both severity and duration of alcohol, cocaine, and tobacco 
addiction (Blum et al. 1995; Ponce et al. 2003; Bannon et al. 2014). Furthermore it has been shown that presence of 
the allele is associated with more severe withdrawal symptoms during abstinence from tobacco, alcohol, and caffeine 
(Osborn et al. 2006), and that this may be the mechanism which maintains continued use of addictive substances and 
makes successful quit attempts less likely (Pato et al. 2011).  
 
Common symptoms of caffeine abstinence include fatigue, negative mood states, irritability, and headache. Since you 
have been identified as a carrier of the A1 allele and are a moderate to heavy coffee drinker you may have a 
heightened risk for experiencing more severe negative moods, fatigue, and headache during abstinence from caffeine. 
 
Researchers either have contacted you or will attempt to contact you to explain the results of this DNA test, however if 
you have any queries or concerns please do not hesitate to call Llew Mills on 0421 032 614 or email him at 
llew.mills@sydney.edu.au. 
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Appendix 4e – Script for ‘Gene Negative’ genetic test results for Study 2 
 
Author’s Note: The following is the script read out over the phone to participants allocated to 
the Gene – condition. 
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EFFECT OF GENES ON NEGATIVE MOOD DURING CAFFEINE ABSTINENCE: Results of DNA Test 
 
Dear ___________ 
 
I am calling to inform you that the buccal mouth swab you provided on the ____ of _______ tested negative for 
presence of the heterozygous dominant Taq 1 A1 (A1) allele of the Dopamine D2 Receptor Gene (DRD2). 
 
Approximately 10-15% of the population carry the A1 allele (Ponce et al. 2003). Research has shown a strong 
positive association between presence of this gene and both severity and duration of alcohol, cocaine, and tobacco 
addiction (Blum et al. 1995; Ponce et al. 2003; Bannon et al. 2014). Furthermore it has been shown that presence of 
the allele is associated with more severe withdrawal symptoms during abstinence from tobacco, alcohol, and 
caffeine (Osborn et al. 2006), and that this may be the mechanism which maintains continued use of addictive 
substances and makes successful quit attempts less likely (Pato et al. 2011).  
 
Common symptoms of caffeine abstinence include fatigue, negative mood states, irritability, and headache. Since 
you are not a carrier of the A1 allele you are unlikely to have a genetically heightened risk for experiencing the 
negative moods, fatigue, headache and other withdrawal symptoms associated with a short period of caffeine 
abstinence.  
 
Researchers either have contacted you or will attempt to contact you to explain the results of this DNA test, however 
if you have any queries or concerns please do not hesitate to call Llew Mills on 0421 032 614 or email him at 
llew.mills@sydney.edu.au. 
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Appendix 4g – Debrief Statement for Participants 
 
Author’s Note: The following is a debrief statement given to all participants upon 
completion of the exit questionnaire.  
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EFFECT OF GENES ON NEGATIVE MOOD DURING CAFFEINE ABSTINENCE 
 
DEBRIEF STATEMENT 
 
Thankyou for participating in this study. The aim of this study was to examine the cognitive processes involved 
in negative placebo effects. A placebo effect refers to when a drug or procedure causes effects that aren’t due 
to the drug or procedure itself. Placebo effects are mostly caused by the expectation of receiving a particular 
treatment. These expectations are generated when we receive information that causes us to believe that the 
effect of a particular drug or treatment is about to take place. We were interested in two questions: 1) does 
providing information about a genetic susceptibility to experiencing increased negative mood symptoms during 
caffeine abstinence actually increase these symptoms? and; 2) Does the belief that caffeine has been 
consumed then reduce these symptoms? 
 
In this study, some people were led to believe that they had a genetic susceptibility to experience more severe 
negative mood states following caffeine abstinence whereas others received information suggesting they did not 
have this susceptibility. IT IS IMPORTANT TO NOTE THAT THESE RESULTS WERE BOGUS AND NO 
GENETIC TESTS WERE CONDUCTED. Though we did collect a mouth swab this was not analysed. The 
alleged results were assigned to you at random (like a coin-flip) and do not reflect any real indication of 
genetic susceptibility. The results were fabricated in order to generate an expectancy of experiencing 
increased negative mood states when you abstained from coffee.  
 
Furthermore it is important to note that no evidence has been found in the research literature of any definitive 
link between any single gene and either abstinence symptoms or tendency to addiction. This is true for all 
drugs, including caffeine. Therefore to our knowledge you do not have any genetic susceptibility to 
experience heightened negative mood states during caffeine abstinence as we led you to believe. 
 
In addition some people were told that they had been given caffeinated coffee while others were told they had 
been given decaffeinated coffee. In fact no participants actually received caffeinated coffee: all participants 
received decaffeinated coffee. We were interested in how the information about the genetic susceptibility and 
about the type of coffee you received affected your mood state.    
 
Because research into the effect of expectations on treatment outcomes requires that people believe they are 
receiving an active treatment, it was necessary for us to keep the true purpose of the study hidden from you 
until after you had completed all of the required tests. We apologise for the deception and for not revealing the 
study’s true aims. After reading this you have the right to withdraw your data from the study. Please inform one 
of the researchers if you wish to do this. Please be assured that there will be no repercussions if you choose to 
do this. 
 
If you would like to know more about the study, your performance in any of the tests, or the results of the study 
please contact Llew Mills on 0421 032 614 or at llew.mills@sydney.edu.au and he will arrange to make these 
available to you. If you have any concerns about your consumption of caffeine or any other substance please 
tell the experimenters and they will be happy to refer you to the University health service or to a local GP who 
can discuss these matters with you to your satisfaction. 
 
 
 
 
Meanwhile, because it is important that other participants do not know precisely what we are looking for before 
they are tested, we ask for your help by not telling other people that might participate in this study in future. 
Once again, thankyou for participating.  
 
 
 
 
Appendix 5: Study 3 
Appendix 5a – Demographics, Caffeine Use, and Expectancy Questionnaire for 
Study 3 
 
Author’s Note: The following is a demographics, caffeine-use, and expectancy 
questionnaire given to participants when they first arrived for testing. The questionnaire 
was administered online via Qualtrics survey software.  All tests were completed by 
participants in the labs at the School of Psychology. 
 
 
 
 
 
Online Caffeine Use and Demographics Screening Questionnaire 
 
1. Demographic Information  
 
Please indicate your gender 
m Male 
m Female 
m Other (please indicate) ____________________ 
 
Please enter your age (in years)  
 
Please indicate your employment status 
m Full time 
m Part time 
m Volunteer 
m Unemployed 
m Student 
m Retired 
m Other (please indicate) ____________________ 
 
Please indicate your highest level of education 
m Primary 
m Secondary 
m College / University 
m Other (please indicate) ____________________ 
 
Please indicate your marital status 
m Single 
m In a relationship 
m Cohabitating 
m Married 
m Divorced 
m Widowed 
m Other (please indicate) ____________________ 
 
Please indicate your predominant ethnicity ____________________ 
 
 
 
 
 
 
 
 
2. Caffeine Use and Expectancy section 
 
In this part of the test we want to get and accurate picture of your dailt caffeine 
use habits. 
 
Do you drink coffee regularly (i.e. every weekday)? 
m Yes 
m No 
 
If you indicated ‘Yes’ above, please indicate how many cups of coffee you would 
consume on an average weekday. If you consume less than 1 cup per day please 
please check ‘0’  
 
Since weekend consumption of caffeine can sometimes differ from consumption during 
the week, we are only interested in the number of cups you would drink ON AN 
AVERAGE WEEKDAY. 
 
m 0 
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Use the slider below to indicate to what extent the beverage listed would change 
the way you feel overall, with 0 indicating no effect and 10 indicating a large effect. 
‘If I was experiencing some caffeine withdrawal symptoms (e.g. feeling tired, headachey, 
in a bad mood, tense, irritable) drinking a cup of coffee right now would...'  
 
 
Do you drink tea every day? 
m Yes 
m No 
 
If you indicated ‘Yes’ above, please indicate how many cups of caffeinated tea you 
would consume on an average weekday. If you consume less than 1 cup per day please 
please check ‘0’. If you only consume herbal tea (e.g. chamomile, Rooibos, ginseng) 
also check ‘0’ (Note: Green tea contains caffeine so if you consume green tea include 
that in your estimate). 
 
m 0 
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
 
 
 
 
 
 
Use the slider below to indicate to what extent the beverage listed would change 
the way you feel overall, with 0 indicating no effect and 10 indicating a large effect. 
‘If I was experiencing some caffeine withdrawal symptoms (e.g. feeling tired, headachey, 
in a bad mood, tense, irritable) drinking a cup of caffeinated tea right now would...'  
 
 
Do you drink cola (e.g. Coke, Pepsi, Mother etc) every day? 
m Yes 
m No 
 
If you indicated ‘Yes’ above, please indicate how many cans or bottles you would 
consume on an average weekday. If you consume cola from large 1.25-, 2-, or 3-Litre 
bottles please estimate how many cans per day this would translate to. If you consume 
less than 1 can on an average weekday answer ‘0’. 
 
m 0 
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
 
 
 
 
 
 
 
 
Use the slider below to indicate to what extent the beverage listed would change 
the way you feel overall, with 0 indicating no effect and 10 indicating a large effect. 
‘If I was experiencing some caffeine withdrawal symptoms (e.g. feeling tired, headachey, 
in a bad mood, tense, irritable) drinking a can of caffeinated cola right now would...'  
 
 
 
Do you energy drinks (e.g. Red Bull, V) every day? 
m Yes 
m No 
 
If you indicated ‘Yes’ above, please indicate how many bottles or cans you would 
consume on an average weekday. (Note. If you regularly order large cans of any of 
these, please count this as 2 cans towards your average total daily use)  
 
m 0 
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
 
 
 
 
 
 
Use the slider below to indicate to what extent the beverage listed would change 
the way you feel overall, with 0 indicating no effect and 10 indicating a large effect. 
‘If I was experiencing some caffeine withdrawal symptoms (e.g. feeling tired, headachey, 
in a bad mood, tense, irritable) drinking a can of my chosen energy drink right now 
would...'  
 
 
Do you decaffeinated coffee (decaf) every day? 
m Yes 
m No 
 
If you indicated ‘Yes’ above, please indicate how many cups of decaffeinated coffee 
(decaf) you would consume on an average weekday. 
 
m 0 
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
 
 
 
 
 
 
 
 
Use the slider below to indicate to what extent the beverage listed would change 
the way you feel overall, with 0 indicating no effect and 10 indicating a large effect. 
‘If I was experiencing some caffeine withdrawal symptoms (e.g. feeling tired, headachey, 
in a bad mood, tense, irritable) drinking a cup of decaffeinated coffee right now 
would...'  
 
 
 
Do you consume caffeine strips every day? 
m Yes 
m No 
 
If you indicated ‘Yes’ above, please indicate how many caffeine strips yuou would 
consume on an average weekday 
 
m 0 
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
 
 
 
 
 
 
 
Use the slider below to indicate to what extent the beverage listed would change 
the way you feel overall, with 0 indicating no effect and 10 indicating a large effect. 
‘If I was experiencing some caffeine withdrawal symptoms (e.g. feeling tired, headachey, 
in a bad mood, tense, irritable) consuming a caffeine strip right now would...'  
 
 
 
Do you drink water every day? 
m Yes 
m No 
 
If you indicated ‘Yes’ above, please indicate how many mls of water you would consume 
on an average weekday 
 
m 0 
m 500 (0.5 litres) 
m 1000 (1 litres) 
m 1500 (1.5 litres) 
m 2000 (2 litres) 
m 2500 (2.5 litres) 
m 3 litres or more 
 
 
 
 
 
 
 
 
 
Use the slider below to indicate to what extent the beverage listed would change 
the way you feel overall, with 0 indicating no effect and 10 indicating a large effect. 
‘If I was experiencing some caffeine withdrawal symptoms (e.g. feeling tired, headachey, 
in a bad mood, tense, irritable) drinking a cup of water right now would...'  
 
 
 
Do you consume pre-workout energy supplements every day? 
m Yes 
m No 
 
If you indicated ‘Yes’ above, please indicate how many caffeine strips yuou would 
consume on an average weekday 
 
m 0 
m 1 
m 2 
m 3 
m 4 
m 5 
m more than 5 
 
 
 
 
 
 
 
 
 
Use the slider below to indicate to what extent the beverage listed would change 
the way you feel overall, with 0 indicating no effect and 10 indicating a large effect. 
‘If I was experiencing some caffeine withdrawal symptoms (e.g. feeling tired, headachey, 
in a bad mood, tense, irritable) consuming a beverage that had pre-workout energy 
supplement added to it right now would...'  
 
 
 
End of Survey 
 
Thankyou for completing this questionnaire. Please indicate your email address 
in the box below and let the researcher know you are finished. 
 
 
 Appendix 5b – Exit Questionnaire for Study 2 
 
Author’s Note: The following are items in the Exit Questionnaire given to all 
participants. The chief purpose of this questionnaire was to determine whether 
participants knew or suspected that the beverage that they were given was other than 
instructed. If questions appear on separate pages this means that they were not visible 
until the previous question had been answered. This was important as the order of 
questions goes from general to more specific.  
 	
Caffeine	Study	Exit	Questionnaire	
	
How	long	have	you	been	a	regular	(i.e.	daily)	user	of	caffeine?	Please	
answer	in	years	and	months?	
	
	
	
Before	taking	part	in	this	study	had	you	ever	attempted	to	quit	or	cut	back	
on	your	use	of	caffeine?	
m Yes	
m No	
	
If	you	answered	yes	to	the	previous	question,	how	many	times	have	you	
attempted	to	quit	or	cut	back	your	caffeine	use?	
m Yes	
m No	
	
During	your	test	session	you	were	given	a	cup	of	coffee/decaffeinated	
coffee/water	(note:	which	of	these	options	was	included	in	the	actual	question	depended	on	the	experimental	group	the	participants	was	allocated	to)	
	
Please	tell	us	what	you	expected	the	effect	of	that	would	be	in	the	following	
questions	
	
What	effect	did	you	anticipate	the	coffee	you	were	given	would	have	on	
your	performance	in	the	second	attention	test,	compared	to	the	first?	
m I	thought	I	would	perform	better	in	the	second	test		
m I	thought	I	would	perform	worse	in	the	second	test	
m I	thought	my	performance	would	be	more	or	less	unchanged			
What	effect	did	you	anticipate	the	coffee	you	were	given	would	have	on	the	
way	you	were	feeling:	
m I	thought	it	would	make	me	feel	better	
m I	thought	it	would	make	me	feel	worse	
m I	thought	it	would	have	no	effect			
What	effect	did	you	anticipate	the	coffee	you	were	given	would	have	on	
your	blood	pressure?	
m I	thought	it	would	raise	my	blood	pressure	
m I	thought	it	would	lower	my	blood	pressure	
m I	thought	my	blood	pressure	would	stay	more	or	less	the	same	
	 `	
Did	you	comply	with	the	request	to	abstain	from	all	sources	of	caffeine		
m Yes	
m No	
	
If	you	answered	‘No’	to	the	above	question,	please	tell	us	what	form	of	
caffeine	you	consumed	in	the	24-h	prior	to	the	test	session,	how	much	of	it	
you	consumed,	and	when	approximately	you	consumed	it.	
	
	
	
	
Did	you	think	the	experimental	procedures	differed	in	any	way	from	what	
you	had	been	told?	
m Yes	
m No	
	
Tell	us	what	you	think	the	purpose	of	the	study	was.		
	
	
	
	
Do	you	have	any	other	comments	on	the	testing	or	procedure?	
	
	
	
	
	
	
Do	you	think	that	there	was	caffeine	in	your	coffee?	
	
If	possible,	when	answering	please	refer	to	what	you	thought	DURING	the	
test	BEFORE	reading	this	question	
	
m Yes	
m No	
	
Estimate	how	likely	it	was	that	the	coffee	you	drank	was	caffeinated?	
m Certainly	decaffeinated	
m Probably	decaffeinated	
m Possibly	decaffeinated	
m Do	not	know	
m Possibly	caffeinated	
m Probably	caffeinated	
m Certainly	caffeinated	
	
	
Appendix 5c – Advertisement for Participants for Study 3 from General 
Population 
 
Author’s Note: The following is an advertisement for recruitment of participants. 
The advertisement appeared on the online classifieds website Gumtree or on the 
University of Sydney careers Website.  		
Regular daily caffeine drinkers 18 years or older are 
wanted to take part in a research study investigating the 
effects of caffeine on cognitive performance. 
 
The study will involve attending a single 90-min test 
session. You will be required to abstain from caffeine for 
24 hours prior to this test session. During the test session 
you will be given a battery of tests: a cognitive test, a 
mood questionnaire, and blood pressure readings. You 
will be given this battery of tests twice, once upon arrival 
and once after you have consumed a cup of coffee 
The study is being conducted at the School of Psychology, 
located at the Camperdown Campus of the University of 
Sydney. 
Note: You will be reimbursed for the costs associated with 
participating. 
If you are interested in participating please email Llew 
Mills at: 
caffeineandcognition@gmail.com 
 
In the email please indicate how many cups of coffee you 
consume on a regular weekday 
  
Appendix 5d – Advertisement for Participants for Study 3 from Student 
Population 
 
Author’s Note: The following is an advertisement for recruitment of participants that 
appeared on the University of Sydney’s research participation website. Participants 
could not see the advertisement unless they indicated on a screening questionnaire 
,completed at the beginning of semester, that they consumed 3 or more cups of 
coffee each day. 
 
  
Description for Students 
 
Sydney University School of Psychology are seeking regular coffee drinkers 
for a research study investigating the effects of caffeine and caffeine 
abstinence on cognitive performance. The study will involve attending a single 
90-min test session. Prior to this test session you will be required to abstain 
from all source of caffeine for 24-h. During the test session you will be given 
a battery of tests: a cognitive test, a mood questionnaire, and blood pressure 
readings. You will be given this battery of tests twice, once upon arrival and 
once after you have consumed a cup of coffee.  
 
 
 
 		
 
 
 
 
Appendix 5e – Screening Questionnaire Used for Study 3 
 
Author’s Note: The following is a screening questionnaire given to Students enrolled in 
the University of Sydney Psychology 1001 or 1002 (ie.e first-year) course. Only students 
who indicated on this questionnaire that they drank 3 or more cups of coffee on a 
standard weekday could see and apply for the study. This ensured that participants could 
not fabricate the extent of their daily caffeine use to take part in the study (i.e. because at 
the time of taking it, they did not know of the Study’s existence). 
  
Please indicate below how many cups of coffee you would usually consume on an 
average weekday. You MUST select at least one option. If you don’t drink coffee just 
select ‘None’. If you only drink it rarely or only on weekends select ‘Less than 1’. 
 
m I don’t drink coffee at all 
m Less than 1 (i.e. I don’t drink coffee every weekday) 
m 1 
m 2 
m 3 
m 4 
m 5 
m 6 
m more than 6 
 
 
 Appendix 6: Study 5 
 
Appendix 6a – Exit Questionnaire for Study 4 
 
Author’s Note: The following are items in the Exit Questionnaire given to all 
participants. The chief purpose of this questionnaire was to determine whether 
participants suspected at any time that their dosing information was spurious. 
 Study	4	Exit	Questionnaire	
	
How	long	have	you	been	a	regular	(i.e.	daily)	user	of	caffeine?	Please	
answer	in	years	and	months?	
	
	
	
Before	taking	part	in	this	study	had	you	ever	attempted	to	quit	or	cut	back	
on	your	use	of	caffeine?	
m Yes	
m No	
	
If	you	answered	yes	to	the	previous	question,	how	many	times	have	you	
attempted	to	quit	or	cut	back	your	caffeine	use?	
m Yes	
m No	
	
In	your	first	baseline	session	(i.e.	your	first	visit	to	us)	we	arranged	a	time	
for	you	to	attend	a	second	baseline	session.	For	this	second	baseline	
session	you	were	asked	not	to	consume	any	caffeine	in	the	24	hours	prior	
to	attending.	
	
Did	you	consume	any	caffeine	during	the	24-hour	period	prior	to	this	
second	session?	
m Yes	
m No	
	
If	you	answered	‘No’	to	the	above	question,	please	tell	us	what	form	of	
caffeine	you	consumed	in	the	24-h	prior	to	the	test	session,	how	much	of	it	
you	consumed,	and	when	approximately	you	consumed	it.	
	
	
	
	During	the	test	period	(i.e.	Monday	morning	this	week	to	right	now)	did	
you	consume	any	caffeine	from	a	source	other	than	the	coffee	given	to	you	
by	experimenters?	
m Yes	
m No		
If	you	answered	yes	to	the	last	question,	please	tell	us	when	you	consumed	
caffeine	from	a	source	other	than	the	coffee	the	experimenters	gave	you.	
	
Please	supply	details	such	as	exactly	when	you	consumed	caffeine,	what	
was	the	source	(e.g.	chocolate,	tea,	cola,	coffee?)	and	how	much	you	had.	
	
	
	
	
Did	you	think	the	experimental	procedures	differed	in	any	way	from	what	
you	had	been	told?	
m Yes	
m No	
	
If	you	answered	yes	to	the	last	question,	please	tell	us	below	how	you	think	
they	differed.	
	
	
	
Tell	us	what	you	think	the	purpose	of	the	study	was.		
	
	
	
	
	
Do	you	have	any	other	comments	on	the	testing	or	procedure?	
	
	
	
	
	
	
Was	there	any	point	during	the	testing	when	you	suspected	your	true	dose	
of	caffeine	may	have	differed	from	the	dose	you	were	told	you	were	given	
by	experimenters?	
	
When	answering	please	think	carefully	and	try	to	answer	based	on	what	
you	thought	or	felt	at	the	time,	rather	than	what	you	might	think	now	after	
reading	this	question.	
m Yes	
m No	
	
If	you	answered	yes	to	the	previous	question	please	take	some	time	to:	
	
a)	tell	us	when	you	may	have	suspected	(e.g.	on	the	evening	of	day	4)		
	
AND		
	
b)	supply	details	of	what	exactly	led	you	to	believe	your	dose	may	have	
been	different	from	what	you	were	told?	
	
When	answering	please	think	carefully	and	once	again	try	to	answer	based	
on	what	you	thought	or	felt	at	the	time	rather	than	what	you	might	think	
now	after	reading	the	previous	question.	
	
	
	
 
Appendix 6b – Recruitment Advertisement for Study 4 (Student Version) 
 
Author’s Note: The following is an advertisement for recruitment of participants. 
The advertisement appeared on the University of Sydney Research Participation 
Website (SONA).  
 
Note: This advertisement could only be seen, and applied for, if participants 
indicated in a screening questionnaire (see Appendix 6d) taken at the commencement 
of semester, that they consumed 3 or more cups per day. 
 
Description for SONA 
 
Moderate to heavy coffee drinkers (i.e. between 3 and 6 cups per day) are 
wanted for a study investigating the effects of reducing daily caffeine intake on 
mood. This study will involve 10 short visits in person over a 7-day period, 
totalling approximately 100 minutes, at the Camperdown campus of the 
University of Sydney. The first two visits will be baseline sessions. The final 8 
visits will be test sessions and will take place over five consecutive weekdays, 
Monday to Friday. During the 5-day test stage your daily intake of caffeine will 
be reduced. For the first three days of the test stage you will need to attend 
twice a day, and on the last two days you will need to attend once a day, 
however for all these visits you will be able to select times which are 
convenient to you. During each test session you will receive a cup of coffee 
and complete a short questionnaire about your mood. Important: We need to 
be able to regulate the daily intake of caffeine of each participant during 
the study. Therefore, during the 5-day test stage, you will be required to 
refrain from consuming ANY caffeine other than the daily cup of coffee 
we give you.  
 
If you need any additional information about the experiment please do not hesitate 
to call Llew Mills on 0421 032 614 and he will be happy to answer any questions 
you might have. 
 
 
 
 
 		
 
Appendix 6c – Recruitment Advertisement for Study 4 (General Population) 
 
Author’s Note: The following is an advertisement for recruitment of participants. 
The advertisement appeared on the University of Sydney Career Hub Website.  
 
Note: In this advertisement participants were required to state how many cups of 
coffee they drank on a regular weekday. Since they were not made aware in the 
advertisement what level of consumption was required it is more likely they would 
have been truthful about their daily consumption. Thus this served as another form of 
screening method, comparable to the screening method used for student participants.  
Regular coffee drinkers 18 years or older are wanted for a study investigating the effects 
of reducing daily caffeine intake on mood.  
 
This study will involve 10 short visits in person over a 7-day period, totalling 
approximately 100 minutes, at the Camperdown/Darlington campus of the University of 
Sydney. The first two visits will be baseline sessions. The final 8 visits will be test 
sessions and will take place over five consecutive weekdays, Monday to Friday. During 
the 5-day test stage your daily intake of caffeine will be reduced. For the first three days 
of the test stage you will need to attend twice a day, and on the last two days you will 
need to attend once a day, however for all these visits you will be able to select times 
which are convenient to you. During each test session you will receive a cup of coffee 
and complete a short questionnaire about your mood.  
 
You will be reimbursed for the costs associated with participating. 
 
If you are interested in participating please email experimenters at: 
 
llew.mills@sydney.edu.au 
 
In the email please state how many cups of coffee you would consume on an 
average weekday. 
 
If you need any additional information about the experiment please do not hesitate 
to call Llew Mills on 0421 032 614 and he will be happy to answer any questions 
you might have. 
 	
 Appendix 6d (MisInformed)– Participant Information Statement Study 4 
 
Author’s Note: The following is a Participant Information Statement given to 
participants when they attended the first of their baseline sessions. This statement is for 
the participants randomised to the MisInformed group. Note that the order of the ad-
libitum and abstinence baselines was counterbalanced, thus different PIS was given to 
those participants, with descriptions of week one procedures appropriate to the order of 
these baselines for the participants in question. This PIS is for participants who had the 
ad-libitum baseline on the first test session. 
  
 
 
 
 
 
 
 
School of Psychology 
   
ABN 15 211 513 464 
 
 Dr Ben Colagiuri 
Lecturer 
Room 444  
Brennan MacCallum, A18 
The University of Sydney  
NSW 2006 AUSTRALIA 
Telephone:   +61 2 9351 4589 
Facsimile:  +61 2 9351 5223 
Email: ben.colagiuri@sydney.edu.au 
Web: http://www.sydney.edu.au/ 
 
DAILY CAFFEINE INTAKE AND MOOD: PARTICIPANT INFORMATION STATEMENT 
 
Thankyou for indicating your interest in participating in this study into the effects of reduction of 
daily caffeine intake on mood. Here is some information about the study. Please read it carefully. It 
contains vital information that you must understand before you take part in the study. 
 
(1) What is the study about? 
 
You are invited to participate in a study into the effects of reduction of caffeine intake on mood. Over the 
course of the study you will have your daily caffeine intake kept stable at 300 mg for three days and then 
reduced to zero (i.e. 0mg) on the final day. We are doing this in order to observe the effect this reduction has 
on your mood and physical symptoms.  
 
(2) Who is carrying out the study? 
 
The study is being conducted by Llew Mills from the University of Sydney as part of research that will be 
presented as part of his PhD, under the supervision of Dr Ben Colagiuri 
 
(3) What does the study involve? 
 
If you choose to take part in the study there are three very important things required of you during this study, 
which you must agree to in order to be admitted: 
 
a) In agreeing to take part in this study you will be agreeing to attend 10 sessions over the course of 
approximately ten days at Room 517, Griffith Taylor Building (A19) at the Darlington/Camperdown 
Campus of the University of Sydney. These sessions will all be short, ranging from 20 min to 5 min, 
however YOU WILL BE REQUIRED TO ATTEND ALL TEN SESSIONS. The schedule will be as 
follows. 
 
Week One: During this week you will be required to attend two sessions. You will be able to arrange 
these two sessions with experimenters on any weekday between 9am and 6pm at times that suit you. At 
Session 1 (20 min) we want to measure your mood on a day when you are consuming caffeine as you 
normally would. At this session we will explain the procedure of the experiment in person and also ask 
you to fill in a mood-state questionnaire. This questionnaire takes 5 min or less to complete. This will 
provide us with a baseline against which we can compare your mood on other days when you have less 
caffeine in your system. At Session 2 (10 min) we want you to complete the same mood-state 
questionnaire, this time after you have been abstinent from all sources of caffeine for 24 hours. 
This will give us an indication of your mood after 24 h of consuming zero caffeine, once again as a 
baseline which we compare scores from future questionnaires. At Session 2 we will take a saliva sample 
to confirm you have been abstinent from caffeine, which will be analysed before the test sessions the 
following week. If you wish you can wait a day or two between Session 1 and Session 2 or you can 
attend Session 2 the day after. Whichever way you choose to schedule these two sessions the important 
thing is that before Session 1 you consume caffeine as you normally would and that for 24 hours before 
Session 2 you consume no caffeine whatsoever. 
 
Week Two: This will be the test week, where we will implement your caffeine reduction plan. Your daily 
intake of caffeine will be kept stable for three days and then reduced to zero on the fourth day You will 
be required to attend Room 517, Griffith Taylor Building (A19) every day of this week, from Monday to 
  
Friday. On Monday, Tuesday and Wednesday you will be required to attend twice a day. On each of 
these two visits you will be given a cup of coffee. Before we give you your first cup of coffee each day we 
will ask you to fill in a questionnaire. On Thursday you will be given no caffeine but will still be required to 
attend to complete a questionnaire. On Friday, the last test day, you will be required to complete a final 
questionnaire. Note: Experimenters will be on call from 9am-6pm each day so you will be free to 
choose times to attend that are convenient for you. Arrangements will be made so that you can 
either just show up at room 517 or call the experimenter in advance and arrange for them to be 
there when is convenient for you. 
 
Please read the following schedule of attendance for Week Two carefully. It lists how many visits per 
day, how long each visit will take, how much caffeine is in each cup of coffee, and how much you will 
receive each day. 
 
Day Requirements Caffeine Per Cup 
Total Intake 
Per Day Time Taken 
Monday 
Visit 1 
 
Visit 2 
 
Questionnaire + Coffee 
 
   Coffee 
 
150mg 
 
150mg 
 
 
300mg 
 
10 min 
 
5 min 
Tuesday 
Visit 1 
 
Visit 2 
 
   Questionnaire + Coffee 
 
   Coffee 
 
150mg 
 
150mg 
 
 
300mg 
 
10 min 
 
5 min 
Wednesday 
Visit 1 
 
Visit 2 
 
Questionnaire + Coffee 
 
   Coffee 
 
150mg 
 
150mg 
 
 
300mg 
 
10 min 
 
5 min 
Thursday 
 
Visit 1 
 
 
Questionnaire Only 
 
 
 
No Coffee 
 
 
0mg 
 
 
5 min 
Friday 
 
Visit 1 
 
 
Questionnaire Only 
 
    
   Final Session/ 
End of 
Experiment 
Final Session/ 
End of 
Experiment 
 
 
10 min 
 
  
b) During the 5 test days in Week Two you MUST NOT CONSUME CAFFEINE FROM ANY SOURCE 
OTHER THAN THE COFFEE GIVEN TO YOU BY THE EXPERIMENTERS. It is very important that you 
comply with this requirement. In order to determine the effects of caffeine intake on mood we need to be 
able to precisely control the amount of caffeine you receive each day. Therefore you will be required to 
completely refrain from consuming any tea, coffee, cola, energy drinks, coffee-flavoured milk, coffee-
flavoured ice cream and chocolate of any kind for 5 days. In the final 48 hours of the test phase in Week 
Two you will receive no coffee from experimenters either but we will still require that you consume no 
caffeine from any source for these two days. Of course you will be free to consume caffeine when you 
leave the final test session. 
 
c) You will be allowed to take your coffee with you after each visit during the test stage in Week Two, 
however we do ask that you drink the entire cup. The amount of caffeine in the coffee you will be 
provided is very precisely controlled and therefore if you don’t drink the whole cup you won’t get the 
whole amount. 
 
Please consider carefully whether you will be able to comply with the above requirements before you 
decide to take part.  
 
 
 
(4) Who is eligible to take part in the study? 
 
To be eligible to participate in this study you need to: 
  
 
a) be 18 yrs-old or over 
b) not have been told by your doctor to stop consuming caffeine for any medical reason, such as 
cardiovascular disease 
c) not be pregnant 
d) not be addicted to any drug other than nicotine 
 
If you do not meet all these criteria please tell researchers as consuming caffeine could be dangerous 
for you. 
 
    (4)         How much time will the study take? 
 
                    You will be asked to attend ten test sessions at the Camperdown Campus of the University of Sydney, 
totalling approximately 100 min. 
 
(5) Can I withdraw from the study? 
 
Being in this study is completely voluntary - you are not under any obligation to consent and - if you do 
consent - you can withdraw at any time without affecting your relationship with The University of 
Sydney  
 
 
(6) Will anyone else know the results? 
 
All aspects of the study, including results, will be strictly confidential and only the researchers will have 
access to information on participants. A report of the study may be submitted for publication, but 
individual participants will not be identifiable in such a report. Other researchers may also be granted 
access to de-identified data for the purpose of further analysis. This data will not include participant 
names or any other information that could identify you. 
 
(7) Will the study benefit me? 
 
If you complete the study you will receive 4.5 hours credit as part of the School of Psychology’s 
Research Participation Scheme or $100.  
 
 
(8) Can I tell other people about the study? 
 
You are welcome to discuss the study with other people, such as your family and friends. However we 
do ask that you try to avoid discussing it with other participants as sometimes this can affect the 
study’s results.  
 
(9) What if I require further information about the study or my involvement in it? 
 
When you have read this information, Llew MIlls will discuss it with you further and answer any 
questions you may have.  If you would like to know more at any stage, please feel free to contact him 
via email at llew.mills@sydney.edu.au or via phone on 04212 032 614.    
 
(10) What if I have a complaint or any concerns? 
 
Any person with concerns or complaints about the conduct of a research study can contact The 
Manager, Human Ethics Administration, University of Sydney on +61 2 8627 8176 (Telephone); +61 2 
8627 8177 (Facsimile) or ro.humanethics@sydney.edu.au (Email). 
 
 
This information sheet is for you to keep 
 Appendix 6e (Informed) – Participant Information Statement Study 4 
 
Author’s Note: The following is a Participant Information Statement given to participants 
when they attended the first of their baseline sessions. This statement is for the participants 
randomised to the Informed group and whose first baseline session was ad-libitum caffeine 
consumption. Note that the order of the ad-libitum and abstinence baselines was 
counterbalanced, thus different PIS was given to those participants, with descriptions of 
week one procedures appropriate to the order of these baselines for the participants in 
question. This PIS is for participants who had the ad-libitum baseline on the first test session.
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DAILY CAFFEINE INTAKE AND MOOD: PARTICIPANT INFORMATION STATEMENT 
 
Thankyou for indicating your interest in participating in this study into the effects of reduction of 
daily caffeine intake on mood. Here is some information about the study. Please read it carefully. It 
contains vital information that you must understand before you take part in the study. 
 
(1) What is the study about? 
 
You are invited to participate in a study into the effects of reduction of caffeine intake on mood. Over the 
course of the study you will have your daily caffeine intake gradually reduced from 300 mg to zero (i.e. 0 
mg). We are doing this in order to observe the effect this reduction has on your mood and physical 
symptoms.  
 
(2) Who is carrying out the study? 
 
The study is being conducted by Llew Mills from the University of Sydney as part of research that will be 
presented as part of his PhD, under the supervision of Dr Ben Colagiuri 
 
(3) What does the study involve? 
 
If you choose to take part in the study there are three very important things required of you during this study, 
which you must agree to in order to be admitted: 
 
a) In agreeing to take part in this study you will be agreeing to attend 10 sessions over the course of 
approximately ten days at Room 517, Griffith Taylor Building (A19) at the Darlington/Camperdown 
Campus of the University of Sydney. These sessions will all be short, ranging from 20 min to 5 min, 
however YOU WILL BE REQUIRED TO ATTEND ALL TEN SESSIONS. The schedule will be as 
follows. 
 
Week One: During this week you will be required to attend two sessions. You will be able to arrange 
these two sessions with experimenters on any weekday between 9am and 6pm at times that suit you. At 
Session 1 (20 min) we want to measure your mood on a day when you are consuming caffeine as you 
normally would. At this session we will explain the procedure of the experiment in person and also ask 
you to fill in a mood-state questionnaire. This questionnaire takes 5 min or less to complete. This will 
provide us with a baseline against which we can compare your mood on other days when you have less 
caffeine in your system. At Session 2 (10 min) we want you to complete the same mood-state 
questionnaire, this time after you have been abstinent from all sources of caffeine for 24 hours. 
This will give us an indication of your mood after 24 h of consuming zero caffeine, once again as a 
baseline which we compare scores from future questionnaires. At Session 2 we will take a saliva sample 
to confirm you have been abstinent from caffeine, which will be analysed before the test sessions the 
following week. If you wish you can wait a day or two between Session 1 and Session 2 or you can 
attend Session 2 the day after. Whichever way you choose to schedule these two sessions the important 
thing is that before Session 1 you consume caffeine as you normally would and that for 24 hours before 
Session 2 you consume no caffeine whatsoever. 
 
Week Two: This will be the test week, where we will implement your caffeine reduction plan. Your daily 
intake of caffeine will be reduced gradually over the 5-day test period. You will be required to attend 
Room 517, Griffith Taylor Building (A19) every day of this week, from Monday to Friday. On Monday, 
  
 
Tuesday and Wednesday you will be required to attend twice a day. On each of these two visits you will 
be given a cup of coffee. Before we give you your first cup of coffee each day we will ask you to fill in a 
questionnaire. On Thursday you will be given no caffeine but will still be required to attend to complete a 
questionnaire. On Friday, the last test day, you will be required to complete a final questionnaire. Note: 
Experimenters will be on call from 9am-6pm each day so you will be free to choose times to 
attend that are convenient for you. Arrangements will be made so that you can either just show 
up at room 517 or call the experimenter in advance and arrange for them to be there when is 
convenient for you. 
 
Please read the following schedule of attendance for Week Two carefully. It lists how many visits per 
day, how long each visit will take, how much caffeine is in each cup of coffee, and how much you will 
receive each day. 
 
Day Requirements Caffeine Per Cup 
Total Intake 
Per Day Time Taken 
Monday 
Visit 1 
 
Visit 2 
 
Questionnaire + Coffee 
 
   Coffee 
 
150mg 
 
150mg 
 
 
300mg 
 
10 min 
 
5 min 
Tuesday 
Visit 1 
 
Visit 2 
 
   Questionnaire + Coffee 
 
   Coffee 
 
100mg 
 
100mg 
 
 
200mg 
 
10 min 
 
5 min 
Wednesday 
Visit 1 
 
Visit 2 
 
Questionnaire + Coffee 
 
   Coffee 
 
50mg 
 
50mg 
 
 
100mg 
 
10 min 
 
5 min 
Thursday 
 
Visit 1 
 
 
Questionnaire Only 
 
 
 
No Coffee 
 
 
0mg 
 
 
5 min 
Friday 
 
Visit 1 
 
 
Questionnaire Only 
 
    
   Final Session/ 
End of 
Experiment 
Final Session/ 
End of 
Experiment 
 
 
10 min 
 
  
b) During the 5 test days in Week Two you MUST NOT CONSUME CAFFEINE FROM ANY SOURCE 
OTHER THAN THE COFFEE GIVEN TO YOU BY THE EXPERIMENTERS. It is very important that you 
comply with this requirement. In order to determine the effects of caffeine intake on mood we need to be 
able to precisely control the amount of caffeine you receive each day. Therefore you will be required to 
completely refrain from consuming any tea, coffee, cola, energy drinks, coffee-flavoured milk, coffee-
flavoured ice cream and chocolate of any kind for 5 days. In the final 48 hours of the test phase in Week 
Two you will receive no coffee from experimenters either but we will still require that you consume no 
caffeine from any source for these two days. Of course you will be free to consume caffeine when you 
leave the final test session. 
 
c) You will be allowed to take your coffee with you after each visit during the test stage in Week Two, 
however we do ask that you drink the entire cup. The amount of caffeine in the coffee you will be 
provided is very precisely controlled and therefore if you don’t drink the whole cup you won’t get the 
whole amount. 
 
Please consider carefully whether you will be able to comply with all the above requirements before you 
decide to take part.  
 
 
 
(4) Who is eligible to take part in the study? 
 
  
 
To be eligible to participate in this study you need to: 
 
a) be 18 yrs-old or over 
b) not have been told by your doctor to stop consuming caffeine for any medical reason, such as 
cardiovascular disease 
c) not be pregnant 
d) not be addicted to any drug other than nicotine 
 
If you do not meet all these criteria please tell researchers as consuming caffeine could be dangerous 
for you. 
 
    (4)         How much time will the study take? 
 
                    You will be asked to attend ten test sessions at the Camperdown Campus of the University of Sydney, 
totalling approximately 100 min. 
 
 
(5) Can I withdraw from the study? 
 
Being in this study is completely voluntary - you are not under any obligation to consent and - if you do 
consent - you can withdraw at any time without affecting your relationship with The University of 
Sydney.  
 
 
(6) Will anyone else know the results? 
 
All aspects of the study, including results, will be strictly confidential and only the researchers will have 
access to information on participants. A report of the study may be submitted for publication, but 
individual participants will not be identifiable in such a report. Other researchers may also be granted 
access to de-identified data for the purpose of further analysis. This data will not include participant 
names or any other information that could identify you. 
 
(7) Will the study benefit me? 
 
If you complete the study you in exchange for your participation you will receive 4.5 hours as part of 
the School of Psychology Research Participation Scheme, or $100.  
 
(8) Can I tell other people about the study? 
 
You are welcome to discuss the study with other people, such as your family and friends. However we 
do ask that you try to avoid discussing it with other participants as sometimes this can affect the 
study’s results.  
 
(9) What if I require further information about the study or my involvement in it? 
 
When you have read this information, Llew MIlls will discuss it with you further and answer any 
questions you may have.  If you would like to know more at any stage, please feel free to contact him 
via email at llew.mills@sydney.edu.au or via phone on 04212 032 614.    
 
(10) What if I have a complaint or any concerns? 
 
Any person with concerns or complaints about the conduct of a research study can contact The 
Manager, Human Ethics Administration, University of Sydney on +61 2 8627 8176 (Telephone); +61 2 
8627 8177 (Facsimile) or ro.humanethics@sydney.edu.au (Email). 
 
 
This information sheet is for you to keep 
Appendix 7: Study 5 	
 
Appendix 7a – Advertisement for Participants for Study 5 
 
Author’s Note: The following is an ad for participants placed on the University of 
Sydney’s Careers Website. Note that, unlike the same ad for Study 4, this 
advertisement makes no mention of dose reduction. 
	
Moderate to heavy coffee drinkers 18 years or older are wanted for a study 
investigating the effects of caffeine dose on mood.  
 
This study will involve 11 short visits in person over a 7-day period, totalling 
approximately 100 minutes, at the Camperdown/Darlington campus of the 
University of Sydney. The first two visits will be baseline sessions. The final 
9 visits will be test sessions and will take place over five consecutive 
weekdays, Monday to Friday. During the 5-day test stage your daily intake of 
caffeine will be altered in order to determine the effect of each day’s dose on 
your mood. For the first four days of the test stage you will need to attend 
twice a day, and on the last day you will need to attend once, however for all 
these visits you will be able to select times which are convenient to you. 
During each test session you will receive a cup of coffee and complete a 
short questionnaire about your mood.  
 
You will be reimbursed for the costs associated with participating. 
 
If you are interested in participating please email experimenters at: 
 
llew.mills@sydney.edu.au 
 
and you will be sent an information sheet. 
 
If you need any additional information about the experiment please do 
not hesitate to call Llew Mills on 0421 032 614 and he will be happy to 
answer any questions you might have. 	
Volunteers wanted… 
Appendix 7b – Advertisement for Participants, Study 5 
 
Author’s Note: The following is the ad for participants placed on the School of Psychology’s 
research participation portal. Students could only view this ad and sign up for the study if they 
indicated on a screening questionnaire at the beginning of semester that they consumed three 
or more cups of coffee each day. Note that, unlike the same ad for Study 4, this advertisement 
makes no mention of dose reduction. 
	
Study Name Caffeine Dose and Mood 
Abstract  This study aims to examine the effect of different daily doses of caffeine on mood.  
Description  
Moderate to heavy coffee drinkers (i.e. between 3 and 6 cups per day) are 
wanted for a study investigating the effects of different caffeine doses on 
mood. This study will involve 11 short visits in person over a 7-day period, 
totalling approximately 100 minutes, at the Camperdown campus of the 
University of Sydney. The first two visits will be baseline sessions. The final 
9 visits will be test sessions and will take place over five consecutive 
weekdays, Monday to Friday. Over the 5-day test stage your daily intake of 
caffeine will be altered in order to determine the effects of each day's dose 
on your mood. For the first four days of the test stage you will need to attend 
twice a day, and on the last day you will need to attend once, however for all 
these visits you will be able to select times which are convenient to you. 
During each test session you will receive a cup of coffee and complete a 
short questionnaire about your mood. Important: We need to be able to 
regulate the daily intake of caffeine of each participant during the study. 
Therefore, during the 5-day test stage, you will be required to refrain from 
consuming any caffeine other than the daily cup of coffee we give you. If 
you need any additional information about the experiment please do not 
hesitate to call Llew Mills on 0421 032 614 and he will be happy to answer 
any questions you might have.  
Eligibility 
Requirements  
You must regularly consume 3 or more cups of coffee on an average 
weekday to qualify for the study 
	
 
 
 
Appendix 7c – Participant Information Statement, Study 5 
 
Author’s Note: The following is the Participant Information Statement (PIS) given to 
participants at their first baseline session. Note that, since participants were not randomly 
allocated to group and informed of their dosing schedule until Monday morning of the test 
week, this PIS makes no mention of reduction of dose. 
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DAILY CAFFEINE INTAKE AND MOOD: PARTICIPANT INFORMATION STATEMENT (STUDENT) 
 
Thankyou for indicating your interest in participating in this study into the effects of daily caffeine 
intake on mood. Here is some information about the study. Please read it carefully. It contains vital 
information that you must understand before you take part in the study. 
 
(1) What is the study about? 
 
You are invited to participate in a study into the effects of caffeine dose on mood. During the test phase of 
the study you will have your daily caffeine dose manipulated over the course of 5 days. We are doing this in 
order to observe the effect this has on your mood and physical symptoms.  
 
(2) Who is carrying out the study? 
 
The study is being conducted by Llew Mills from the University of Sydney as part of research that will be 
presented as part of his PhD, under the supervision of Dr Ben Colagiuri. 
 
(3) What does the study involve? 
 
If you choose to take part in the study there are three very important things required of you, which you must 
agree to in order to be admitted: 
 
a) In agreeing to take part in this study you will be agreeing to attend 11 sessions over the course of 
approximately ten days at Room 322, Griffith Taylor Building (A19) at the Darlington/Camperdown 
Campus of the University of Sydney. These sessions will all be short, ranging from 20 min to 5 min, 
however YOU WILL BE REQUIRED TO ATTEND ALL ELEVEN SESSIONS. The schedule will be as 
follows. 
 
Week One: During this week you will be required to attend two sessions. You will be able to arrange 
these two sessions with experimenters on any weekday between 9am and 6pm at times that suit you. At 
Session 1 (20 min) we want to measure your mood on a day when you are consuming caffeine as you 
normally would. At this session we will explain the procedure of the experiment in person and also ask 
you to fill in a mood-state questionnaire. This questionnaire takes 5 min or less to complete. This will 
provide us with a baseline against which we can compare your mood on other days when you have less 
caffeine in your system. At Session 2 (10 min) we want you to complete the same mood-state 
questionnaire, this time after you have been abstinent from all sources of caffeine for 24 hours. 
This will give us an indication of your mood after 24 h of consuming zero caffeine, once again as a 
baseline which we compare scores from future questionnaires. At Session 2 we will take a saliva sample 
to confirm you have been abstinent from caffeine, which will be analysed before the test sessions the 
following week. If you wish you can wait a day or two between Session 1 and Session 2 or you can 
attend Session 2 the day after. Whichever way you choose to schedule these two sessions the important 
thing is that before Session 1 you consume caffeine as you normally would and that for 24 hours before 
Session 2 you consume no caffeine whatsoever. 
 
Week Two: This will be the test week, where we will manipulate your caffeine dose. You will be required 
to attend Room 322, Griffith Taylor Building (A19) every day of this week, from Monday to Friday. On 
Monday, Tuesday, Wednesday, and Thursday you will be required to attend twice a day. On each of 
these two visits you will be given a cup of coffee. Before we give you your cup of coffee each visit we will 
  
 
ask you to fill in a questionnaire. On Friday, the last test day, you will be required to attend once to 
complete a final questionnaire. Note: Experimenters will be on call from 9am-6pm each day so you 
will be free to choose times to attend that are convenient for you. Arrangements will be made so 
that you can either just show up at room 322 or call the experimenter in advance and arrange for 
them to be there when is convenient for you. 
 
Please read the following schedule of attendance for Week Two carefully. It lists how many visits per 
day, how long each visit will take, how much caffeine is in each cup of coffee, and how much you will 
receive each day. 
 
Day Requirements Time Taken 
Monday 
Visit 1 
 
Visit 2 
 
Questionnaire + Coffee 
 
Questionnaire + Coffee 
 
5 min 
 
5 min 
Tuesday 
Visit 1 
 
Visit 2 
 
   Questionnaire + Coffee 
 
Questionnaire + Coffee 
 
5 min 
 
5 min 
Wednesday 
Visit 1 
 
Visit 2 
 
Questionnaire + Coffee 
 
Questionnaire + Coffee 
 
5 min 
 
5 min 
Thursday 
Visit 1 
 
Visit 2 
 
Questionnaire + Coffee 
 
Questionnaire + Coffee 
 
 
5 min 
 
5 min 
Friday 
 
Visit 1 
 
 
Questionnaire Only 
 
 
10 min 
 
  
b) During the 5 test days in Week Two you MUST NOT CONSUME CAFFEINE FROM ANY SOURCE 
OTHER THAN THE COFFEE GIVEN TO YOU BY THE EXPERIMENTERS. It is very important that you 
comply with this requirement. In order to determine the effects of caffeine intake on mood we need to be 
able to precisely control the amount of caffeine you receive each day. Therefore you will be required to 
completely refrain from consuming any tea, coffee, cola, energy drinks, coffee-flavoured milk, coffee-
flavoured ice cream and chocolate of any kind for 5 days. Of course you will be free to consume caffeine 
when you leave the final test session. We will be randomly collecting saliva samples during the test week 
to determine whether participants have complied with this request, so please make sure you follow this 
instruction. 
 
c) You will be allowed to take your coffee with you after each visit during the test stage in Week Two, 
however we do ask that you drink the entire cup. The amount of caffeine in the coffee you will be 
provided is very precisely controlled and therefore if you don’t drink the whole cup you won’t get the 
whole amount. 
 
Please consider carefully whether you will be able to comply with all the above requirements before you 
decide to take part.  
 
 
 
 
 
 
(4) Who is eligible to take part in the study? 
  
 
 
To be eligible to participate in this study you need to: 
 
a) be 18 yrs-old or over 
b) not have been told by your doctor to stop consuming caffeine for any medical reason, such as 
cardiovascular disease 
c) not be pregnant 
d) not be addicted to any drug other than nicotine 
 
If you do not meet all these criteria please tell researchers as consuming caffeine could be dangerous 
for you. 
 
    (4)         How much time will the study take? 
 
                    You will be asked to attend ten test sessions at the Camperdown Campus of the University of Sydney, 
totalling approximately 100 min. 
 
 
(5) Can I withdraw from the study? 
 
Being in this study is completely voluntary - you are not under any obligation to consent and - if you do 
consent - you can withdraw at any time without affecting your relationship with The University of 
Sydney.  
 
 
(6) Will anyone else know the results? 
 
All aspects of the study, including results, will be strictly confidential and only the researchers will have 
access to information on participants. A report of the study may be submitted for publication, but 
individual participants will not be identifiable in such a report. Other researchers may also be granted 
access to de-identified data for the purpose of further analysis. This data will not include participant 
names or any other information that could identify you. 
 
(7) Will the study benefit me? 
 
If you complete the study you will receive 4.5 hours credit as part of the School of Psychology’s 
Research Participation Scheme.  
 
(8) Can I tell other people about the study? 
 
You are welcome to discuss the study with other people, such as your family and friends. However we 
do ask that you try to avoid discussing it with other participants as sometimes this can affect the 
study’s results.  
 
(9) What if I require further information about the study or my involvement in it? 
 
When you have read this information, Llew Mills will discuss it with you further and answer any 
questions you may have.  If you would like to know more at any stage, please feel free to contact him 
via email at llew.mills@sydney.edu.au or via phone on 0421 032 614.    
 
(10) What if I have a complaint or any concerns? 
 
Any person with concerns or complaints about the conduct of a research study can contact The 
Manager, Human Ethics Administration, University of Sydney on +61 2 8627 8176 (Telephone); +61 2 
8627 8177 (Facsimile) or ro.humanethics@sydney.edu.au (Email). 
 
 
This information sheet is for you to keep 
		
	
Appendix 7d – Exit Questionnaire, Study 5 
Author’s Note: The following is the Exit Questionnaire given to participants at the 
end of the study. The primary purpose of this was to determine whether participants 
suspected their dose was different to the dose they had been told (Note: Questions 4 
and 5 were not in the version of the questionnaire given to participants in the 
NonInformed group, since they received no dose information). 
 
Caffeine Study Exit Questionnaire 
 
	
1.	Tell	us	what	you	think	the	purpose	of	the	study	was.		
	
	
	
	
	
	
2.	Do	you	have	any	other	comments	on	the	testing	or	procedure?	
	
	
	
	
	
	
	
	
3.	Did	you	think	the	experimental	procedures	differed	in	any	way	from	
what	you	had	been	told?	
m Yes	
m No	
	
If	yes,	how	did	they	differ?	
	
	
		
	
4.	Was	there	any	point	during	the	testing	when	you	suspected	your	true	
dose	of	caffeine	may	have	been	different	from	the	dose	you	were	told	you	
received	by	experimenters?	(Note:	Please	answer	truthfully	based	on	what	you	thought	or	felt	at	the	time,	rather	than	based	of	what	you	now	think	after	reading	these	questions).	
m Yes	
m No	
	
	
5.	If	you	answered	yes	to	the	previous	question	please	tell	us	when	you	suspected	
(e.g.	on	the	evening	of	Day	4)	and	supply	details	of	what	led	you	to	believe	your	
dose	may	have	been	different.	
	
	
	
	
	
		
